University of Kentucky

UKnowledge
Theses and Dissertations--Pharmacy

College of Pharmacy

2018

USING THE QBEST EQUATION TO EVALUATE ELLAGIC ACID
SAFETY DATA: GENERATING A QNOAEL WITH CONFIDENCE
LEVELS FROM DISPARATE LITERATURE
Cynthia Rose Dickerson
University of Kentucky, crdi223@uky.edu
Author ORCID Identifier:

https://orcid.org/0000-0002-3572-9374

Digital Object Identifier: https://doi.org/10.13023/etd.2018.394

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Dickerson, Cynthia Rose, "USING THE QBEST EQUATION TO EVALUATE ELLAGIC ACID SAFETY DATA:
GENERATING A QNOAEL WITH CONFIDENCE LEVELS FROM DISPARATE LITERATURE" (2018). Theses
and Dissertations--Pharmacy. 94.
https://uknowledge.uky.edu/pharmacy_etds/94

This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Cynthia Rose Dickerson, Student
Dr. Robert A. Lodder, Major Professor
Dr. David Feola, Director of Graduate Studies

USING THE QBEST EQUATION TO EVALUATE ELLAGIC ACID SAFETY DATA:
GENERATING A QNOAEL WITH CONFIDENCE LEVELS FROM DISPARATE
LITERATURE

________________________________________
DISSERTATION
________________________________________

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in the College of Pharmacy at the University of Kentucky

By Cynthia Rose Dickerson
Lexington, Kentucky
Director: Dr. Robert A. Lodder, Professor of Pharmacy, Chemical Engineering
Lexington, Kentucky
2018
Copyright © Cynthia Dickerson 2018

ABSTRACT OF DISSERTATION

USING THE QBEST EQUATION TO EVALUATE ELLAGIC ACID SAFETY DATA:
GENERATING A QNOAEL WITH CONFIDENCE LEVELS FROM DISPARATE
LITERATURE
QBEST, a novel statistical method, can be applied to the problem of estimating the No
Observed Adverse Effect Level (NOAEL or QNOAEL) of a New Molecular Entity (NME)
in order to anticipate a safe starting dose for beginning clinical trials. The NOAEL from
QBEST (called the QNOAEL) can be calculated using multiple disparate studies in the
literature and/or from the lab. The QNOAEL is similar in some ways to the Benchmark
Dose Method (BMD) used widely in toxicological research, but is superior to the BMD in
some ways. The QNOAEL simulation generates an intuitive curve that is comparable to
the dose-response curve. The NOAEL of ellagic acid (EA) is calculated for clinical trials
as a component therapeutic agent (in BSN476) for treating Chikungunya infections.
Results are used in a simulation based on nonparametric cluster analysis methods to
calculate confidence levels on the difference between the Effect and the No Effect
studies. In order to evaluate the statistical power of the algorithm, simulated data
clusters with known parameters are fed into the algorithm in a separate study, testing the
algorithm’s accuracy and precision “Around the Compass Rose” at known coordinates
along the circumference of a multidimensional data cluster. The specific aims of the
proposed study are to evaluate the accuracy and precision of the QBEST Simulation and
QNOAEL compared to the Benchmark Dose Method, and to calculate the QNOAEL of
EA for BSN476 Drug Development.
KEYWORDS: Non-parametric Multivariate Statistical Analysis, Mahalanobis Equation,
No Observed Adverse Effect Limit, Discriminant Cluster Analysis
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CHAPTER 1: INTRODUCTION

What is the Quantile Bootstrap Error Statistical Test?
The Quantile Bootstrap Error-adjusted Statistical Test (QBEST) is a novel statistical
method for the nonparametric analysis of multivariate data. It is similar in many ways to
the Mahalanobis test, but represents an important mathematical improvement over the
Mahalanobis methodology, as the QBEST is not forced to use a symmetric standard
deviation (SD) to analyze a data cluster even when the data cluster is skewed. Instead,
QBEST measures a distance in asymmetric nonparametric central 68% confidence
intervals (equivalent to SDs for a normal distribution) from the center point of a cluster
out to the test sample point1, 3-9. In other words, the QBEST metric represents an
asymmetric nonparametric central 68% confidence interval for the mean. This property
allows QBEST to competently handle abnormally-shaped clusters of data for which the
standard deviation along opposite vectors of an axis from the center ought to vary3,5-9.
Furthermore, QBEST relies on simple mathematical calculations of Euclidean distance;
its calculation is fairly simple, and requires far less memory than the Mahalanobis test for
large matrix problems3,5-9. QBEST makes calculations that are currently technologically
impossible to complete on supercomputers using the Mahalanobis equation possible to
be run at home on a standard PC laptop. QBEST is the multivariate analysis equation of
the future and will allow for the processing of ever-increasing stores of complex Big
Data.

What is Multivariate Variation, in Layman’s Terms?
Data are considered to be multivariate when two or more independent variables describe
a single data point. For example, a person can be described by his height and weight,
which can affect blood pressure. So a set of data containing people, characterized by
height and weight to predict blood pressure, is multivariate. Any data that can be plotted
in a 3-dimensional space (2 independent variables and 1 dependent variable) is
multivariate by definition.
Furthermore, complex samples that seem on the surface to be a single continuous
measurement can also be treated as multivariate data sets. Consider, for example, an
infrared spectrum that represents the absorbance of light across a range of wavelengths:

1

Figure 1: Sample Spectrum
(Note: In chemistry, “wavelength” is denoted by the Greek letter ƛ.)
While these data may not seem to be multivariate at first glance, in reality, the
absorbance at each individual wavelength of light used in the test may be considered a
variable. This entire spectrum could be graphed as a single point in a large multivariate
space. One would start by assigning each wavelength to an axis. For simplicity, let us
first assume that we are only interested in ƛ1 and ƛ2 (labelled on the graph). We can
assign absorbance at ƛ1 to the x-axis and absorbance at ƛ2 to the y-axis. Then, we can
use the values derived from the original spectrum to graph a point reflecting these data.

2

Figure 2: Graphing a Sample Spectrum
On the left, see the original infrared
spectrum. Two wavelengths of interest
are labeled ƛ1 and ƛ2.

On the right, see the entire spectrum
graphed as a single point in
two-dimensional space. The x-coordinate
is the absorbance at ƛ1 and the
y-coordinate is the absorbance at ƛ2.

We can use this method to graph any complex data, utilizing any number of axes.
Pictured below are a standard x-y chart (a 2-dimensional graph) and a 3-dimensional
graph. A graph can have any finite number of axes, though they become difficult to draw
on paper and even more difficult to imagine. Though this is certainly difficult for a
human, machines are incredibly capable at handling this kind of data. For this reason, it
is important to be able to simplify complex data into a series of coordinate points that a
computer can manipulate, and from the resulting clusters, determine statistical trends.
2-Dimensional Graph

3-Dimensional Graph

4-Dimensional Graph

In this image, the x- and yaxes hold the two
variables.

Adding a third dimension
means adding a third axis.

A fourth dimension has to
be graphically represented
as an array of graphs.

Figure 3: Graphing Increasingly Multivariate Data
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Finally, we can use a single graph to keep track of large numbers of different multivariate
samples. Imagine that we had run an infrared spectral analysis on the same chemical a
number of times, and each time we found slightly different results. We could graph all of
the individual spectra on the same axis, as follows. When we look at the data, it
becomes apparent that similar samples cluster together when represented as data
points. These groups of points are referred to as clusters of data. These clusters have
unique properties; the points may be very closely clustered along one axis, and more
spread out along another. The significance of this will be discussed shortly.

Figure 4: Clusters Spatially Separated

Figure 5: An Irregular Cluster

Pharmaceutical Applications of Multivariate Data Analysis
Pharmaceutical applications of multivariate data analysis include the determination of the
toxicity of novel pharmaceuticals. Toxicity determinations can be performed by
experimentally determining the subject’s current blood levels of a pharmaceutical and
the dosage that subject was administered, and noting whether the pharmaceutical then
produced an adverse effect in the subject. QBEST and discriminant cluster analysis can
be applied to determine the safe dosage of the novel pharmaceutical agent. QBEST can
be applied to the problem of calculating No-Observed Adverse Effect Levels (NOAELs)
from published animal studies and clinical trials in a similar manner. The dosage and
some numerical outcome variable (a minimum of one outcome variable) can be
analyzed. Chapter 4 of this work addresses the generation of QNOAELs from the
literature.
Additionally, QBEST can be used in the future to manage the increasingly vast amounts
of health data generated in clinical trials and post marketing studies. The Mahalanobis
equation is incapable of calculating a Mahalanobis distance in multidimensional SDs for
all the data generated by many clinical trials. This is because the Mahalanobis requires

4

more data observations (e.g., subjects) than dimensions or independent variables (e.g.,
blood chemistry values, pathology measurements, etc.) in order to be calculated.
Additionally, clinical studies observe a great number of other characteristics ranging from
blood pressure and heart rate to weight and food intake. A single clinical study may
record 50 or 100 data values for each patient. Unfortunately, because clinical trials are
expensive, a phase 1 or phase 2 trial can easily have more data variables than subjects.
Furthermore, in meta-analyses, it is unlikely that more than 50 or 100 clinical trials would
be reported in the literature for a given pharmaceutical, again in large part because of
cost. This means that all 50 or 100 variables measured could not be used as data in a
Mahalanobis distance calculated by the Mahalanobis equation. QBEST, however, can
be used even when the number of variables measured far exceeds the number of
samples (subjects or clinical trials) measured. Data supporting this (situations where
number of dimensions is far higher than number of training points) can be found in
Chapter 5. For this reason, QBEST offers the best solution to solving clinical trial data
problems and using all of the data generated in one single statistical test.
Even personal health monitoring systems could be improved by the implementation of
QBEST. Numerous personal fitness systems currently monitor consumers’ vitals almost
continuously. Smartwatches, FitBits™, phones, and similar devices store information
about heart rate, activity level, and even sleep quality. These devices generally establish
a baseline for the person’s vitals and note if an abnormal event happens. QBEST could
easily be implemented in these device algorithms to detect the significance of deviation
from normal, and to identify the nature of the aberration. For example, a test heart rate
and pulse pattern could be compared to the patient’s baseline training set as well as to a
stored library of heart attack patterns and arrhythmias. Using QBEST, even a simple
smartwatch could serve as an early detection system for heart conditions. Of course, if
QBEST could be implemented in consumer devices, it could be put to even better use in
medical devices such as continuous glucose monitoring insulin pumps.

Why a Statistical Method is Needed Beyond Simple Standard Deviation:
Most individuals involved in the sciences are familiar with the standard deviation. A
standard deviation is a measure of variation around a central value. Distance in
standard deviations often serves as a sort of limit by which we measure the
reproducibility of data. (A limit of 3 SDs or 6 SDs is commonly used to denote class
membership, for example.) I could state that I am 5’5” tall. Does that make me typical
for a human being? Or am I gigantic, or perhaps diminutive? Answering that question is
simple enough; One could estimate the average height of a human being with a good
sampling of human beings, and then calculate the standard deviation of height. 68% of
the height data should fall within one standard deviation of average if the heights follow
the normal (Gaussian) distribution. By comparing my height to the average human
height plus or minus one standard deviation, it becomes apparent that I fall within the +/34% of most people. So 5’5” tall is not an abnormal height.
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But standard deviation is a mathematical parameter that is defined only in regard to a
single variable. While it is possible to answer simple questions with standard deviation,
such as “Is my height typical?”, more complicated questions cannot be answered using
standard deviation alone. For instance, take the question, “Is my height and weight
typical for a human?” It becomes readily apparent that adding a second variable
(weight), thus making the problem multivariate, complicates the question considerably.
To know whether my height and weight are typical, I need to know four things:
1) What is the average height and weight of all humans?
2) How much does height vary from person to person? (What is the standard
deviation of height?)
3) How much does weight vary from person to person? (What is the standard
deviation of weight?)
-and4) How do height and weight vary with regard to each other?
A covariance matrix is required to answer that last question. The covariance matrix is
part of the Mahalanobis distance Equation. Specifically, the Mahalanobis equation
represents the first statistical method capable of determining the difference between a
test data point and a known cluster of multivariate data.

What is the Mahalanobis distance Equation?
The Mahalanobis metric has been described as “a rubber ruler.”2,3 The rubber ruler
analogy can be explained as follows, by graphing a data sample of coordinate points.2,3
1. The Mahalanobis equation starts with the center of a data sample. Along any
line drawn in coordinate space that passes through the center of the data
distribution, the Mahalanobis equation can be used to determine the scalar size
of a standard deviation unit. In this way, the scalar standard deviation units are
the markings along the ruler. The ruler stretches to different lengths in different
directions to maintain 1 SD as a central 68% confidence interval for normally
distributed data. In the figure below, the distribution is wider than it is high, so the
ruler must stretch in the horizontal direction compared to the vertical direction.
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Figure 6.1: A Sample Distribution with Known Center
2. Rubber rulers can be thought of as being laid from end to end across the
distribution to make the initial measurement to a new sample point (a point not in
the original training set). Imagine laying a blank ruler one SD long across the
data in a line through the center. Then, like a tailor flipping a ruler end-over-end
to measure a bolt of cloth, we can extend that measurement infinitely out into
hyperspace in the direction of each new sample point.
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Figure 6.2: Centering the Rubber Ruler; Flipping the Ruler Out into
Hyperspace
3. The markings on a “rubber ruler” indicate the number of standard deviation units
a new sample point is from center. This is the “ruler” part of the rubber ruler
analogy (with more than 1 SD marked on it).
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Figure 6.3: Determining Standard Deviation Unit Size Along the First Axis
4. The “rubber” part of the analogy is illustrated when you measure in a new
direction. The same Mahalanobis equation can be used then to determine the
standard deviation across any other line passing through the center of the
distribution. Imagine picking up the ruler that you just made and rotating it 90
degrees to find the standard deviation units across the orthogonal direction of the
data cluster. You center the ruler on the center of the cluster, but what do you
find? The ruler is too short to cover the span of the data in this direction! So, you
pinch both ends of the ruler and stretch it out until it extends to both ends of the
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distribution. Now you know the standard deviation units of points along this axis
as well.

Figure 6.4: Stretching the Rubber Ruler to Fit the Second Axis
5. In statistical terms, what this “rubber ruler” means is that SD is not equivalent
along all directions; and to determine the confidence with which a single
datapoint fits a distribution, your statistical test must be able to take into account
the differing variation along any direction in a cluster, a major axis, a minor one,
or a line falling anywhere in between.

10

Figure 6.5: Determining Standard Deviation Unit Size Along the Second
Axis
6. By laying the “rubber ruler” over our cluster, we can see that one unit of spatial
distance can be very big along one axis, while it is not so in another. The
Mahalanobis equation allows us to quantify this change.
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Figure 6.6: The Standard Deviation Unit Size is Reflective of the Spread of
the Data Along Each Axis

Why is the Mahalanobis distance Insufficient?
The Mahalanobis equation is Inaccurate When Handling Asymmetrical and Irregular
Data Clusters
Because the Mahalanobis equation is a rubber ruler whose length is determined by the
span of a data cluster on a line passing through the center, the Mahalanobis equation is
inherently prone to error when asymmetrical or irregular clusters of data are involved.
Consider the following theoretical data clusters:
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Figure 7: Three Asymmetrically-Distributed Data Clusters with Mahalanobis Rubber
Ruler Drawn
Do the proposed rubber rulers really fit? Visually, it is apparent that it is ridiculous to
measure the left and right-hand sides of these distributions with the same units of
standard deviation. All of the pictured distributions have unequal dispersion along the
left-hand or right-hand directional vector. This is where the QBEST is better, as will be
explained later, because QBEST independently determines the right-hand and left-hand
standard deviation units, that is the standard deviations along a line in opposite
directions.
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The Mahalanobis equation is Mathematically Incapable of Calculating Distances For
Datasets with More Variables Than Observations
The Mahalanobis equation involves several matrix math operations that cannot be
performed when there are fewer rows than columns of the matrices. In terms of
pharmaceutical science, the Mahalanobis equation cannot be computed when the
number of observations is less than the number of variables that describe those
observations. Moreover, even when the number of samples exceeds the number of data
observations, as the number of variables approaches the number of samples observed
(the number of rows approaches the number of columns), the Mahalanobis equation
loses accuracy and precision. However, QBEST is able to calculate a distance in SDs
under those conditions with accuracy and precision.
What This Means in a Pharmaceutical Context
This capability of QBEST is particularly important in applications of multivariate data
processing such as the meta-analysis of clinical trials. In such instances, a very few
clinical studies may have been performed (clinical studies are expensive), but each
study collected perhaps 100 endpoints. Even animal studies are very expensive to
perform, both in terms of money and time resources, but human studies are even more
so. As a result, studies tend to be fairly limited in quantity, and the researchers who
have performed them use their subjects to the maximum extent possible. Animal studies
and human subjects trials tend to have a lot of clinical endpoints (variables) monitored
and reported at the end of the study.
Clinical monitoring is a multivariate by nature. All of the many biological factors noted
about an organism are variables that could give some insight into the organisms
well-being or condition. Until now, it has not been possible, mathematically speaking, to
process all of the data provided by handful of clinical studies using a single
comprehensive statistical test. The QBEST is the first statistical method following the
form of the Mahalanobis equation that is able to comprehensively test all data as a single
multivariate data points comparable to other multivariate data point clusters, and is also
able mathematically to process a matrix with a greater number of columns than rows.
In more practical terms, what this means is that QBEST is capable of analyzing, for
instance, six clinical trials that each assayed the same 60 clinical end points. That feat is
mathematically impossible using the Mahalanobis equation.
The Mahalanobis Requires Too Much Computing Power
The Mahalanobis equation is an order of d3 equation, which means that for every d
increase in the number of dimensions or variables describing the data, the equation
takes d3 more computing power to process. QBEST is an order of d equation, which
means that for every d increase in the number of dimensions or variables describing the
data, the equation takes d more computing power to process (a d2 advantage in running
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time) . This allows QBEST to quickly calculate the solution to Big Data problems with
run times that would be prohibitively long for Mahalanobis equation calculation.

What is the Quantile Bootstrap Error Statistical Test in Detail?
The Quantile Bootstrap Error Statistical Test (QBEST) is a novel statistical method for
the determination of the degree of difference between a test point and a training set of
data points.
QBEST functions first by taking bootstrap replicates from a sample of data (called the
training set). Then QBEST determines the center of the training set. QBEST relies on the
Euclidean metric to determine the spatial distance between the two points along a
straight line. (These straight lines are the hyperline between the center of the training set
and each new sample test point, and the hyperline connecting the center of the training
set to each bootstrap replicate point. The word “hyperline” is used because this line
ordinarily exists in a hyperspace of many dimensions.) While it would be ideal to be able
to consider just bootstrap replicate points that fall on this hyperline in making
measurements of standard deviation in that direction, a line is infinitely thin, so the
likelihood that any other given bootstrap replicate point will fall directly upon the
hyperline is incredibly low.
If the hyperline used to measure the distance between the training set center and a test
point is infinitely thin and no bootstrap replicates in the distribution fall on it, how do we
measure the distribution of bootstrap replicate points along that hyperline in the direction
of the new sample point? Instead of using an infinitely thin line, we instead use a
hypercylinder in hyperspace. The radius of the hyper cylinder is increased until at least
50 bootstrap replicate points are captured within it. Replicate points in the direction of
the test point will be engulfed by the growing hypercylinder. The QBEST equation
requires that the user specify a “radfrac” or fraction of the training point spectra that
should be included in this hypercylinder. Basically, the radfrac determines how big the
radius of the hypercylinder should be - fat or thin depending on what proportion of the
points should be included. The computer sets the radius based off of the radfrac input by
the user.

Why is QBEST Superior to the Mahalanobis equation?
The Mahalanobis equation is limited in two very simple but very critical ways. First, the
Mahalanobis equation is incapable of calculating a Mahalanobis distance when the
number of variables comprising the data exceed the number of samples.3 That is to say,
the Mahalanobis equation requires that the number of observations must far exceed the
number of variables of the multivariate data In order to produce results with accuracy
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and precision. Secondly, the Mahalanobis equation is very costly calculation to run in
terms of computation.3 This means that for a given calculation, the Mahalanobis
equation needs significantly more time and computational power than the QBEST does
(more on that later).3

Observations vs. Variables
What This Means for Pharmaceutical Studies
Clinical trials and animal studies are incredibly expensive. This naturally limits the
number of such studies that are conducted and published in the literature. Imagine that a
dozen or so clinical trials are performed for a given therapeutic agent with roughly the
same endpoints being measured. In these studies, blood concentrations of the drug are
measured at many time points. Continuous blood pressure and heart rate monitoring
are performed. Additionally, metabolic panels, lipid panels, and a number of
drug-specific tests are done and the outcomes reported. Remember that continuous
data can be broken down into a series of variables, so that where time is important, each
time point at which blood pressure (for example) was measured becomes an additional
variable. It is reasonable to expect that perhaps one hundred variables are measured in
the course of a single clinical trial.
In this example, it is mathematically impossible to calculate a Mahalanobis distance
using the Mahalanobis equation. There are simply too few clinical trials in relation to the
number of variables measured for each trial. QBEST, however, can handle the given
problem with statistical accuracy and precision.
Computational Cost
The Mahalanobis equation is order of d3 in computational complexity, which is to say that
for every d increase in variables (or dimensions), the computation cost increases by d3.3
In practical application, this causes the computer running the Mahalanobis equation to
very quickly become “bogged down” as more variables are collected.
QBEST is an order of d equation, which means that for every d increase in the number
of dimensions of the data, QBEST requires only d more memory and computational
power to complete the calculation. The same problem that would cause a
supercomputer running the Mahalanobis equation to freeze or take hundreds of years to
run can easily be completed using the QBEST method on a cheap personal laptop
computer.3 QBEST makes advanced computation possible for individuals, researchers,
and small corporations using the most meager of resources; QBEST allows researchers
using advanced supercomputers to attempt multivariate data problems not yet dreamed
of.
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What is the QBEST?
“A Rubber Ruler with a Nail in the Center”
If the Mahalanobis equation is a rubber ruler, then the QBEST equation is a rubber ruler
with a nail in the center. The QBEST ruler can be stretched longer or shorter
independently on opposite sides of a data cluster. In this way, it is capable of
independently calculating different-sized standard deviation units for opposite halves of
an asymmetric data cluster1,3-9.

Figure 8: QBEST is a “Rubber Ruler with a Nail”
Shown in green is the left-hand QBEST rubber ruler with a small standard deviation.
Shown in blue is the right-hand QBEST rubber ruler with a larger standard deviation.
The standard deviation units for each side are calculated independently by QBEST,
which is reflective of the skew of the data.

How Does QBEST Work?
QBEST is a multivariate nonparametric statistical method. First, the original training set
is replicated using a Monte Carlo integration of the bootstrap distribution function. The
replicates allow for the approximation of traditional parametric statistics like bias,
variance, confidence intervals and prediction error.5-9
The QBEST calculates the number of standard deviation units between a test point and
the center of the training set. It does this by calculating the Euclidean distance between
the two points and scaling that distance with the Euclidean distance of one SD of the
training set points. A hypercylinder is used for the selection of comparable training
spectrum points.5-9
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The equation for determining two-dimensional Euclidean distance is defined as the
following:
dist((x,y),(a,b))=

√(x − a)

2

+ (y − b) 2

The equation for determining multidimensional Euclidean distance is defined as follows:
d

D ij2 = ∑ (x vi − x vj ) 2
v=1

What is Discriminant Cluster Analysis?
Simply put, discriminant cluster analysis is the process of determining whether a given
point belongs to one cluster of data points or another.

How Can Discriminant Cluster Analysis be Applied to Drug Development?
Detecting Contamination
Suppose there are two clusters of data, one describing safe dosages of a
pharmaceutical and one describing adulterated drug. Given a new unknown test article,
analysis via QBEST would determine the likelihood that the test point belonged to one
category (safe) or the other (adulterated). This method has been used to differentiate
between the near infrared spectra of pharmaceutical capsules contaminated with
cyanide and normal capsules.4,5

No Observed Adverse Effect Limits
Alternatively, suppose that the two clusters of data represent drug studies done on a
novel pharmaceutical agent. Each point represents one dosage given in a study along
with any number of multivariate factors on different spatial dimensions, including
pharmacokinetic information like Cmax, or a measure of physiological changes induced
by the medication, such as a measure of the increase in heart rate after dosage. One
cluster represents dosages that produced no adverse effects in the patient; the other
represents dosages that caused some adverse effect. From the existing literature
available on this novel therapeutic, we want to determine the maximum “safe” dose of
the agent to aid us in powering our clinical studies. To do this, we would like to
determine the No Observed Adverse Effect Limit (NOAEL). This metric represents the
highest dose of an agent that can be administered to a patient that will cause no adverse
effects. (Any higher dose is likely to cause some negative effect.)
Traditionally, NOAELs and No Observed Effect Levels (NOELs) have been
experimentally determined in a single experiment by administering increasingly high

18

doses of an agent to patients and determining which of the doses was the highest given
that produced no adverse effect. The scientific problems with this methodology are fairly
obvious: it is impossible to determine a NOAEL or NOEL value for any dose other than
an exact dosage that was administered, leaving much room for error because the levels
are usually spaced an order of magnitude or more apart. NOAEL studies cannot be
easily meta-analyzed or pooled, as methodology of the study protocol can greatly
influence the outcome of the study. It is costly to repeat NOAEL studies to increase
precision and requires the use of new human or animal subjects.
Discriminant cluster analysis using QBEST can be used for meta-analysis in place of a
traditional NOAEL study or the Benchmark Dose Method . QBEST provides greater
accuracy and reproducibility than a traditional NOAEL and yields more intuitively
comprehensible results than a BMD (Benchmark Dose) analysis. Furthermore,
performing a discriminant cluster meta-analysis re-utilizes data that has already been
generated and published in the literature and prevents the waste of resources and
research animals in redundant studies. Finally, QBEST can provide an estimate of an
effect level that can be used to power additional preclinical and clinical trials. QNOAEL
and QNOEL determination are described in detail in Chapter 2 and Chapter 4.

What is new about QBEST?
Nonparametric Method
QBEST represents a novel means to analyze data in several ways. First, QBEST is a
nonparametric statistical method, which means that it is capable of treating data that
does not follow a known statistical distribution (such as a normal distribution).
Parametric methods require an assumption that the data follows a certain distribution. If
these assumptions are not met, the results of the analysis are inaccurate and it is
inappropriate to apply the method in question. QBEST is unique in that it makes no
assumptions about the distribution of the data. As such, QBEST can also be applied to
parametric data.
Unique Handling of Skewed Data
QBEST is novel in that it treats opposite sides of a data cluster separately when
determining standard deviation units from center. QBEST does not assume that the leftand right-hand sides of a cluster are equally distributed. This allows QBEST to
accurately determine the significance of the distance of a test point from the center of a
cluster even when the cluster is abnormally-shaped. The most widely used method, the
Mahalanobis method, does not account for skewed clusters. The QBEST distance is
considerably more accurate than the Mahalanobis distance for irregular and skewed
data clusters.
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Discriminant Cluster Analysis Applied Non-Traditionally
Discriminant cluster analysis, the method of determining whether a test point belongs to
one or the other possibly overlapping classified clusters of data points, has never been
applied to the determination of toxicology studies11. This method is primarily used in
analytical chemistry for the classification of substances and the determination of
impurities. The method has been used in other applications, but is not used as widely as
perhaps it should be. Some current applications include analysis in the tourism industry
and data analysis in banking10, 11. Discriminant cluster analysis is an incredibly powerful
statistical technique with many possible applications from business to science to artificial
intelligence and machine learning. The application of discriminant cluster analysis to
toxicology data is a novel aspect of this work that lays the ground for future medical
applications of discriminant cluster analysis.

How do you use QBEST?
The Variables
The Training Set
The training set is the set of data points of known outcomes used to test a new
(unknown) “test point”. Training sets are common in calibrating neural networks, for
example. In a pharmaceutical context, the training sets could be groups of points
representing preclinical or clinical studies of medication that caused no adverse effects
and groups of points representing studies of medication that caused adverse effects. A
test point could be an individual study.
The training points input into the QBEST are critical to obtaining valid results. The old
maxim, "garbage in, garbage out" holds for all training sets, not just QBEST, but the
Mahalanobis equation and neural networks as well. As with all data analysis, first and
foremost it is important that quality data representative of the population are used.
Precautions such as Cochrane Review of data can ensure that appropriate data are
chosen in the first place.
After quality data have been selected, it is the task of the researcher to inspect the data.
The size of the training set and the distribution of training points determine the value of
other parameters that should be set when using the QBEST equation. Guidelines for
setting these parameters can be found in Chapter 4.
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Radfrac
The radfrac is the fraction of bootstrap replicate points used to generate the
hypercylinder. Points within the hypercylinder form the basis of statistical comparison to
the test point.
When is it appropriate to use a large/small radfrac?
Radfrac is important because it determines how bootstrap replicate points are
determined to be relevant to the test point. When the number of bootstrap replicate
points is very large, one can decrease the radfrac because the large number of points
provides more in the hypercylinder, and narrowing the radius of the hypercylinder
increases accuracy in this case for clusters that contain a concavity. Furthermore, when
the cluster is highly irregular, it is important to decrease the radfrac in order to avoid
including points that do not fit a concave surface for that part of the cluster.

Number of Bootstrap Replicates
The number of bootstrap replicate points made for a new training set is important
because having more points increases precision, albeit at a small cost of increased
memory and computation time.

Number of Variables or Dimensions
The number of variables or dimensions of the multivariate data affects the accuracy of
the algorithm. The algorithm is more accurate when largely multivariate data also has a
large training set size.

When Is QBEST Insufficient?
QBEST is meant for the analysis of multivariate data. It can be used effectively for
numerical response variables. QBEST can also theoretically be used to compare ordinal
or binary response variables (given that the variable is assigned a numerical score)
alone or in combination with numerical response variables. However, at present, no
testing has been done on ordinal or binary response data.
As with any meta-analysis method, the accuracy of QBEST is most negatively impacted
when the quality of the training set of data is poor. Increasing the quality of the training
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set and the quantity of the training set observations increases the accuracy and
reproducibility of QBEST. When a very few training set observations are supplied, the
reproducibility of QBEST’s output is decreased. These trends are discussed in detail in
Chapter 5.
As with any other statistical method, the researcher should always visually inspect all
combinations of two variables of the data graphed against one another to ensure that
there are no problems (like nonlinearities) that would complicate discriminant cluster
analysis. QBEST takes into account the typical variation in points. So, for example, for
ultrasonic resonance spectral data that follow a Lissajous function, QBEST may
generate a less accurate probability measurement.
Many irregular clusters can be evaluated with accuracy if the radfrac is set to be
appropriately high or low after the data are inspected. The danger of setting radfrac
without visually inspecting the data on all axes is that too high of a radfrac could include
points that are not indicative of the trend along a given vector, while too low of a radfrac
would exclude points that ought to be included. This principle is especially important for
data clusters that include concavities, which could otherwise be handled poorly by the
algorithm. (See the Conclusion for an explanation of data with concavities.) The
selection of an appropriate radfrac for the shape of an irregular cluster of data very
strongly affects the accuracy of the algorithm and great care should be taken in
assigning this value.
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CHAPTER 2: A NOVEL STATISTICAL APPROACH TO NOAEL: QBEST
APPLIED TO DOSING OF ELLAGIC ACID AND THE QNOAEL VS. BMD FOR
POINT OF DEPARTURE
Purpose: This article describes the research strategy and goals for this thesis. This
chapter was published as “The QNOAEL vs. BMD for Point of Departure” on BioRxiv. It
is the preprint of a later paper, published as “A Novel Statistical Approach to NOAEL:
QBEST Applied to Dosing of Ellagic Acid,” on Webmedcentral.com.

Publication and Copyright Information:
This section was published to Biorxiv.com as follows:
Cynthia Dickerson, Robert A. Lodder. (2018) “The QNOAEL vs. BMD for Point of
Departure.” 24 May 2018, bioRxiv doi: https://doi.org/10.1101/329763
“The copyright holder for this preprint (which was not peer-reviewed) is the
author/funder. It is made available under a CC-BY 4.0 International license.”
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The QNOAEL vs. BMD for Point of Departure
Abstract
Quantile bootstrap (QB) methods can be applied to the problem of estimating the No
Observed Adverse Effect Level (NOAEL) of a New Molecular Entity (NME) to anticipate
a safe starting dose for beginning clinical trials. An estimate of the NOAEL from the
extended QB method (called the QNOAEL) can be calculated using multiple disparate
studies in the literature and/or from laboratory experiments. The QNOAEL is similar in
some ways to the Benchmark Dose (BMD) and is superior to the BMD in others. The
Benchmark Dose method is currently widely used in toxicological research.
Results are used in a simulation based on nonparametric cluster analysis methods to
calculate confidence levels on the difference between the Effect and the No Effect
studies. The QNOAEL simulation generates an intuitive curve that is comparable to the
dose-response curve.
The QNOAEL of ellagic acid (EA) will be calculated for clinical trials of its use as a
component therapeutic agent (in BSN476) for treating Chikungunya infections. This will
be the first application of QB to the problem of NOAEL estimation for a drug. The specific
aims of the proposed study are to evaluate the accuracy and precision of the QB
Simulation and QNOAEL compared to the Benchmark Dose Method, and to calculate
the QNOAEL of EA for BSN476 Drug Development.

Specific Aims
Nonparametric statistics are statistics that are not based on parameterized families of
probability distributions, like the normal distribution. They are important because data
frequently follow a distribution other than a known one, like the normal distribution.
The NOAEL is an important part of the non-clinical risk assessment for new drugs like
BSN476, a drug for treating Chikungunya. The NOAEL is a professional opinion based
on the design of the study, indication of the drug, expected pharmacology, and spectrum
of off-target effects. It is the highest dose at which there was not an observed toxic or
adverse effect11. There are important theoretical limitations to the traditional NOAEL
calculation, which led to the newer Benchmark Dose method, which also has a number
of problems. In brief, the traditional NOAEL is determined by administering a few
different doses of drug to a group of subjects, observing those subjects for physiological
change, and assigning the dosages to the categories of “having an adverse effect” and
“not having an adverse effect”. The highest dosage resulting in no adverse effect is
determined to be the NOAEL.
The NOAEL method is problematic because (1) dose levels are often an order of
magnitude apart, and it is highly unlikely that the exact NOAEL dosage will be
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administered in any particular study; (2) determination of what constitutes an “effect” can
be difficult when negative effects are of a highly subjective nature (for example, when
mood is affected)4. A nonparametric simulation using extended QB (Quantile Bootstrap)
methods can solve the problems associated with the use of the traditional NOAEL or the
Benchmark Dose (BMD) and enable accurate toxicological estimates to be made.

Evaluate the accuracy and precision of the QB Simulation and QNOAEL compared to
the Benchmark Dose Method
Utilizing synthetic data with known characteristics, the BMD and QNOAEL will be
calculated. The QNOAEL will then be compared to the BMD to determine which is
closest to be known answer for the synthetic data.

Calculate the QNOAEL of Ellagic Acid for BSN476 Drug Development
Chikungunya is a rapidly spreading mosquito-borne disease that now infects over 3
million people worldwide12. BSN476, a drug for treating chikungunya infections, contains
in part EA. QB will estimate a safe level of EA for the first-in-human study in order to
develop a treatment for Chikungunya. An EA toxicity meta-analysis using food
consumption will be completed as part of the Investigational New Drug (IND) application
to the FDA. Studies will be selected from the literature and analyzed according to the
Cochrane protocols, and the QNOAEL of EA will be calculated along with the NOAEL
and BMD. These results will serve as the basis for the first-in-human study of EA.

Strategy
Significance
Method Significance
The NOAEL depends strongly on the dose selection, dose spacing, and sample size of a
single study from which the critical effect has been identified. The primary goal of BMD
modeling is to define a point of departure that is largely independent of study design. But
while the BMD effectively enables multiple studies to be pooled to increase accuracy, it
does not handle studies with conflicting results gracefully, as will be seen below3.

25

Table 1: Advantages and Disadvantages of the NOAEL, BMD, and QNOAEL
NOAEL

Benchmark Dose

QNOAEL

Advantages

● Very simple, early
method of deriving
a POD that has
been utilized for
years
● Defined as the
highest dose which
generates no effect
in the studied
population
● Can be used
when data will not
work with BMD
mode

● Calculation is not
limited to specific
experimental
doses, but can
calculate a BMD
within the tested
range
● Multiple studies
may be pooled to
increase accuracy
● Allows for
weighting of results
based on study
quality
● Accounts for
dose-response
curve and
pharmacokinetic
modeling
● Benchmark Dose
is defined as the
dose which
generates a
specific benchmark
effect

The advantages of
BMD, plus:
● Calculates
statistical measures
of certainty to
gracefully handle
conflicting input
study results
● Generates an
intuitive correlation
vs. dose curve that
shows the
statistical likelihood
of effect at a given
dose
● Able to account
for publication bias
in the literature
● Bootstrapping
algorithm is robust
and nonparametric
(and thus able to
solve problems in
which the
underlying
distribution is
unknown )
● Can extrapolate
to lower doses than
dosing range
studied/reported in
the literature.
● Computed
quickly(an order of
n1 algorithm)

Limitations

● Limited to doses
studied/reported in
the literature
● Lowest Observed
Average Effect
Level (LOAEL)

● More complicated
and
time-consuming
process than
simple NOAEL
● Limited strongly

● More complicated
and
time-consuming
process than
simple NOAEL
● Limited

26

Table 1 Continued
cannot be used to
generate NOAEL
● Not designed for
pooling of multiple
studies
● Does not take
into account the
statistical likelihood
of effect across a
large population
● Does not
represent the
population as a
whole; is limited to
the population
studied

by the quality of
information and the
inclusion criteria
chosen by the
researcher
● Unable to
account well for
conflicting study
results
● Generates a
non-intuitive mean
response x dose
line which is
ambiguous for
doses which
sometimes cause
an effect, or which
cause an effect in a
certain percentage
of the population
● Results do not
well indicate the
response of a large
population to a drug
● Parametric test.
● “Effect” vs. “No
Effect” classification
can be difficult
when studies
examined different
endpoints; ex:
effect on heart rate
vs. mood alteration

somewhat by the
quality of
information and the
study inclusion
criteria chosen by
the researcher

The BMDL (the statistical lower confidence limit on the benchmark dose, or BMD) is
used as the point of departure (POD) for most non-cancer and cancer risk estimates
derived by the U.S. EPA. The initial step in the risk assessment process is hazard
identification, which is defined as the identification of effects on health noted as the result
of exposure to a specified chemical. Hazard identification is followed by determination of
the critical effect on which to construct NOAELs (No Adverse Effect Levels) or BMDs
and BMDLs.
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Both the NOAEL and BMD approach require some common considerations of the
general quality of a particular study. A few of these considerations include:
a. Sample Size. Were the sample sizes used large enough to properly detect treatment
effects?
b. Exposure. Were the exposure durations adequate? Were relevant routes of exposure
employed in the study?
c. Endpoints. Did the study measure endpoints of interest?
d. Quality. Did the study employ standard quality control procedures like good laboratory
practice (GLP)?
In addition to these common data quality considerations that affect both the NOAEL and
BMD estimates, there are added BMD-specific points to consider in the identification of
datasets that are appropriate for BMD modeling. For example, when sample size
decreases, which results in decreased power to detect treatment effects, the NOAEL
procedure produces POD estimates while the BMD approach produces lower (extra
precautionary) PODs. To maintain consistency and reproducibility, most scientists
employ a six-step process for BMD analysis. The six steps involved in the BMD analysis
are (1) choice of a BMR, (2) selecting a set of models, (3) assessing model fit, (4) model
selection when BMDLs are divergent, (5) model selection when BMDLs are not
divergent, and (6) data reporting.
The new QB nonparametric meta-analysis of multiple studies so far appears to be
superior to BMD modeling. Unlike BMD, the QNOAEL estimate is not limited by the
format of the data presented. The QNOAEL is no more time-consuming to calculate than
the BMD, and provides a simpler decision-making process. For example, the graphs
below show the BMD and QB simulations for THC in hemp seed. Note that the same
clinical studies were used for both analyses. QB not only more clearly demonstrates the
trend of data, but also produces a correlation curve which is intuitively noncontradictory.
(It is to be expected that different studies may reach contradictory results on the effects
of a given dosage, as study methods and populations vary.)
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Figure 9: Linear BMD Model for THC in Hemp Seed
The BMD method attempts to fit a model to studies at different THC doses (green
circles) that sometimes show an effect, and sometimes do not. This fitting process can
seem to make little sense considering the data. Note that two different studies at 10
mg THC show opposite effects. (Dosages falling on the 0 line of “Mean Response” are
no-effect dosages in this figure.)
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Figure 10: THC Doses Showing Effect or No Effect Graphed in Multivariate
Space
On the other hand, in multivariate space the doses show no discontinuities. Red
circles are test set study results (showed effect on heart rate HR and blood pressure
BP). Blue squares are training set study results (no effect on HR or BP, sometimes an
effect on Cmax). Orange circles are test set after recentering on the training set.

30

Figure 11: Determining 98% Confidence Levels
In the new nonparametric method, 98% confidence limits are set on the No Effect Set
(or Training Set) by correlating integrals of bootstrap replicates of the training set with
themselves. The simulation then projects the Effect Set (or Test Set) into the same
space as the No Effect Set, and then translates the Effect Set toward/away from the
center of the No Effect Set to determine when the correlations between the No Effect
and Effect replicate integrals become significantly different.
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Figure 12: Determining the QNOEL of THC
The gradual approach of the line to the 98% confidence limit reveals that the scale of
the test set is larger than the scale of the training set. The horizontal blue line
represents the 98% confidence limit on the training set (the no effect on HR/BP set).
The 98% confidence limit on the training set was 9.1 mg orally (which is the NOEL for
heart rate) with a Cmax = 2.8 ng/ml.

Application Significance
Chikungunya is a rapidly spreading mosquito-borne disease that now infects over 3
million people worldwide12. The disease originated in Africa around 1700 A.D., and until
recent years, reported infections were limited to the African continent and Southeast
Asia1. The disease was first identified in 1952 during an outbreak so serious that
infections were clinically indistinguishable from dengue fever19. Throughout the 1960s
and 1970’s, outbreaks were reported in Southeast Asia19. After decades without another
Southeast Asian outbreak, a 1999 outbreak in Indonesia led to a massive outbreak
reported in India in 2006, the strain responsible for this resurgence bearing 99%
similarity to the strain responsible for a 1989 outbreak in Uganda3,19. In December, 2013,
the disease made its debut in the Americas, with its first local transmission occurring on
the island of St. Martin; local transmission in French Guiana on the South American
continent occurred later that month15,17,18. After only two years, local transmission had
been documented in 19 Caribbean countries, including Puerto Rico, as well as in nearly
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every country on the South American continent15-18. The WHO has currently issued a
level-1 watch for travelers visiting South America and the Caribbean and expects
Chikungunya to spread15,18.
BSN476 contains in part EA. EA is a polyphenolic compound with antiproliferative and
antiviral properties6. EA at 10 uM produces 99.6% inhibition of Chikungunya virus in
vitro6. EA is found in a number of plant extracts, usually in the form of hydrolyzable
ellagitannins which are complex esters of EA with glucose5,14. Ellagitannins are broken
down in the intestine to eventually release EA5,14. To develop BSN476 as a treatment for
Chikungunya, the PK of the drug must be studied in a first-in-human (FIH) trial, and a
safe range of exposure must be determined for that trial.

Figure 13: Map of Chikungunya Outbreaks
Yellow dots mark the locations of chikungunya outbreaks, while the green areas mark
the ranges of the mosquitoes able to propagate the outbreaks. This map was shows
data only from June, 2015 and earlier.12

QB is applied within the Cochrane framework for meta-analysis (the Cochrane
framework provides a “Garbage-In-Garbage-Out” standard for data inputs - generally
clinical studies) to determine doses for the first in human study2. The QNOAEL of EA will
be estimated from previously published food consumption studies. Bootstrap replication
and manipulation of data clusters will reveal the QNOAEL of EA with 98% confidence.
This project will use the QNOAEL to estimate a safe range of exposure to EA for the FIH
study on the way to developing a treatment for Chikungunya. QB is a robust O(n)
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algorithm that is designed for massively parallel computers, and is a very powerful
meta-analysis tool (most algorithms use matrix factorization and are O(n3) in execution
time). The QB algorithm will be translated from MATLAB into Python to make it more
accessible to the scientific community. Very large sample datasets will be used to test
the memory usage and reproducibility of the results of the algorithm, as well as minimum
parameters for its usage. These data have permitted estimation of the maximum
analysis capability of cloud computing services and the National Science Foundation
XSEDE supercomputer (Comet).

Innovation
This proposed study utilizes a Quantile Bootstrap statistical method designed for Big
Data problems, SOB, inside a new simulation to estimate the QNOAEL for a drug with
98% confidence from a set of small studies7-10. SOB is a form of cluster analysis, which
is a common analytical technique for determining chemical identity and purity7-10. So far,
the QNOAEL appears to be superior to the NOAEL and the BMD.

Figure 14: QBEST Distance to a Test Point for Various Clusters
Distances in BEST SDs depend not only on the direction in space, but also on the
cluster selected to develop the metric.
QB is applied within the Cochrane framework for meta-analysis. QB works by analyzing
clusters of studies that found an effect, and clusters of studies that found no effect (the
studies can use different dose levels). By analyzing the quantiles of each cluster and
adjusting for cluster skew, QB can measure the distance between clusters in probability
space, until it finds the dose that yields no adverse effects for the entire human
population at a specified level of statistical significance (see Figure 21, 98% level set by
default).
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Approach

Figure 15: The V-model for the Systems Engineering Process13
This is a software development project undertaken as part of a larger drug development
project. Good Engineering Practice, Standard Operating Procedures (SOPs) and
working practice guidelines have been implemented for project design as well as
execution (see Figure 22). A robust change control system must be implemented in this
project.
The Design SOPs and Configuration Management system will be applied to the system
designed to resolve each specific aim in this project. Each specific aim will begin with a
Needs Analysis to determine what the new system needs to be able to do. A
requirements analysis will also be conducted to determine what is required to fill those
needs. A System Requirements Review (SRR) will demonstrate understanding of the
requirements documents (scope, specifications, schedule, validation plans, and budget).
SRR will determine the initial design direction and describe preliminary data and
progress, and how these will converge to an optimum and complete system
configuration for the specific aim. The memory needed to run QB on large datasets and
evaluate the performance of the algorithm must be quantified. (Very large sample
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datasets to test the memory usage and reproducibility of the results of the QB algorithm
are being created, as well as to set ranges of parameters for its usage. Parameters
include the number of bootstrap replications desired (b), the number of variables in the
multivariate analysis (d), and the size of the dataset used (n). Preliminary data indicate
that the typical laptop computer can process over one million bootstrap replication
samples, independent variables, or sample data points when the other two parameters
are minimized, or over one-thousand bootstrap replications, variables, and data points
[all maximized at approximately 1000 inputs]).
As the system evolves through the development process, topic experts will be invited to
later design reviews (especially CDR, TRR, and MRR). System Design Review (SDR)
acts as a control gate that reviews and approves the top-level system design solution
and rationale13. It is the decision point to proceed with system specification flow down to
individual physical and process configuration items13. System limitations will be refined at
SDR.
Using the run-time and memory usage data determined in Specific Aim 1, the
performance capabilities of the algorithm on an NSF supercomputer (XSEDE Comet) will
be calculated. QB is capable of tackling immensely large datasets, and the computing
capabilities of the algorithm will be stretched on a massively parallel machine to
demonstrate proof-of-concept. An SDR report will be added to the Design History file for
FDA.
A Preliminary Design Review (PDR) will be performed on each configuration item or
group of configuration items to: (1) Evaluate the progress, technical acceptability, and
risk resolution, (2) Measure its harmony with performance and engineering specialty
requirements of the Configuration Item development specification, (3) Evaluate the
extent of definition and evaluate the technical risk connected with the selected
methods/processes, and (4) Demonstrate the existence and compatibility of the physical
and functional interfaces among the configuration item and other items of equipment,
facilities, computer software, and personnel13. Topic experts will also be invited to the
review. A Blue team and a Red team are used for design and validation, respectively. A
PDR report will be added to the Design History file for FDA in the annual reporting
system.
Critical Design Review (CDR) is the last design review conducted before an action is
taken that is irreversible. (1) CDR is a review to establish that detail design of the
configuration item under review meets cost, schedule, and performance requirements.
(2) CDR will establish detail design compatibility among the configuration item and other
items of equipment, facilities, computer software and personnel. (3) CDR will gauge
configuration item risk areas (on a technical performance, cost, and schedule basis).
Topic experts will again be invited to the review. A Blue team and a Red team are used
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for design and validation, respectively. A CDR report will be added to the Design History
file for FDA in the annual reporting system.
Deployment Readiness Review (DRR) is held to confirm readiness for deployment. This
review is conducted to ensure that all deficiencies are corrected before actual use. The
complete system is challenged every feasible way (conceptually, physically, cyber-, etc.).
The DRR demands the review and analysis of all subsystem/unit level testing preceding
the formal acceptance tests. Topic experts will be invited to the review. A Blue team and
a Red team are used for design and validation, respectively. A DRR report will be added
to the Design History file for FDA.
The QB algorithm will be translated into Python to make it more accessible to the
scientific community. Once QB is available in Python it will run on Amazon Web
Services, Microsoft Azure, and Google Compute Engine as well as the NSF XSEDE
Comet supercomputer currently being used. The REPLICA algorithm has already been
translated from Matlab into Python to make it more accessible to the scientific
community. However, the algorithm on which QB relies has yet to be translated and the
entirety of the program remains to be validated.
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CHAPTER 3: ESTABLISHING EDI FOR A CLINICAL TRIAL OF A
TREATMENT FOR CHIKUNGUNYA

Purpose: Establishing the EDI of ellagic acid will assist in the determination of a safe
starting dose of ellagic acid for clinical trials in BSN476.

Publication and Copyright Information:
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38

Establishing EDI for a Clinical Trial of a Treatment for Chikungunya
Abstract
Ellagic acid (EA) is a polyphenolic compound with antiviral activity against chikungunya,
a rapidly spreading new tropical disease transmitted to humans by mosquitoes and now
affecting millions worldwide. The most common symptoms of chikungunya virus infection
are fever and joint pain. Other manifestations of infection can include encephalitis and an
arthritic joint swelling with pain that may persist for months or years after the initial
infection. The disease has recently spread to the U.S.A., with locally-transmitted cases
of chikungunya virus reported in Florida. There is no approved vaccine to prevent or
medicine to treat chikungunya virus infections. In this study, the Estimated Daily Intake
(EDI) of EA from the food supply established using the National Health and Nutrition
Examination Survey (NHANES) is used to set a maximum dose of an EA formulation for
a high priority clinical trial.
Keywords: Tropical disease NHANES Drug development

1 Introduction
1.1 Compound
Ellagic acid (EA) is a polyphenolic compound with health benefits including antioxidant,
anti-inflammatory, anti-proliferative, athero-protective, anti-hepatotoxic and anti-viral
properties1,2. EA is found in many plant extracts, fruits and nuts, usually in the form of
hydrolyzable ellagitannins that are complex esters of EA with glucose. Natural sources
high in ellagitannins include a variety of plant extracts including green tea, nuts such as
walnuts, pecans and almonds, and fruits, particularly berries, such as blackberries,
raspberries and strawberries, as well as grapes and pomegranates.
1.2 Chikungunya
Chikungunya virus is transmitted to humans by mosquitoes. Typical symptoms of
chikungunya virus infection are fever and joint pain. Other manifestations may include
headache, encephalitis, muscle pain, rash, and an arthritis-like joint swelling with pain
that may persist for months or years after the initial infection. The word ‘chikungunya’ is
thought to be derived from its description in the Makonde language, meaning “that which
bends up” the deformed posture of people with the severe joint pain and arthritic
symptoms associated with this disease3. There is no vaccine to prevent or medicine to
treat chikungunya
virus infections.
Millions of people worldwide suffer from chikungunya infections. The disease spreads
quickly once it is established in an area. Outbreaks of chikungunya have occurred in
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countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. Before 2006,
chikungunya virus disease was only rarely pinpointed in U.S. travelers. In 2006–2013,
studies found a mean of 28 people per year in the United States with positive tests for
recent chikungunya infection. All of these people were travelers visiting or returning to
the United States from affected areas in Asia, Africa, or the Indian Ocean.
In late 2013, the first local transmission of chikungunya virus in the Americas was
identified on the island of St. Martin, and since then all of the other Caribbean countries
and territories. (Local transmission means that mosquitoes in the area have been
infected with the virus and are spreading it to people.)
Beginning in 2014, chikungunya virus disease cases were reported among U.S. travelers
returning from affected areas in the Americas and local transmission was identified in
Florida, Puerto Rico, and the U.S. Virgin Islands. In 2014, there were 11
locally-transmitted cases of chikungunya virus in the U.S. All were reported in Florida.
There were 2,781 travel-associated cases reported in the U.S. The first locally acquired
cases of chikungunya were reported in Florida on July 17, 2014. These cases represent
the first time that mosquitoes in the continental United States are thought to have spread
the virus to non-travelers. Unfortunately, this new disease seems certain to spread
quickly. Data Driven Computational Science (DDCS) offers ways to accelerate drug
development in response to the spread of this disease.
EA has been shown to be an inhibitor of chikungunya virus replication in high throughput
screening of small molecules for chikungunya4. In screening a natural products library of
502 compounds from Enzo Life Sciences, EA at 10 μM produced 99.6% inhibition of
chikungunya in an in vitro assay.

1.3 Metabolism
Ellagitannins are broken down in the intestine to eventually release EA. The
bioavailability of ellagitannins and EA have been shown to be low in both humans and in
animal models, likely because the compounds are hydrophobic and they because are
metabolized by gut microorganisms5-8. The amount of ellagitannins and EA reaching the
systemic circulation and peripheral tissues after ingestion is small to none7. It is
established that ellagitannins are not absorbed while there is high variability in EA and
EA metabolites found in human plasma after ingestion of standardized amounts of
ellagitannins and EA9-11. These studies indicate that small amounts of EA are absorbed
and detectable in plasma with a Cmax of approximately 100 nM (using standardized
doses) and a Tmax of 1 h9, 10. EA is metabolized to glucuronides and methyl-glucuronide
derivatives in the plasma. The most common metabolite found in urine and plasma is EA
dimethyl ether glucuronide12.
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It appears that the majority of ingested ellagitannins and EA are metabolized by the gut
microbiota into a variety of urolithins. Urolithins are dibenzopyran-6-one derivatives that
are produced from EA through the loss of one of the two lactones present in EA and then
by successive removal of hydroxyl groups. Urolithin D is produced first, followed
sequentially by urolithin C, urolithin A, and urolithin B. Urolithins appear in the circulatory
system almost exclusively as glucuronide, sulfate and methylated forms as a result of
phase II metabolism after absorption in the colon and passage through the liver13. While
the amount of EA in the circulation is in the nanomolar range, urolithins and their
glucuronide and sulfate conjugates circulate at concentrations in the range of 0.2–20
lM14. In light of the much larger concentrations of urolithins in the circulation compared to
EA, it is must be considered that the reported in vivo health effects of ellagitannin and
EA may be largely due to the gut-produced urolithins. Growing evidence, mostly in vitro,
supports the idea that urolithins have many of the same effects as EA in vitro. Various
studies have shown evidence of anti-inflammatory15-17, anticarcinogenic18-21,
anti-glycative22, possibly antioxidant6, 23, and antimicrobial24 effects of urolithins.
There is variation in how people metabolize EA into the various urolithins25-27. This is not
surprising in light of the known differences between individuals in intestinal microbiotic
composition. Tomás-Barberán26 evaluated the urinary urolithin profiles of healthy
volunteers after consuming walnuts and pomegranate extracts. They found that,
consistent with previous findings, that urolithin A was the main metabolite produced in
humans. However, they noted that the subjects could be divided into three groups based
on their urinary profiles of urolithins. One group excreted only urolithin A metabolites
while a second group excreted urolithin A and isourolithin A in addition to urolithin B. The
third group had undetectable levels of urolithins in their urine. These results suggest that
people will benefit differently from eating ellagitannin rich foods.

1.4 Use of EDI
Knowledge of the Estimated Daily Intake (EDI) can permit pharmacokinetic and
formulation studies to be conducted without prior expensive and time-consuming
toxicology studies, especially when the molecule is naturally present in the food supply
(see Figure 16). A subject’s dietary level of the compound would normally vary around
the EDI. A subject is brought in to the drug evaluation unit, and after the usual ICH E6
procedures and informed consent, is “washed out” of any of the compound might be
present from previous food consumption. Typically, washout is accomplished by
maintaining the subject on a diet containing none of the compound to be investigated
for a period of five or more half-lives. The subject then receives a dose of the compound
and blood samples are collected for pharmacokinetic or other analysis. The
concentration of the dose is calculated to keep the subject’s exposure below the EDI.
For this reason, it is important to establish the EDI before the clinical trial is designed
and executed. After sufficient samples have been collected, the subject is released and
the trial is complete for that subject. The subject then returns to a normal diet and levels
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increase again to levels similar to those before the study.

Figure 16: A Pharmacokinetic Study Can be Conducted Below the EDI of EA

2 Assessment of EA Use
An assessment of the consumption of EA (EA) by the U.S. population resulting from
the approved uses of EA was conducted. Estimates for the intake of EA were based on
the approved food uses and maximum use level in conjunction with food consumption
data included in the National Center for Health Statistics’ (NCHS) 2009–2010, 2011–
2012, and 2013–2014 National Health and Nutrition Examination Surveys (NHANES)
[27–29]. Calculations for the mean and 90th percentile intakes were performed for
representative approved food uses of EA combined. The intakes were reported for these
seven population groups:
1. infants, age 0 to 1 year
2. toddlers, age 1 to 2 years
3. children, ages 2 to 5 years
4. children, ages 6 to 12 years
5. teenagers, ages 13 to 19 years
6. adults, ages 20 years and up
7. total population (all age groups combined, excluding ages 0–2 years).
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3 Food Consumption Survey Data
3.1 Survey Description
The most recent National Health and Nutrition Examination Surveys (NHANES) for
the years 2013–2014 are available for public use. NHANES are conducted as a
continuous, annual survey, and are released in 2-year cycles. In each cycle,
approximately 10,000 people across the U.S. complete the health examination
component of the survey. Any combination of consecutive years of data collection is a
nationally representative sample of the U.S. population. It is well established that the
length of a dietary survey affects the estimated consumption of individual users and that
short-term surveys, such as the typical 1-day dietary survey, overestimate consumption
over longer time periods31. Because two 24-h dietary recalls administered on 2
non-consecutive days (Day 1 and Day 2) are available from the NHANES 2003–2004
and 2013–2014 surveys, these data were used to generate estimates for the current
intake analysis.
The NHANES provide the most appropriate data for evaluating food-use and
food-consumption patterns in the United States, containing 2 years of data on individuals
selected via stratified multistage probability sample of civilian
non-institutionalized population of the U.S. NHANES survey data were collected from
individuals and households via 24-h dietary recalls administered on 2 non-consecutive
days (Day 1 and Day 2) throughout all 4 seasons of the year. Day 1 data were collected
in-person in the Mobile Examination Center (MEC), and Day 2 data were collected by
telephone in the following 3 to 10 days, on different days of the week, to achieve the
desired degree of statistical independence. The data were collected by first selecting
Primary Sampling Units (PSUs), which were counties throughout the U.S. Small
counties were combined to attain a minimum population size. These PSUs were
segmented and households were chosen within each segment. One or more participants
within a household were interviewed. Fifteen PSUs are visited each year. For example,
in the 2009–2010 NHANES, there were 13,272 persons selected; of these 10,253 were
considered respondents to the MEC examination and data collection. 9754 of the MEC
respondents provided complete dietary intakes for Day 1 and of those providing the
Day 1 data, 8,405 provided complete dietary intakes for Day 2. The release data does
not necessarily include all the questions asked in a section. Data items may have been
removed due to confidentiality, quality, or other considerations. For this reason, it is
possible that a dataset does not completely match all the questions asked in a
questionnaire section. Each data file has been edited to include only those sample
persons eligible for that particular section or component, so the numbers vary.
In addition to collecting information on the types and quantities of foods being
consumed, the NHANES surveys collected socioeconomic, physiological, and
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demographic information from individual participants in the survey, such as sex, age,
height and weight, and other variables useful in characterizing consumption. The
inclusion of this information allows for further assessment of food intake based on
consumption by specific population groups of interest within the total population.
Sample weights were incorporated with NHANES surveys to compensate for the
potential under-representation of intakes from specific population groups as a result of
sample variability due to survey design, differential non-response rates, or other factors,
such as deficiencies in the sampling frame29, 30.

3.2 Methods
Consumption data from individual dietary records, detailing food items ingested by each
survey participant, were collated by computer in Matlab and used to generate estimates
for the intake of EA by the U.S. population. Estimates for the daily intake of EA represent
projected 2-day averages for each individual from Day 1 and Day 2 of NHANES data;
these average amounts comprised the distribution from which mean and percentile
intake estimates were produced. Mean and percentile estimates were generated
incorporating sample weights in order to provide representative intakes for the entire
U.S. population. “All-user” intake refers to the estimated intake of EA by those individuals
consuming food products containing EA. Individuals were considered users if they
consumed 1 or more food products containing EA on either Day 1 or Day 2 of the survey.

3.3 Food Data
Food codes representative of each approved use were chosen from the Food and
Nutrition Database for Dietary Studies (FNDDS) for the corresponding biennial NHANES
survey. In FNDDS, the primary (usually generic) description of a given food is assigned a
unique 8-digit food code29, 30.

3.4 Food Survey Results
The estimated “all-user” total intakes of EA from all approved food uses of EA in the U.S.
by population group is summarized in Figures 17, 18, 19 and 20.
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Figure 17: Ellagic Acid Mean EDI
Children consume more EA on average than adults. Baby foods are often made from
ingredients high in EA. The blue line shows data from the 2009–2010 NHANES, the
red line data from the 2011–2012 NHANES, and the green line data from the
2013–2014 NHANES.
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Figure 18: Ellagic Acid 90th %-tile EDI
Teenagers contribute the highest peak in the 90th percentile consumers of EA. The
blue line shows data from the 2009–2010 NHANES, the red line data from the
2011–2012 NHANES, and the green line data from the 2013–2014 NHANES.
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Figure 19: Ellagic Acid Mean Weight-Based EDI When EA exposure is calculated
on a per kilogram of body weight basis, toddlers aged 1 to 2 years are exposed to the
most EA on average. The blue line shows data from the 2009–2010 NHANES, the red
line data from the 2011–2012 NHANES, and the green line data from the 2013–2014
NHANES.
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Figure 20: Ellagic Acid 90th %-tile Weight-Based EDI
When EA exposure is calculated on a per kilogram of body weight basis for the 90th
percentile consumers, toddlers aged 1 to 2 years are again exposed to the most EA.
The blue line shows data from the 2009–2010 NHANES, the red line data from the
2011–2012 NHANES, and the green line data from the 2013–2014 NHANES.
The estimated “all-user” total intakes of EA from all approved food uses of EA in the U.S.
by population group are graphed using NHANES data in Figs. 17, 18, 19 and 20 for
2009–2010, 2011–2012, and 2013–2014. The figures show that over 6 years, the
consumption of EA has been fairly constant and that children and teenagers are the
major consumers.

4 Conclusions
In summary, 28.3% of the total U.S. population of 2+ years was identified as consumers
of EA from the approved food uses in the 2013–2014 survey. The mean intakes of EA by
all EA consumers age 2+ (“all-user”) from all approved food uses were estimated to be
69.58 μg/person/day or 1.05 μg/kg body weight/day. The heavy consumer (90th
percentile all-user) intakes of EA from all approved food-uses were estimated to be
258.33 μg/person/day or 3.89 μg/kg body weight/day. The EDI (red line in Figure 16) is
set at 70 μg/person/day from the 2013-2014 NHANES for consumers ages 2 and up.
The next experiment will be an actual trial of EA in human subjects at the EDI with a
dose of 3.89 μg/kg body weight/day (see Figure 16), as determined by this DDCS study.
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CHAPTER 4: CALCULATING THE ACCEPTABLE DAILY INTAKE OR NOAEL
WITH QBEST (QNOAEL)
Purpose: The acceptable daily intake (QNOAEL) of ellagic acid is calculated using an
analysis of animal studies. This is proof-of-concept that QBEST can be used to
generate NOAELs and NOELs in a novel fashion.
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Calculating the Acceptable Daily Intake or NOEL with QBEST (QNOEL)

Introduction:
Current Best Practice
Before a novel therapeutic agent can progress from animal studies to first-in-human
studies, the FDA requires evidence that the investigational new drug will be safe for
human use. Determining the No Observed Adverse Effect Limit (NOAEL), or the highest
dose of a drug that can be administered to an animal without producing any undesirable
effects, is important in this process because it places an upper bound on the dosage that
should be administered to a human. In general, the maximum dose administered to
humans is limited even further as a precaution in case the drug has unexpectedly
greater toxicity in humans than in the animal model.
Traditionally, NOAELs have been determined by administering increasingly large doses
of a drug compound to animal subjects until adverse effects become apparent. The
highest dose administered during the course of the study that did not produce any
adverse effect is designated the NOAEL. There are problems with this method, namely
that the NOAEL must be determined to be a dose that was administered in the study,
and often only 3 or 4 doses, spaced an order of magnitude or more apart, are used
because of cost. For this reason, the NOAEL determined through traditional means often
does not capture the true population NOAEL well. Traditional NOAEL determinations
can be confounded in other ways, as well, and it is difficult to meta-analyze and pool
NOAEL studies. This can lead to NOAEL determinations that are influenced strongly by
sampling.
The Benchmark Dose Method is another way of estimating toxicity. The benchmark
dose is defined as the statistically calculated lower 95 % confidence limit on the dose
that produces a defined response (called the benchmark response or BMR, usually 5 %
or 10 %) of an adverse effect compared to background, often defined as 0 % or 5 %.
The benchmark dose describes a quantity that is in some ways very different from a
NOAEL; the benchmark dose is an estimate of the quantity of therapeutic agent that will
cause an adverse reaction, whereas NOAEL indicates the highest dose that is
completely tolerable. The benchmark dose (BMD) can be calculated from a series of
separate studies, unlike to NOAEL. However, the BMD can be confounded by conflicting
studies. In any given population, it is expected that there will be some variation in
response. When calculated with conflicting studies shown later in this dissertation, some
of which found an effect to occur at a given dose while some found no effect at the same
given dose, the Benchmark Dose Method generates a mean dose-response line through
studies with opposite conclusions. Though the Benchmark Dose Method is in many
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ways superior to the traditional determination of NOAEL, as it is able to meta-analyze
multiple toxicity studies and can generate a BMD that was not a dose directly
administered in a study, it is still not an ideal method.

Discriminant Cluster Analysis and QNOAEL
Discriminant cluster analysis is a method commonly utilized in chemometrics and
analytical chemistry for determining whether a given sample belongs in the same class
as a set of training samples. The QBEST equation is an application of this method to
estimation of NOAELs.
At present, the Mahalanobis distance is the more commonly used metric for statistical
multivariate discriminant cluster analysis. Though the premise of the Mahalanobis
equation is basically the same as that of QBEST, the Mahalanobis is limited by a crucial
requirement: In order to calculate a Mahalanobis distance, the algorithm requires that
significantly more data points be included in the analysis than variables that describe
those data points. In terms of meta-analysis of drug development data, this means that
in order to use the Mahalanobis equation, one would need to have significantly more
clinical trials or animal studies than clinical parameters measured in those studies.
Clinical trials and animal studies are very expensive, and generate vast amounts of data.
This means that while there may be a dozen or so relevant clinical studies for a given
drug in the literature (which form rows in a matrix), perhaps upwards of a hundred
separate measurements will have been collected for each patient (columns in the
matrix). Moreover, the change in many biological parameters may be recorded over
time. It is mathematically impossible to calculate a Mahalanobis distance using all of the
parameters of the studies given so very few studies - the number of rows of the matrix
must exceed the number of columns. This problem is a result of the matrix inversion /
factorization method by which Mahalanobis distances are calculated.
QBEST is ideal for these circumstances, and can be applied to generate a QNOAEL
which is in many ways superior to the traditional NOAEL or BMD. The method of
calculation differs from the Mahalanobis equation, and in consequence the number of
studies can be very low in comparison to the number of variables and the equation still
maintains mathematical accuracy and precision. QBEST is able to maximally utilize the
vast amounts of data generated by clinical studies. Meta-analyzing with QBEST can
reduce the need to repeat costly clinical studies, as often occurs with traditional NOAEL
determination. Like the Benchmark Dose Method, QBEST is capable of calculating a
safety limit other than a dose that was administered. Unlike the Benchmark Dose
Method, however, QBEST generates a QNOAEL that represents the dose which at a
given confidence level will produce no effect in the population. QBEST handles
conflicting studies in a more intuitively acceptable way than the Benchmark Dose Model,
which will be seen below. Unlike the Benchmark Dose Method, the QBEST is a
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nonparametric statistical test and can be more accurately applied when parametric
assumptions (such as assumptions of normality) are not met.

Ellagic Acid
Ellagic acid (EA) is a naturally-occurring polyphenol with strong antiviral,
anti-inflammatory, and anti-cancer properties. EA has been shown to significantly
reduce growth rate and multiplicity of tumors in animals with various cancers. It also
affects the clotting of blood and the lipid profile of animals with diabetes or models of
heart disease. EA has been reported numerous times to have an attenuating effect on
physiological changes induced by various chronic disease states. EA is also the
principal component of an investigational new drug, BSN476, which will be moved into
clinical trials as a treatment for Chikungunya. Toxicology tests must be conducted in at
least one rodent and one nonrodent species prior to human exposure. (Often rats and
beagles are used. Rats are usually the first species, and the rat results help select the
range of doses for the beagle studies. The rodent and nonrodent results, in turn, help to
select the range of doses for first-in-human studies.) Currently, no NOAEL or NOEL has
been published in the literature for human consumption of EA, nor has a Generally
Recognized as Safe (GRAS) memorandum from the US FDA been made publicly
available. Tasaki et al estimated the no-observed-effect level (NOEL) to be 3011 mg/kg
b.w./day for male F344 rats and the NOAEL and NOEL in females were to be 3254
mg/kg b.w./day and <778 mg/kg b.w./day, respectively20. This determination was made
on the clinical endpoint of body weight gain suppression20. Tasaki et al. also measured
alkaline phosphatase activity, but concluded that alterations in this and other enzymatic
activity were sporadic and not dose-dependent, so did not consider these or blood
content levels of various ions to be grounds for determining the NOAEL or NOEL20.
Methods:
Literature Search:
In order to access a sufficiently large sampling of the literature on ellagic acid, several
search methods were used. The results of these searches were documented for
reproducibility. A total of 156 published peer-reviewed journal articles were indicated as
useful by search results. Only one of the indicated articles could not be obtained,
namely Yang 2008. Of the 156 published articles, 82 described animal studies in which
ellagic acid was administered. Details of the literature search are as follows.

Literature Search Methodology
A private corporation provided a small database of studies on ellagic acid, many of which
were animal studies. These were all included in the literature review. Toxnet, University
of Kentucky Library “InfoKat” database, and Google Scholar were utilized. Finally,
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relevant sources cited by all materials were included. To ensure data integrity, a
Cochrane protocol was put in place before the selection of studies for review.

Cochrane Protocol:
In order to maintain research integrity, the following Cochrane Protocol for data selection
was utilized:
1. Only animal studies with an n of 6 or greater were considered.
2. The studies were analyzed for sameness of endpoints. The most common
endpoints shared were oxidative damage and inflammatory markers (such as
levels of interleukins).
3. All studies falling into these categories of endpoints were compared, and the
endpoint with the most studies having been conducted using the same
administrative route in the same animal species for the same time scale (chronic
or acute administration) was selected.
4. In the event that there was a tie in the endpoint with the highest number of
representative studies, priority would have been given first to an endpoint for
which all studies shared an additional endpoint and then to a numeric response
variable over a categorical variable.
5. All studies were validated to have significant difference between the control and
disease-state control group.
The study criteria determined by this method were as follows: chronic oral-administration
studies of ellagic acid performed in rats for a time period of no less than one week that
reported alkaline phosphatase activity as an endpoint. Eight studies were isolated that
met these criteria. [Gumus (2011); Murugan (2009); Panchal (2013); Ahad (2014); Singh
(2009); Thresiamma (1996); Devipriya (2007); Umesalma (2010)] Tasaki (2008) was not
considered. Distribution of the doses of ellagic acid and the activity of alkaline
phosphatase are shown in Figure 21. The level of confidence for this designation was
p<0.05 for all included studies.
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Figure 21: Distribution of Ellagic Acid Doses and the Corresponding Alkaline
Phosphatase Levels

Converting Enzymatic Activity Units:
One of the studies indicated by the study criteria, Thresiamma (1996), reported alkaline
phosphatase activity in terms of Kingston-Armstrong units per 100 mL serum. The
activity was converted into international units per liter utilizing conversion data from
“International Enzyme Units and Isoenzyme Nomenclature”. The 2-point format of a line
was used to extrapolate the conversion of KAUs first to Bodansky units, and then to
international units. It should be noted that the extrapolated quantity was outside the
literature range for estimation, which likely contributes to the fact that the alkaline
phosphatase activity of all groups was reported to be noticeably higher for this study
than the others.

Application of QBEST to Determine QNOAEL
First, a bootstrap replication method was applied to the data. Bootstrapping utilizes
random sampling of data from the training set of n rows, with replacement from the
training set, to form a new set of samples of n rows (called a bootstrap sample).
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Repeated resampling of the training set, forming repeated bootstrap samples, yields the
bootstrap sample distribution. The bootstrapping process utilized is multidimensional.
This bootstrapping method is applied because it is nonparametric. Empirical cumulative
distribution functions (ECDFs) are functions that approximate the true cumulative
distribution function of the data. When the original observational data are bootstrapped
nonparametrically using a Monte Carlo approximation to the bootstrap distribution, an
estimate of the underlying true cumulative distribution function is obtained.
Doses that were determined to have no significant effect on the activity of alkaline
phosphatase were assigned the label “No Effect Doses”. Doses that were determined to
have significant effect on the activity of alkaline phosphatase were assigned the label
“Effect Doses”. The ECDF of the “No Effect Doses” dataset was integrated and
compared with the ECDF of the set of the combined “Effect Doses” and “No Effect
Doses”, quantile-by-quantile. The test statistic of this procedure is the correlation
coefficient between the two ECDFs, based off of the quantile-quantile plot and the
location and scales of quantiles. The hypothesis tested is that the two distributions are
the same - that the correlation between the two ECDFs is close to one - with a
confidence limit of 98% (the default setting, which can be changed by the user if
desired).
A simulation run was conducted in which the test set and the training set were moved far
apart in hyperspace (correlation coefficient <1) and then closer together in hyperspace to
generate a curve of correlation coefficients at various distances separating the training
set and test set. When the simulation finally centered the “Effect Doses” (training) set on
the “No Effect Doses” (test) set, the correlation coefficient was close to 1 and there was
no significant difference between the two sets. The simulation employed a bisecting
divide and conquer algorithm to move the training set and test set together. As long as
the two sets remained statistically different, each successive iteration of the simulation
run would move the test set one-half the remaining distance toward the training set. The
process was repeated until the difference between the sets became statistically
insignificant, as indicated by a correlation greater than the 98% level between the two
ECDFs formed by testing the training set against itself. Stated another way, the
algorithm progressively translated both sets or clusters of data away from each other
until it became statistically apparent that the clusters were different. The 98%
confidence limits (of the x- and y-axes) on the “Effects” were determined to be the
QNOAEL for ellagic acid.
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Figure 22: Translating Clusters of Data to Attain the 98% Confidence Level of
Difference
The above depicts two theoretical clusters of data being translated toward each other
in a stepwise fashion along both axes until the 98% confidence level of difference
between the two ECDFs is reached.

Results:
Out of the 82 animal studies reviewed for this experiment, only the following doses were
reported to have caused harm to the animal rather than attenuation of a symptom or
imbalance induced by a disease state.
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Table 2: Studies Showing Adverse Effects After Administration of Ellagic Acid
Study

Dose

Effect

Damas 1987 “Studies…”

30 mg/kg Intravenous
Injection

Swelling of the spleen and
noticeable histological
changes in lymph nodes.

Paivarinta 2006

1,565 mg/kg/day Oral
Feeding for a Prolonged
Period

Increases size of
adenomas in the
duodenum.
p=0.029

Damas 1987
“Thrombopenic…”

30 mg/kg Intravenous
Injection

Hematological aberrations
and swelling of the
lymphatic tissues.

Hassoun 1997

6 mg/kg/day on days
10,11,12 of pregnancy and
3 mg/kg on day 13

Ellagic acid control
significantly increased fetal
death rate despite
generally protective effects
against teratogenesis
when co-administered with
TCDD

Bohn 1993

20 microliters in DMSO
(0.2 microCi and 100
micrograms) injected into a
random uterine horn

Apparent increase in fetal
mortality, though the
sample size was only three
rats.

The most common reported statistically significant effects in the literature were the
attenuations of various markers of oxidative stress, malignancy, and metabolic
imbalance. In all of the eight studies selected, ellagic acid controls showed no significant
change in alkaline phosphatase activity. Only in rats with chronic conditions that lowered
the activity of alkaline phosphatase were significant effects of EA administration
observed, and levels of alkaline phosphatase were attenuated. In light of this finding, the
No Observed Effect Level (QNOEL) of ellagic acid was calculated rather than the
NOAEL.
The 98% confidence limit on the “Effects Set” was 32.8129 mg/kg/day ellagic acid. This
indicates that the QNOEL of ellagic acid is 32.8129 mg/kg/day in rats.

58

Discussion:
This study demonstrates the feasibility of using the QBEST equation to generate
QNOAELs and QNOELs from animal studies or clinical trials published in the literature.
The QBEST equation was utilized to perform discriminant cluster analysis between
“Effects Doses” and “No Effects Doses” of ellagic acid orally administered to rats.
“Effect” versus “No Effect” classification was done on the basis of the author’s
determination that the clinical endpoint was or was not significantly affected with p<0.05.
The result of this discriminant cluster analysis was a 98% confidence limit QNOEL of
ellagic acid, or a dose that would cause no observed effects 98% of the time if the same
studies were to be repeated. This is the first published study demonstrating the
feasibility of generating a QNOEL value using the QBEST equation. It is a novel method
for estimating the acceptable daily intake (ADI) of a food additive that takes advantage of
the published literature, reducing the need to perform costly animal studies (or human
studies where human data is available from the literature).
The QNOEL of ellagic acid was determined to be 32.8129 mg/kg/day in rats on the basis
of significant increase in alkaline phosphatase activity. This is generally in keeping with
the literature in that amelioration of symptoms or attenuation of illness-induced
symptoms seems generally to be noted at oral doses up to 30 mg/kg.
However, it should be noted that this determination was largely limited by the literature
available. Of the studies surveyed, few had overlapping numeric endpoints and as a
result, only eight studies were eligible for analysis. A number of doses were repeated in
those studies, as well, reducing the scope of the analysis further. Though the QBEST
Equation is capable of calculating a QNOEL based off of this data, increasing training set
size has been shown to improve the accuracy of the output. (See Chapter 5 for the
effects of training set size on accuracy and precision of QBEST.)
Furthermore, the designation of adverse effect versus effect doses is complicated in the
case of ellagic acid. Attenuation of alkaline phosphatase activity which has been
decreased by an induced illness could arguably be called an effect, but not an adverse
effect of ellagic acid administration. Consistently, doses of up to 0.5g/kg are reported to
have caused attenuation of a symptom when administered to rats with induced chronic
conditions but no effect on the same endpoint when tested in healthy rats. In fact,
Mandal 1990 reported no adverse effects when doses ranging from 0.4 - 8g/kg/day of
ellagic acid were orally-administered to rats for a period of four weeks.
Paller et al. has administered ellagic acid orally to human cancer patients as a
component of muscadine grape extract tablets. At the highest dose permitted by the
study protocol, 8 tablets/day containing at total of 9.6 mg of ellagic acid per day, patients
still experienced no adverse effects except for “flatulence, soft stools, and eructation”
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when the sample size was increased to 14. Assuming that the average patient in the
study weighed 62 kg, the highest daily dose of ellagic acid that patients received was
0.15 mg/kg/day. This daily dose is approximately 220-fold lower than the calculated
QNOEL of 32.8129 mg/kg/day in rats.
This discrepancy is important because the literature on ellagic acid strongly suggests a
dose-dependent attenuation of cancer symptoms, inflammatory responses, and
inhibition of metastasis and tumor growth. Largely, though, these effects are not seen
when less than 30 mg/kg/day is administered orally in rodents. This is likely due in part
to EA’s poor solubility in water and relatively poor absorption in its natural state.
The results of the present study suggest that ellagic acid has a wider therapeutic window
than is currently recognized. In future human clinical trials, it may be appropriate to
increase the starting dose of ellagic acid. Here, the QNOEL of ellagic acid was
determined to be 32.81 mg/kg/day in rats but current human clinical trials administer a
maximum daily dose of roughly 0.15 mg/kg/day. The calculated QNOEL indicates that
the maximum daily human dose is insufficient to achieve attenuating effects of ellagic
acid, as measured by alkaline phosphatase activity.
A study of American food consumption data from the NHANES database found that the
mean estimated intake of ellagic acid from the food supply is 1.05 μg/kg body
weight/day, while the 90th percentile daily intake is 3.89 μg/kg body weight/day154. The
90th percentile daily intake of ellagic acid from the food supply is indicative of a “heavy
user” dose for human administration. In order to elucidate the NOEL of ellagic acid in
humans, an administration study should be performed between this value and QNOEL
determined in rats (with the maximum dose being reduced by a factor of 6.2155, as is
suggested when moving from rat toxicity studies into human studies). A clarification for
whether adverse effects are induced by pure ellagic acid at the dose of 0.15 mg/kg/day,
the ellagic acid dose-equivalent for muscadine grape tablets administered in human
clinical trials by Paller et al., should be provided by the proposed study and will indicate
whether ellagic acid alone produces observed effects
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Appendix: Search Methodology & Cochrane Protocol
Literature Search Methodology
Corporate Literature Provision:
A private corporation provided a small database of studies on ellagic acid, many of which
were animal studies. These were all included in the literature review.

Web-Based Search Terms:
1. “Ellagic Acid” search on Toxnet yielded few relevant results, though all were
included in the source database.
2. “Ellagic Acid NOAEL” was searched on the University of Kentucky Library
“InfoKat” database. All relevant papers returned in the 69 results were included.
3. “Ellagic Acid NOEL” returned no relevant results on the first page of UK library
search, so this search was concluded.
4. “ellagic acid noael” Searched on 5/22/2018 returned on Google Scholar 726
results. Many are duplicates of papers from Company Files or UK Library
search. Relevant non duplicate items in the first 40 results were obtained.
5. Johanningsmeier 2011 was not included due to the large number of pomegranate
review papers already included.

Sources Cited by Previous Entries:
Relevant sources cited by the papers found by the above methods (company files, UKY
search, and Google Scholar search) were determined. Because the corporate literature
search provided a fairly comprehensive sampling of papers published up to 2008,
citations were taken from all papers published in 2008 or later.
1. In reviewing previously obtained sources, some citations stood out in the bodies
of the text as being particularly relevant. If a source was noted in the body of text
as being a human or animal study involving ellagic acid, the cited source was
generally obtained immediately.
2. The titles of all sources in the citation sections were reviewed. Any titles
including the words “ellagic acid” were obtained, unless the study titles directly
indicated that the source was an in vitro study or cell assay. Studies whose titles
indicated that they covered only the administration of pomegranate products or
plant extracts were also omitted. Articles of questionable relevance were
reviewed briefly before being included in the in-depth literature review.
3. Resources were not duplicated if they were already included.
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4. Sources were not taken from Faria 2011 because a copy was not obtained before
the citation search. No sources were used from this article as it could not be
gotten in full and there are more recent pomegranate review articles, the sources
of which were reviewed.
5. The search for cited sources was begun with the most recent references.
6. A very few papers used citation methods that omit the title of the cited article.
The text was searched for instances of relevant citations, and then relevance was
validated by obtaining the journal article.

Cochrane Protocol:
In order to maintain research integrity, the following Cochrane Protocol for data selection
was utilized:
6. Only animal studies were considered with an n of 6 or greater.
7. The studies were analyzed for sameness of endpoints. The most common
endpoints shared were oxidative damage and inflammatory markers (such as
levels of interleukins).
8. All studies falling into these categories of endpoints were compared, and the
endpoint with the most studies having been conducted using the same
administrative route in the same animal species for the same time scale (chronic
or acute administration) was selected.
9. In the event that there was a tie in the endpoint with the highest number of
representative studies, priority would have been given first to an endpoint for
which all studies shared an additional endpoint and then to a numeric response
variable over a categorical variable.
10. All studies were validated to have significant difference between the control and
disease-state control group.
The study criteria determined by this method were as follows: chronic oral-administration
studies of ellagic acid performed in rats for a time period of no less than one week that
reported alkaline phosphatase activity as an endpoint.
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CHAPTER 5: VALIDATING THE ACCURACY OF QBEST ON SYNTHETIC
DATA: ROUND THE COMPASS ROSE
Purpose: This chapter evaluates the accuracy of the QBEST algorithm on synthetic data
and evaluates what factors most affect the accuracy of the algorithm.
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Validating the Accuracy of QBEST on Synthetic Data: Round the Compass
Rose

Introduction:
QBEST is a discriminant cluster analysis method that can be used to identify whether a
new point ought to be classified as a member of one or another multivariate data
clusters4. It is an improvement over the Mahalanobis equation, which has been
described as “a rubber ruler”. Specifically, the Mahalanobis equation calculates the
number of standard deviation units of a point from the center of a cluster of normally
distributed data points along a given axis, or off that axis. QBEST, on the other hand, is
a “rubber ruler with a nail in the center”, meaning that it calculates the standard deviation
of a point from a cluster of data points along a given vector, extending from the center of
the cluster towards the test point. This strength allows the QBEST to be applied to
multivariate clusters of data that are irregular in shape (e.g., not normally distributed)
with greater accuracy than the Mahalanobis.
QBEST has already been applied to real-world problems of sample differentiation.
QBEST has been applied to the problem of differentiating clusters of data from infrared
(IR) spectroscopy of medicine capsule samples1, 5. QBEST was demonstrated to be able
to identify capsules contaminated with metals or cyanide5. In another experiment
utilizing QBEST, pure Anacin capsules were distinguished from capsules contaminated
with common industrial contaminants, such as aluminum powder and dust6. It has also
been used to differentiate between benzoic acid and false samples via IR analysis7.
The algorithm’s accuracy and performance when handling spherically distributed N(0,1)
data has been evaluated 3,4, but an evaluation of the algorithm’s accuracy and bias when
handling elliptically distributed N(0,1) data has never been calculated. The purposes of
this experiment were (1) to validate QBEST’s accurate handling of elliptical data; (2) to
evaluate what factors most influence the accuracy of the algorithm; (3) to determine the
maximum accuracy with which the average laptop computer could calculate BEST
distances for elliptical data. To this end, synthetic data clusters’ known statistical
parameters were compared to the theoretical QBEST distance calculated by the
algorithm. A standard ellipse served as the basis of this model. Future research should
evaluate QBEST’s treatment of skewed clusters.
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Materials:
System Specifications:
As reported by Matlab’s “memory” command, the laptop used for the memory usage test
had the following capabilities:
Maximum possible array:
Memory available for all arrays:
Memory used by MATLAB:
Physical Memory (RAM):

5089 MB (5.337e+009 bytes) *
5089 MB (5.337e+009 bytes) *
624 MB (6.545e+008 bytes)
7366 MB (7.724e+009 bytes)

All memory data was generated on a laptop PC with 7366 MB of RAM. The operating
system used was Windows 10.
Other data were generated on a Lenovo 3437CTO X-64 based laptop PC with an IntelⓇ
Core™ i7-3520M CPU at 2.90 GHz, 2901 MHz, with 2 cores and 4 logical processors.
The operating system used was Windows 7 Professional, Version 6.1.701 Service Pack
1 Build 7601.
Matlab R2017a was used for all calculations.
Methods:
Standard Circular Data:
In order to validate the program for the standard data generation, first a circular cluster of
data were generated in Matlab. Utilizing the mvnrnd() function, data with a known
standard deviation of 1 along both the x and y axes, centered on the point (0,0) were
generated. Figure 23 is an example of a cluster of data thus generated. The mean, or
center point, of the cluster is shown as a red point and the theoretical first standard
deviation is shown as a red circle with radius=1. The second standard deviation is
shown in blue. In this example, 45/100 fall within the red circle. 43/100 points fall
between the red and blue circles or on the blue circle. 12/100 points fall further from
center than the second standard deviation. Theoretically, for normally distributed data,
68% of the points should fall within one standard deviation of the mean, and 95% within
two standard deviations, leaving less than 2% of data outside the blue circle. It is known
that random number generators do not perfectly generate data fitting the input
parameters, but an approximation is required for this research. Furthermore, it is likely
that the command in question merely considers the standard deviation along the x axis
when generating the x coordinates and the standard deviation along the y-axis when
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generating the y-coordinates; that is to say that Matlab does not use a target covariance
matrix when generating points using mvrnd().

Figure 23: Standard Circle
A standard circular cluster of data with center (0,0) and standard deviation of 1 in all
directions. The first standard deviation distance is shown in red and the second
standard deviation distance in blue.
Standard Elliptical Data:
Then, using the mvnrnd() function, data were generated with a known standard deviation
of 1 along the y axis and 2 along the x axis. Figure 32 is an example of 100 data points
generated in this fashion with center shown in red and the standard ellipse with principal
axis length equal to 2 and minor axis length equal to 1 shown in red. The eight compass
points utilized in the experiment are shown in red.
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Figure 24: Stylized
Standard Ellipse
A stylized standard ellipse
with major principal axis
points shown in black, minor
principal axis points in blue,
and diagonal points in pink.

Figure 25: Standard Ellipse with Compass Points
An example of the elliptical cluster of data generated in this experiment with mu =
(0,0) and sigma=(2,1). Compass points on the standard ellipse shown in red. The red
line indicates 1 standard deviation distance from center.
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The eight compass points shown are as follows, and comprise the farthest points along
the major and minor axes as well as the points located at a 45-degree angle from the x
and y axes:
Table 3: The Eight Compass Points of the Standard Ellipse
Principal Axis Points

Non-Principal Axis Points

45 Degree Diagonal Points

( -2,0)

(0,1)

(-2/(sqrt(5))),(2/(sqrt(5)))

( 2,0)

( 0,-1)

(-2/(sqrt(5))),(-2/(sqrt(5)))
(2/(sqrt(5))),(-2/(sqrt(5)))
(2/(sqrt(5))),(2/(sqrt(5)))

Increasing Dimensions:
The same process was used to increase the dimensionality of the circular and elliptical
clusters. For increased dimensions in the data, the center remained the same but was
assigned additional zero-coordinates. For example, the three-dimensional center would
be (0,0,0). A standard deviation of 1 was assigned to the mvrnd() cluster in all
directions.

Nested Iterative Loops
The program Round_The_Compass_Rose_increasing_training_set.m was used to
evaluate the algorithm’s handling of the data as each variable increased. This program,
available at our lab website (link) utilizes a series of nested iterative loops.
The outermost loop changes the fraction of data points used in the generation of the
hypercylinder, “radfrac”. A minimum, step, and maximum value are set for radfrac.
The second nested iterative loop increases the number of datapoints in the training set
(denoted by the variable “u”) by increasing the number of points generated by the
mvrnd() function. Note that the actual number of training points generated is equivalent
to 50*u. The line of code relevant to this command is:
TNSPEC=mvnrnd(mu,sigma,50*u);
The third nested iterative loop increases the dimensions or number of wavelengths of the
data points (denoted by the variable “v”). “v” is indicative of the number of dimensions of
the data points above two. That is, when v=0, the data is generated in a 2-D ellipse.
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When v=1, the data is three-dimensional; when v=2, the data is four-dimensional; etc.
Dimension is increased in the training set by centering the mvrnd() cluster on
(0,0,........0), with the appropriate number of zeroes being added to the coordinate for the
number of dimensions - that center point being assigned to the variable “mu”. Then,
“sigma” is addended such that the standard deviation of the mvrnd() cluster is (2,1,
1…...1), with ones being appended such that the number of dimensions is increased to
the proper value. In this loop, as well, the compass points are defined and addended
with zeroes to make them the proper dimensions. The compass points are defined:
compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));
0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))];
Compass points of increased dimensions would have all further dimensions equal to
zero. (0,1, 0,0…...0), for example.
Furthermore, this loop defines the expected standard deviation from center of each
compass point:
expected_standard_deviation = [1;1.2649;2;1.2649;1;1.2649;2;1.2649];
The fourth nested iterative loop defines “newspec”, the test spectrum, as being
equivalent to one of the eight compass points. This loop tests each compass point using
the method of the fifth iterative loop. It also creates storage for the solutions generated
in the fifth iterative loop. The fifth iterative loop is run a total of six times, with different
bootstrap replicates being generated, and the average and standard deviation of the
outputs is calculated and stored.
The fifth iterative loop increases the number of bootstrap replicates generated.
Bootstrap replicates are equivalent to 50* “z”. This loop actually calls the qb.m program.
The code for this loop is:
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
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The program used for multivariate polynomial regression of the final results was
https://www.mathworks.com/matlabcentral/fileexchange/34918-multivariate-polynomial-r
egression .
Memory Usage Tests:
In order to determine the maximum parameter size for each required input of the
algorithm, the input values of each variable training set size, number of bootstrap
replications, and dimension were increased until the program ran for a continuous 20
minutes without completing. (This was determined to be indicative that the program
would not complete its run, even given more than an hour.) Then, variables were
increased together. For these tests, the same input was used for both or all variables
being tested. All variables were increased until the run time exceeded 20 minutes, the
program raised a memory error and terminated, or the cpu time of the last run
approached 200 seconds (as this was also indicative of an imminent crash).
Results:
Memory Usage:
The following chart shows the maximum input sizes attained for each variable alone or in
concert with another variable. The amount of data that a personal laptop computer can
analyze far exceeds what is possible using the Mahalanobis equation. A personal laptop
computer can run up to 6 million bootstrap replications with a small dataset, or can
handle 1 million dimensional data, or 5 million training points provided that the other
parameters are small with a run time of less than 20 minutes. This far exceeds the
needs of most research scientists.
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Table 4: Memory Usage of QBEST

Bootstrap

Dimension

6*10^6

TNSPEC

Not
100 Determined

Not
Determined

Not
150 Determined

Not
Determined

2 5*10^6

Not
Determined

Not
Determined

2 10^4

490

11.803887

1257

839.131357

100 1225

194.179892

2
100 10^6
100

10^4
100 10^4
10^4

10^4

10^3

10^3

3*10^6

Clock Time of
Memory Used
Second
by Matlab (MB) Operation (s)

10^4

10^3

464

2 2*10^2

3*10^6

30
100 5*10^5

100
1.5*10^2

150 5*10^5

150

42.909076
500

87.75957

1182

66.53017

1422

268.2744

1608

405.3309

5*10^3

350 5*10^3

473

198.7201

10^4

200 10^4

476

489.2994

125 10^4

10^4

1257

1359.073

150 5*10^3

5*10^3

685

155.3649

10^4

10^4

150

1257

387.0736

5*10^3

5*10^3

200

668

105.0412

50 2.5*10^6

1466

1073.131

2 2.5*10^6

579

56.26981

100
10^2
Relative Error or Bias

The algorithm’s absolute error was calculated to be equal to one minus the average sds
output of qb.m, over a course of six runs. Tested at each compass point, the theoretical
true number of standard deviations of distance that each test point has from center is
one. SDs represents the number of standard deviations of distance calculated by the
algorithm. Thus, the absolute error of the answer is one minus the average value of sds.
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Effect of Radfrac & Bootstrap Replication on Average Relative Error:
Relative error remains constant regardless of the the number of bootstrap replications
performed or the fraction of points used in generating the hypercylinder (when
considering elliptical data that has no concavities). As shown in Figure 26, the average
percent error remains relatively unchanged as bootstrap replicates increase (across the
x-axes of each graph) or as radfrac increases (increased from top figure to bottom
figure).
Figure 26: Average Percent Error As Bootstrap Replications and Radfrac
Increase
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Figure 26 Continued
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Figure 26 Continued

Effect of Training Spectrum Size and Dimension on Relative Error:
Neither training spectrum size nor dimension are significant predictors of relative error.
Increasing the size of the training spectrum appears to decrease the percent error
slightly, though it is difficult to say how much of this decrease is due to the inborn error of
the training spectrum generation by the mvrnd() command and how much of the
decrease is due to increased competency when the algorithm bootstrap replicates from a
larger training set of data. Increasing the number of dimensions of the datapoints in
question while holding other factors constant appears to slightly increase absolute error.
These effects are largely negligible, though. This data is shown in Figure 27.
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Figure 27: Effect of Training Spectrum Size and Dimension on Relative Error
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Figure 27 Continued

Effect of Compass Point on Relative Error:
Compass point is not a significant predictor of relative error. However, like compass
points tend to cluster together in terms of relative error due to eccentricities in the
training set. The training set largely determines the relative error of each compass point.
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Figure 28: Average Relative Error As Bootstrap Replicates Increase by Compass
Point
Non-principal axis points are marked in red, principal axis points in black, and diagonal
points in blue.
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Relative Standard Deviation:
The algorithm’s relative standard deviation (RSD) was calculated by dividing the
standard deviation of the six runs by the average distances in SDs of the six runs.
Relative standard deviation is decreased by increasing the number of bootstrap
replications run on the data. Increasing the size of the training spectrum or increasing
the number of dimensions of the data appears to have no significant effect on the
relative standard deviation of the output of the algorithm. This indicates that the
algorithm handles with equivalent precision increasingly multivariate datasets, as well as
datasets for which more or less training points were input. The effect of radfrac, or
fraction of points used to generate the hypercylinder on relative standard deviation is low
in proportion to the effect of bootstrap replication for data that is elliptical, or lacking in
concavities. Non-linear functions, such as those seen in acoustic data, can create data
clusters with concavities (e.g., clusters that appear shaped like the letter “c”). In these
instances, the influence of radfrac should theoretically be quite great. Further research
should be done on data clusters including concavities to determine the nature of this
effect.
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Figure 29: Relative Standard Deviation as Bootstrap Replicates and Radfrac Increase
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Figure 29 Continued
Reseeded with rng(2)

*
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RSD is Dependent on Training Set
The relative standard deviation of QBEST’s output is most significantly affected by the
training set chosen. In Figure 30, below, three different elliptical clusters of data have
been randomly generated using the same parameters. The RSD vs. bootstrap replicate
graphs below them are three graphs generated from the same training spectrum, but
bootstrap replicated with a different random number generator seed. Graphs generated
from the same training spectrum are nearly identical to one another, but significant
variation exists between graphs generated from a different training spectrum.
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Figure 30: Relative Standard Deviation as Bootstrap Replicates Increase: Effect
of Training Sample and Random Bootstrap Replicates
Training Set 1

Training Set 2
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Training Set 3

Number of Training Points Does Not Significantly Affect RSD
Figure 31 below shows elliptical clusters with the same parameters but different numbers
of generated points. RSD calculations were run in triplicate for each training spectrum
using a different random number generator seed for the bootstrapping process.
Changing the training set size does not appear to significantly affect relative standard
deviation and is not a significant predictor of RSD. Increasing the number of bootstrap
replicates even marginally drastically reduces the RSD. Bootstrap replicate number is a
far more important factor in the RSD than number of training points.
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Figure 31: Relative Standard Deviation as Bootstrap Replicates Increase: Effect
of Training Set Size and Random Bootstrap Replicates

rng(1)

rng(1)

rng(1)

rng(10)

rng(10)

rng(10)

rng(20)

rng(20)

rng(20)
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Relative Standard Deviation as TNSPEC and Dimension Increase:
RSD is not significantly affected by the training spectrum size or dimension increase.
Neither of these are significant predictors of RSD.
Figure 32: Relative Standard Deviation as Training Set Size and Dimension
Increase
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Figure 32 Continued
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Mahalanobis Comparison

Figure 33: Standard Circle Used for Mahalanobis vs. BEST Comparison3
When the number of samples greatly exceeds the number of dimensions (independent
variables), the BEST and the Mahalanobis metrics produce similar answers.
Theoretically, the on-axis points (1,3, and 5) should be 1 SD from the center while the
off-axis points (2,4, and 6) should be 1.414 SD away.
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Figure 34: Comparison of Mahalanobis and BEST to Actual Distance when
Dimension is Low and Number of Samples is High
With only 2 dimensions (independent variables) and 100 samples from a synthetic
N(0,1) distribution, the accuracy of the BEST metric is about the same as the
Mahalanobis metric. The error in the red and green lines comes from the 100
randomly selected samples poorly representing the N(0,1) distribution. The variation
from run to run largely results from differences in the training set.
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Figure 35: Accuracy and Precision of the BEST and Mahalanobis Metrics Using
an N(0,1) Synthetic Data Set
In this experiment, the number of samples (rows) always exceeded the number of
dimensions (columns) by 2. The Mahalanobis metric can be very wrong.
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Figure 36: Run Time of Mahalanobis and QBEST as Dimension Increases
The running time of the BEST calculation is n2 faster than the Mahalanobis even
without parallelization.

Discussion:
Equal Precision for Small and Large Datasets
Relative error is slightly decreased when the number of training points input are
increased, but precision as measured by the relative standard deviation of the output is
unaffected. This indicates that QBEST is capable of calculating multivariate standard
deviation units with predictable error for both small and large datasets. QBEST is ideal
for extrapolation from small datasets, as it is able to process these with nearly the same
precision as large datasets.

Influence of Bootstrap Replication
For elliptical data, bias remains constant regardless of the the number of bootstrap
replications, but relative standard deviation of the algorithm’s output is decreased by
increasing the number of bootstrap replications run on the data. This indicates that the
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number of bootstrap replications does not significantly affect the accuracy of the
algorithm’s measurements, but by increasing the number of bootstrap replications, the
user can ensure greater precision and a more consistent output from run to run.
Influence of Dimension
For data with very large numbers of dimensions, it is important that the training set size
be increased to offset increasing bias.
Influence of Radfrac
For this elliptically-distributed data that has no concavities, bias remains constant
regardless of the fraction of points used in generating the hypercylinder. The effect of
radfrac, or fraction of points used to generate the hypercylinder on relative standard
deviation is low, as is to be expected with symmetrically-dispersed data. In other words,
it is safe to use a radfrac of 1.0, all of the data points in the cluster, for elliptical data.
Relative Error
Bias remains constant regardless of the the number of bootstrap replications performed
or the fraction of points used in generating the hypercylinder (when considering elliptical
data that has no concavities).
Increasing the size of the training spectrum appears to decrease the bias slightly, though
it is difficult to say how much of this decrease is due to the inborn error of the training
spectrum generation by the mvrnd() command and how much of the decrease is due to
increased competency when the algorithm bootstrap replicates from a larger training set
of data. Increasing the number of dimensions of the datapoints in question while holding
other factors constant appears to slightly increase bias.
Relative Standard Deviation (RSD)
The algorithm’s precision was calculated by dividing the standard deviation of the six
runs by the average sds of the six runs. Relative standard deviation is decreased by
increasing the number of bootstrap replications run on the data. Increasing the size of
the training spectrum or increasing the number of dimensions of the data appears to
have no significant effect on the relative standard deviation of the output of the algorithm.
This indicates that the algorithm handles with equivalent precision increasingly
multivariate datasets, as well as datasets for which more or less training points were
input.
The effect of radfrac, or fraction of points used to generate the hypercylinder on relative
standard deviation is low in proportion to the effect of bootstrap replication for data that is
elliptical, or lacking in concavities. Non-linear functions, such as those seen in acoustic
data, can create data clusters with concavities (clusters that appear shaped like the letter
“c”). In these instances, the influence of radfrac should theoretically be quite great.
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Further research should be done on data clusters including concavities to determine the
nature of this effect.

Influence of Training Spectrum
The most important factor that influences relative standard deviation of the QBEST
output is the quality of the training set. The particular points chosen for the training set
can cause a great deal of variability in the relative standard deviation of the output. This
is to be expected, because good results require good data input.
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CONCLUSION
Summary of Chapters
Chapter 1
Summary: Chapter 1 introduced the QBEST method and compared it in general to the
Mahalanobis method.
QBEST is a statistical algorithm for discriminant cluster analysis, and is the basis for
qb.m, a program written in Matlab (and currently being translated into Python 2.7) for
testing whether a test sample varies from a training set, library of spectra, or other
multivariate data. A bootstrap replication method is used to generate a hypercluster
from training spectra samples and the QB program calculates the probability that the test
sample is the same as the training samples by measuring the distance of the test sample
from the center of the hypercluster in multidimensional skew-adjusted nonparametric
standard deviations. The method allows for differential directional weight of different
variables.
Chapter 2
Summary: Chapter 2 outlined the method of research for the following chapters and
discussed the application of quantile bootstrap (QB) methods to the problem of
estimating the No Observed Adverse Effect Level (NOAEL) of a New Molecular Entity
(NME) to anticipate a safe starting dose for beginning clinical trials. An estimate of the
NOAEL from the extended QB method (called the QNOAEL) can be calculated using
multiple disparate studies in the literature and/or from laboratory experiments. The
QNOAEL of ellagic acid was calculated using this method in Chapter 4, and is the ADI
(Acceptable Daily Intake).
Significance: The QNOAEL is similar in some ways to the Benchmark Dose (BMD) and
is superior to the BMD in others. The Benchmark Dose method is currently widely used
in toxicological research. Results are used in a meta-analysis simulation based on
nonparametric cluster analysis methods to calculate confidence levels on the difference
between the Effect and the No Effect studies. The QNOAEL simulation generates an
intuitive curve that is comparable to the dose-response curve. The QNOAEL of ellagic
acid (EA) was calculated in Chapter 4 for clinical trials of its use as a component
therapeutic agent (in BSN476) for treating Chikungunya infections. This is the first
application of QB to the problem of NOAEL estimation for a drug.
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Chapter 3
Summary: Chapter 3 describes the determination of the Estimated Daily Intake (EDI) of
ellagic acid. The purpose of this paper was to determine how much ellagic acid is
consumed daily by the average American to serve as a baseline safe dose for human
clinical trials. The United States Food and Drug Administration (FDA) describes food
stuffs as “Generally Recognized as Safe” (GRAS) at some level (the ADI or less). For
example, many GRAS products are classified as dietary supplements, which require less
testing than drugs. Products that are GRAS typically do not require the manufacturers to
repeatedly conduct the same battery of toxicity testing and clinical trials that drugs need
to have to be be FDA-approved.
Ellagic acid is a major component of BSN476. It is also a naturally-occurring polyphenol
found in fruits and nuts. In this paper, the mean EDI of ellagic acid was determined to be
69.58 micrograms/person/day or 1.05 micrograms/kg body weight/day. The 90th
percentile EDI was determined to be 258.33 μg/person/day or 3.89 μg/kg body
weight/day, far less than the ADI and QNOAEL. This provides support for starting any
human clinical trial of BSN476 at a daily dose containing a comparable amount of ellagic
acid to the 95th percentile of ellagic acid consumption. Ellagic acid is safe in the food
supply at a dose of 3.89 micrograms/kg body weight/day, so as long as there are no
interactions between other components of the drug, there should be no concerns of
toxicity to humans. Having demonstrated the expected daily intake of ellagic acid, there
is little reason for any initial toxicity tests of ellagic acid before studies proceed to clinical
trials.
Significance: The 90th percentile daily intake of a chemical occurring naturally in the
food supply should be indicative of a safe dose for PK/PD. This number provides
evidence for the level of a compound as Generally Recognized as Safe and represents
an upper threshold for the starting dose in human clinical trials. This data analysis
indicated that the 90th percentile expected daily intake of ellagic acid is 3.89
micrograms/kg body weight/day. Future PK human trials therefore should be started at a
dose equal to or less than 3.89 micrograms/kg body weight/day.
Chapter 4
Summary: In Chapter 4, the acceptable daily intake has been extrapolated from animals
studies treated with the QBEST to yield a QNOAEL of 32.8 mg/kg body weight/day. The
ADI reinforces the assertion that conducting a PK trial below the EDI should be a safe
approach to formulation development. Chapter 3 demonstrated that ellagic acid is a safe
component of the food supply up to a dose of 3.89 μg/kg body weight/day (which was
determined as a safe dose because it is the 90th percentile daily intake of ellagic acid
from the food supply). In this chapter, the acceptable daily intake of ellagic acid was
calculated to be 32.8129 mg/kg/day. Human clinical studies should be started at a
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value below the 90th percentile estimated daily intake, well below the QNOAEL. Taken
together, these two chapters form the basis for an exploratory IND filing at the FDA to
expedite formulation testing for human clinical trials.
Significance: More than simply providing this specific opportunity to expedite the testing
of BSN476 and to avoid early costly toxicity testing of a formulation, this chapter is
important because it specifically provides proof of concept that QBEST and discriminant
cluster analysis can be applied to obtain QNOAELs. QBEST is superior to the current
standard practice of safety data analysis. It allows for the meta-analysis of data that has
already been generated by numerous small studies, increasing the statistical power of
small studies by bootstrap replication from numerous small studies. The QBEST method
of generating QNOAELs clearly solves numerous scientific issues encountered when
calculating a traditional NOAEL. QBEST can be used to determine with statistical
confidence limits the highest dose of a drug that will cause no adverse effect; traditional
NOAELs are determined by simply increasing an administered dose by arbitrary
increments until an adverse effect is noted. Whatever highest dose was administered
that is less than the lowest adverse effect dose is considered to be the NOAEL.
NOAELs can never be determined to be anything other than an exact dose which was
administered, so the NOAEL determination is imprecise. Furthermore, it is difficult to
meta-analyze NOAELs, so to increase the precision of a NOAEL test, a completely new
test would be required.
The current alternate method to safety determination is the Benchmark Dose Method
(BMD). The BMD is determined by administering increasing doses of a pharmaceutical
until a specific physiological response is elicited. The benchmark dose is considered to
be the dose at which it is likely that a given response will occur. The BMD can be used
to meta-analyze multiple studies, but can generate confusing and non-intuitive response
curve when there are conflicting results of studies. QBEST solves this problem by
generating a single QNOAEL from an array of studies in a simulation. Finally,
QNOAELs remove the subject bias from study weighting that accompanies any
meta-analysis. The bootstrapping algorithm causes there to be no need to subjectively
assign weights to studies. QBEST naturally causes the typical studies to outweigh the
outlier studies through a simple rule of probability.

Chapter 5
Summary: Chapter 5 covered the Round-the-Compass Rose experiment which validates
that the QBEST is capable of handling non-spherical distributions of data, like that used
in the ADI calculation, accurately and reproducibly. It also proves the concept that this
algorithm can be used for very large datasets even on a personal laptop computer,
unlike the Mahalanobis distance.

95

The purpose of this experiment was to explore sources of bias in the output of the QB
program. To that end, synthetic data with known parameters were generated and the
output number of distances in standard deviation units calculated by the QB program
was analyzed for consistency and accuracy. Furthermore, symmetrical elliptical clusters
of data were analyzed in order to determine whether compass location around the
cluster significantly affected consistency or accuracy of the algorithm’s output.
It was determined that the most significant factor that affects the algorithm’s accuracy is
the training spectrum used, which makes intuitive sense. Accurate results require good
input data. The training set must accurately reflect the population that it seeks to
represent. Average bias is largely unaffected by the number of bootstrap replicates
used. Percent error is largely unaffected by the training set size. QBEST is capable of
calculating with accuracy even when input parameters are at the extremes. Relative
standard deviation of the algorithm’s outputs is reduced when the number of bootstrap
replicates is increased.
Significance: The specific aim of Chapter 5 is to evaluate the accuracy and precision of
the QB Simulation. The differential directional weight is a key attribute of the QB
program, as the direction of skew of a sample from the training sample may shed light on
the nature of an impurity. This concept can be illustrated by the following: in an elliptical
cluster of training points, there is a "long axis" - that is, an axis in which greater deviation
can be expected from the mean, as well as a "short axis" along which training points are
tightly clustered and little variation is expected of a pure sample in keeping with the
training samples. The QB program is able to analyze points along any axis of any
n-dimensional cluster of training points and determine whether significant skew exists
along any of those axes. Before this work, only data clusters having an equivalent
standard deviation along all vectors - that is, circular, spherical, or similar n-dimensional
data clusters - had been analyzed. This work was the first to analyze the performance
of QBEST when faced with clusters having non-equal standard deviations along two
axes. The differential handling of data on the left versus right-hand side of the center of
the cluster is the most important improvement of QBEST over the Mahalanobis equation;
this experiment paves the way for future experiments exploring data that are
asymmetrically distributed on either side of the center (unlike the ellipses used in this
experiment).

Future Applications:
QBEST represents a significant improvement over the Mahalanobis equation for the
nonparametric analysis of multivariate data. The most notable improvements are (1) that
QBEST calculates standard deviation units separately for points to one side or the other
of center (asymmetrical determination of standard deviation units); (2) QBEST is
mathematically capable of determining with accuracy the QBEST distance even when
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the number of observations are fewer than the number of dimensions or variables of the
data; and (3) QBEST requires d2 less computing power than the Mahalanobis equation.
These improvements are functionally important, respectively, because:
1) Calculating the symmetrical Mahalanobis distance introduces inaccuracy when
the cluster being evaluated is asymmetrically distributed. The Mahalanobis
equation is insufficient for evaluating data that are not symmetrically distributed
along any given line. Real-world data does not tend to be symmetrically
distributed. Furthermore, the tailing observed in data clusters can show
important information about a dataset. It is inappropriate to ignore the distribution
of points differently along the “left and right hand” vectors from the center of the
data distribution to a given test point.
2) It is mathematically impossible to utilize the Mahalanobis equation to determine a
Mahalanobis distance when the number of datapoints or observations are far less
than the number of dimensions or variables measured describing the data. The
Mahalanobis equation relies on matrix factorization that cannot be performed in
this instance. This means that the Mahalanobis equation cannot be utilized to
evaluate, for example, all of the data gathered by a handful of clinical trials with
one hundred endpoints each; the infrared spectra of a hundred duplicate
chemical samples taken at ten-thousand wavelengths; or the massive amounts of
data processed by an artificial intelligence program that it uses to make
decisions. When the number of variables is close to the number of observations,
but still exceeds the number of observations, QBEST is often more accurate. As
the number of observations approaches the number of variables, the
Mahalanobis distance becomes increasingly inaccurate.The QBEST Equation is
capable of solving these mathematical problems and as yet unimagined others
as our world rapidly becomes dependent on larger and more complicated
massive data sets. In this way, QBEST is the statistical equation of the future.
3) Even if the number of observations required by the Mahalanobis equation is met,
the number of dimensions of data that can be analyzed in a reasonable amount
of time is severely limited. The Mahalanobis equation is an order of d3 algorithm,
which means that for every d dimensions increased in the data, the computer will
need d3 more computing power to solve for the Mahalanobis distance. In
comparison, QBEST is an order of d algorithm. Computing power equates to run
time for a given processor. Simply stated, a QBEST distance that could be run in
an afternoon on a typical personal computer would have to be run on a
supercomputer to be solved with the Mahalanobis equation in the same amount
of time. In Chapter 5, it was determined that a typical laptop personal computer
can calculate the QBEST distance for data with 6*106 dimensions in
approximately twenty minutes or less. It is difficult to imagine any current
pharmaceutical application which would require 6*106 dimensions of data, but
this is an emerging problem in the physical and computer sciences. However, as
medical monitoring becomes more advanced, an increasing amount of data will
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be generated and stored, particularly in the case of biological parameters which
are continuously monitored. The analysis of increasingly massively multivariate
data is a serious emerging problem in statistics. QBEST provides the best
solution to this problem at present.

Applications in Pharmaceutical Science:
As pharmaceutical science and computer science progress, Big Data continue to get
bigger. Unfortunately, computing power is not improving as quickly as the capability to
generate information, leaving scientists and businessmen alike with an information
surplus. Before QBEST, there was not an algorithm capable of discriminant cluster
analysis on massively multivariate data that could be run on a personal computer. In
practical terms, QBEST can process with accuracy a handful of instances of
million-dimensional data. This capability will allow scientists at startup research
companies and university researchers, including students, to perform the kind of
calculations that traditionally required the use of a supercomputer.
At present, most pharmaceutical data are generally not considered to fall under the
umbrella of Big Data, or databases consisting of hundreds of thousands of datapoints
with thousands of variables, but the trend of technology in medicine is moving toward Big
Data. Currently, insurance databases and hospital databases do fall into the category of
big data. Pharmaceutical companies, health care providers, and public policy makers
draw on these massive databases to make generalizations about populations and enact
policy changes. The push towards personalized medicine will also require the analysis
of big data problems increasingly in the future.
Big Data in Health Insurance
Major insurance providers now complement their own massive databases by purchasing
additional databases from commercial vendors. This strategy is necessary to be
competitive in the modern market2. The decisions that insurers make regarding care has
a tremendous impact on the treatment chosen for a given patient, particularly as the
industry pushes wellness incentives as a cost-saving measure.
Humana’s proprietary algorithm, the Anvita Engine™, analyzes basic wellness
measurements, such as weight, heart rate, BMI, etc. measured over time and makes
predictions about possible chronic conditions that the patient could develop, based on
patterns of disease progression noted in a training sample of patients5,6. The algorithm
then places flags in the patient’s online medical file that appear to any physician who
bills the insurance5,6. These flags suggest that the doctor perform various routine tests
or recommend preventative medicine for the patient. If performed, the treating physician
is paid a fee by the insurer5,6. This is only one of the first generation of algorithms storing
and comparing massively multivariate patient data to make treatment decisions for a
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patient. These databases grow larger and more sophisticated each year. As the scope
of data analysis increases, it is necessary to have statistical algorithms capable of
keeping pace while making accurate decisions for patient care.
On the surface, algorithms such as Humana’s Anvita Engine appear to work using only
information recorded by a patient’s doctor. In reality, major insurers pool information
from all of their patients for training sets, and actually purchase databases of outside
information from commercial vendors and compile this information when making
predictions for a given patient. Some examples of the types of databases bought by
major insurers are as follows:
● Store loyalty card information - Major grocery store chains maintain records of
grocery purchases. Healthy and unhealthy foods, cigarettes, alcohol, pregnancy
tests, prophylactics, prescriptions, over-the-counter medicines, and pharmacy
purchases made at grocery store chains using the store loyalty or discount card
are stored in the corporate database. Grocery store chains such as Kroger,
Safeway and Target use this information when sending out personalized coupons
and deals. There is a great deal of money to be made in predicting certain
medical conditions, and then in marketing to that prediction. Target has openly
admitted to predicting which of its customers are pregnant as early as possible so
that it can mail coupons for large-ticket baby necessities, such as cribs, before
the shopper has the opportunity to purchase those items from a competitor4. In
fact, Target’s loyalty card algorithm is so accurate that it has been documented to
have predicted a woman’s pregnancy before her family was made aware of it4. A
Target spokesperson has confirmed that Target’s shopper algorithm can predict
not only pregnancy, but also the trimester of a customer’s pregnancy with
accuracy from a single shopping visit4. Pregnancy is not the only condition that a
store chain has the impetus to monitor; consider that major retailers of exercise
equipment, orthotics, and prescription medications also collect shopper data.
● Social Media - Some insurance companies are purchasing databases from social
media sites such as Facebook. One Facebook algorithm keeps track of a user’s
mood based off of whether his posts seem to be positive or negative7,8,9. In a
recent scandal, Facebook was accused of performing unethical research on
unwilling subjects by altering the number of positive or negative posts a user saw
on his news feed and then monitoring the user’s mood over time7,8,9. Social
media posts have the potential to provide incredible insight into the risk of
insuring a potential policyholder, as they include information about the person’s
habits, including drinking, tobacco use, recreational drug use, mental health,
sexual activity and orientation, current health conditions, and all of the
aforementioned information as it relates to the user’s relatives. Harnessing
Facebook’s mood algorithm could prove extremely valuable in the treatment of
depression, suicidal tendencies, and other mental disorders.
● Phone Applications or “Apps” - Numerous applications exist for smartphone
users wishing to monitor their personal health. Some are free, while others are
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paid services that collect and analyze daily health information. Various insurers
have contracts with various app makers to receive databases of these user
reports2.
Commercial Fitness Devices - According to a recent report, John Hancock has a
standing contract with Vitality that integrates wellness initiatives into its life
insurance policies2. Policyholders can earn discounts on their life insurance
policies if they register internet-connected commercial wellness devices, such as
FitBits2. In this way, John Hancock is using big data analysis when analyzing
basic vital signs of policy holders and comparing them to standards of healthy
and at-risk patients2.
Workplace Wellness Programs - Workplace wellness programs are
company-instituted programs that encourage employees to increase their
fitness1. These programs are largely unregulated with very lax privacy laws, as
they are not subject to HIPAA or to the provisions of Obamacare that prevent
premium discrimination on the basis of pre-existing conditions1. Increasingly,
workplace wellness program data are being used to increase the costs of
company insurance by up to 30% for overweight or otherwise unhealthy
non-tobacco using employees1. Associations such as the American Diabetes
Association warn that under the guise of giving monetary incentive for healthy
employees, employers are legally penalizing people with chronic conditions such
as diabetes by increasing the cost of their health insurance, leading to decreased
access to medical care for people with chronic and pre-chronic conditions1.

Algorithms owned by data-mining companies piece together and re-identify consumer
information, attempting to pair consumers to their respective identities as insurance
customers. This is an easy task in the case of store loyalty cards, social media
accounts, and personal health devices, since these things are tied to consumer names,
addresses, and/or phone numbers. However, for those databases of truly de-identified
data, there are algorithms capable of re-identifying particular consumers. In this way, the
insurance company stores a comprehensive database of not only strict health
information, but also related dietary health, wellness, and behavioral risk information for
each of its customers. There is a large push in the industry now to develop newer and
more powerful methods of analyzing and using this data to increase profits, either by
adjusting policy payments for at-risk policy holders, or by implementing wellness
programs that include preventative medicine and health screenings. Additionally,
de-identified but localized data can shed light on the health of particular populations,
such as the alcohol consumption across a particular zip code, or the purchases of
populations of various racial compositions.
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Big Data in Personalized Medicine
Personalized medicine, the process of tailoring treatment to the individual patient on the
basis of metrics relating to that patient, is also an emerging necessity in the industry.
Some pharmaceutical devices have already begun to move toward the storing of
continuous health data for patients; this is most clearly seen in the blood glucose
monitoring systems and paired insulin pumps that have been developed for Type I
diabetics. Recall from Chapter 1 that any variable with continuous monitoring can be
represented as a multivariate data point with coordinates at each time point (or
wavelength in the case of spectral data). As more health endpoint monitors become
continuous (such as heart rate monitors, blood content monitors, physical exercise
monitors, and neurological activity monitors), more data will be generated for each
individual patient, which can be utilized in care decisions. Even now, Fitbits™ and smart
devices continuously monitor basic vital signs. Most of these devices have their own
apps that can be synced with physician’s offices, but there is a large push to make a
universal record keeping system that can store the information generated by all of these
devices and make comparisons across the patient population.
This massive amount of information is useless, however, unless baselines are
established for a particular patient and deviations from that baseline are monitored.
QBEST answers the important question: Does the current state differ significantly from
the baseline training set of data? QBEST allows a chunk of daily data - either in blood
glucose patterns or general vital signs - to serve as a training set, while the present
measurements could be used as a test set. QBEST would then detect whether there
was a significant difference between the spectra of patient’s current status and the blood
glucose spectra corresponding to the last finger stick. It could also compare a
significantly different result with training sets of known glucose levels or disease states
and suggest what problem was developing in the patient.

Big Data in Safety Analysis
Finally, QBEST has the potential to revolutionize analysis of toxicology data. Risk is an
important factor in the regulation of pharmaceuticals. Initially, determinations of risk vs.
benefit form the basis of FDA decisions regarding the approval and marketing of a new
pharmaceutical, including its on-label usage, dose, and black box warnings.
Post-marketing, risk plays strongly into civil suits when an injury has occurred, allegedly
caused by a pharmaceutical agent. QBEST offers a method for the statistical
determination of risk. As demonstrated in Chapter 4, QBEST can be used to determine
a 98% confidence limit QNOEL of a drug, or a dose that would cause no observed
effects 98% of the time if the same studies were to be repeated. Pre-marketing, QBEST
can be used to inform executive decisions regarding the safety of a pharmaceutical and,
as demonstrated in this work, can help to clarify the therapeutic window.
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Post-marketing, QBEST can assist in retrospective analysis of what was known about
the safety of a pharmaceutical agent at the time it was administered (a key component of
pharmaceutical and other toxic exposure lawsuits) by simply performing an analysis with
all data published at the time of the incident.
Applications in Computer Science and Robotics
Future applications of the QBEST will likely involve Artificial Intelligence and adaptive
resonance. When does a neural net need to be re-trained? QBEST could provide an
answer. With the QBEST, it is now possible to solve mathematical problems not even
dreamed of before. QBEST’s efficient computation makes it an ideal algorithm that can
compute six million bootstrap replications, find significant differences in data with one
million dimensions, or process 5 million training data points on a cheap laptop computer.
This convenient method of quickly analyzing health data will become integral in
personalized medicine.

Weaknesses of QBEST and Further Work that Must Be Done
Though QBEST represents a significant improvement over the Mahalanobis equation
and fulfills a similar purpose, there are still some datasets which would be handled very
ineffectively by QBEST. Nonlinear data sets present potential problems. Take for
example the figure below:
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Figure 37: An Example of a Poor Dataset for Application of QBEST
The above data cluster has an obvious concavity. The red star marks the center of the
cluster as calculated by QBEST and the green point is a theoretical test point. Note
that if a QBEST “rubber ruler with a nail in the center” were drawn from the center to
the green test point, no other points would fall along the ruler unless the width of the
ruler (radfrac) was very great.
In the above example, QBEST would generate a poor QBEST distance between the
calculated center and the green test point. There is not a linear relationship between the
x axis and the y axis. Use of QBEST is not advisable when the test point falls on the
other side of a concavity from center in the data. It is also not advisable to use QBEST
when an obvious visual pattern in the data would indicate that there are zones where
points should not ever fall in space (for example, if data were following a sine curve,
there would be obvious concavities in the data following a clear visual pattern). These
types of nonlinear patterns are difficult for the algorithm to handle because QBEST
assumes that the center of the data cluster actually falls within the data cluster. Before
using QBEST, the analyst should graph the data and visually inspect the clusters. As
with any statistical analysis method, the analyst should plot all combinations of variables
against one another and determine that nothing contraindicates use of the QBEST
method.
It has been suggested by a colleague that QBEST could be improved upon by defining
the center of the data cluster differently10. Rather than finding the average coordinate
value on each axis and defining that point as the center (as was done in the example
above), it is possible to define coordinate space as the area inside of a multidimensional
figure10. Then, the calculated center of the data would be forced to fall within the defined
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coordinate space10. In this way, the center of the data could never be calculated to fall
within a concavity of the figure10. This method is in keeping with the Principal Curve
Method, which calculates a center curve through a gray zone and measures points back
orthogonally3. A similar definition of coordinate space could be used in the QBEST
distance calculation. QBEST is not currently written to do this, but could be. However, it
would probably be better to use a central curve (or a 1-D manifold) as in Hastie et al3.
See Figure 38, below.

Figure 38: An Example of Coordinate Space Redefined for Purposes of
Calculating the Center of a Data Cluster
It should be noted, however, that QBEST can in fact be used to calculate a QBEST
distance in the given example (Figure 37). The test spectrum is defined as the point
(2,1). The QBEST distance is 2.2976 standard deviation units, with 2.8302 standard
deviation units of skew.
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APPENDICES:

Appendix A: Equations
The Mahalanobis equation:
The Mahalanobis distance of an observation

from a set of

observations with mean

and covariance matrix S is defined as:

Equation Source:
R. De Maesschalck, D. Jouan-Rimbaud, D.L. Massart. “The Mahalanobis distance.”
Chemometrics and Intelligent Laboratory Systems. Volume 50, Issue 1,
2000, Pages 1-18. ISSN 0169-7439. <https://doi.org/10.1016/S0169-7439(99)00047-7>

105

Appendix B: Computer Programs
QBEST Algorithm:
REPLICA
function [BTRAIN,CNTER]=replica(TNSPEC,B)
% TNSPEC=training spectra, B=number of replicates desired.
% REPLICA outputs BTRAIN replicates, and the center of the replicates in CNTER
% "Copyright 2003 Robert A. Lodder & Bin Dai"
[N,D]=size(TNSPEC);
BTRAIN=zeros(B,D);
CNTER=zeros(D,1);
BSAMP=zeros(N,D);
PICKS=rand(B*N,1);
index=find(PICKS==1);
PICKS(index)=0.9999;
PICKS=reshape(PICKS,B,N);
PICKS=fix(N*PICKS+1);
for I=1:B
BSAMP=TNSPEC(PICKS(I,:),:);
BTRAIN(I,:)=sum(BSAMP)/N;
end
BTRAIN;
CNTER=sum(BTRAIN)/B;
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SOB
function [ECDF,TCDF,R]=SOB(BTRAIN,CTN,NTN,TESTSPEC)
% This routine takes 2 spectral groups (with = numbers of samples)
% and calculates an ECDF and TCDF for QQ plotting. The routine
% also returns a correlation coefficient between the 2 CDFs.
% Training replicates and center must be provided, along with
% test spectra. BNUM = the number of replicates used.
% Note: you may have to set EPSILON(1e-200) or greater to prevent
% underflow errors in high dimensional hyperspaces
% Copyright 2003 Dr. Robert.A.Lodder & Bin Dai
[NTEST,C]=size(TESTSPEC);
[BTEST,CTEST]=replica(TESTSPEC,NTN);
[M,C]=size(BTRAIN);
p=0.1;
CTNN=repmat(CTN,M,1);
ST=(sum(((BTRAIN-CTNN).^C)')).^(1/C);
CTNN=repmat(CTN,NTN,1);
SX=(sum(((BTEST-CTNN).^C)')).^(1/C);
M=2*M;
TRIM=fix((M*p)+1):fix(M-(M*p));
ECDF=[ST,SX];
TCDF=[ST,ST];
ECDF=sort(ECDF);
TCDF=sort(TCDF);
ECDF=ECDF(TRIM);
TCDF=TCDF(TRIM);
R=corrcoef(TCDF,ECDF)
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Estimated Daily Intake Programs:
EDI
function [zarray] = EDI(serving_sizes,dose,age,day1,day2,mass)
%% This function solves for Expected Daily Intakes (EDIs) using the NHANES and
FNDDS databases.
% This program requires that the “NHANES basic startup workspace.mat” workspace be
present.
% The programs searchnzero, searchfoods.m, and searchsizes.m must all be in
% the working directory path.
% serving sizes = in rows to target_codes, 1st col.=food codes, 2nd
%
col. = serving sizes in g
% dose is a scalar variable specified by the client
% age, day1, day2, and mass are all in the “NHANES basic startup workspace.mat”
workspace
% zarray returns the mean mass of all ages just to put something into the output variable
and avoid an error
%
% Start with all patient sequence numbers in age groups
% Time to make food code tables for each group
%
% loop through Day1 and check each row to see if the SEQN in the first column is in the
set of SEQN for each age group
% if so, leave the row as is. if not, then replace the row with all zeros and eliminate the
zeros later
% get all foods consumed by each age group
target_codes = serving_sizes(:,1); % target_codes is a vector food codes of length =
number of rows in serving_sizes
% find the infant groups
ind_age0_1 = find((age(:,2)>0)&(age(:,2)<13)) ;
age0_1=age(ind_age0_1,1);
disp('Number of infants aged 0-1')
size(ind_age0_1)
ind_age1_2 = find((age(:,2)>14)&(age(:,2)<24));
age1_2=age(ind_age1_2,1);
disp('Number of toddlers aged 1-2')
size(ind_age1_2)
ind_age2_5 = find((age(:,2)>23)&(age(:,2)<61)); % create indexes for age groups, ages
are given in months, not years
age2_5=age(ind_age2_5,1);
disp('Number of subjects aged 2-5')
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size(age2_5)
ind_age6_12 = find((age(:,2)>62)&(age(:,2)<145));
age6_12=age(ind_age6_12,1);
disp('Number of subjects aged 6-12')
size(age6_12)
ind_age13_19 = find((age(:,2)>146)&(age(:,2)<229));
age13_19=age(ind_age13_19,1);
disp('Number of subjects aged 13-19')
size(age13_19)
ind_age20_up = find((age(:,2)>229));
age20_up=age(ind_age20_up,1);
disp('Number of subjects aged 20 and up')
size(ind_age20_up)
% find all ages > 2 years
ind_age2up = find((age(:,2)>23)&(age(:,2)<2000));
age2up=age(ind_age2up,1);
disp('Total number of subjects aged 2 and up')
size(ind_age2up)
% Day 1, delete entries not in specified age group
day1_age0_1 = searchnzero(age0_1,day1);
day1_age1_2 = searchnzero(age1_2,day1);
day1_age2_5 = searchnzero(age2_5,day1);
day1_age6_12 = searchnzero(age6_12,day1);
day1_age13_19 = searchnzero(age13_19,day1);
day1_age20_up = searchnzero(age20_up,day1);
day1_age2up = searchnzero(age2up,day1);
% Day 2
day2_age0_1 = searchnzero(age0_1,day2);
day2_age1_2 = searchnzero(age1_2,day2);
day2_age2_5 = searchnzero(age2_5,day2);
day2_age6_12 = searchnzero(age6_12,day2);
day2_age13_19 = searchnzero(age13_19,day2);
day2_age20_up = searchnzero(age20_up,day2);
day2_age2up = searchnzero(age2up,day2);
% throw away all food codes for each age's dietary data that are not in the targeted food
code list
%
day1_fc_age0_1 = searchfoods(day1_age0_1,target_codes);
day1_fc_age1_2 = searchfoods(day1_age1_2,target_codes);
day1_fc_age2_5 = searchfoods(day1_age2_5,target_codes);
day1_fc_age6_12 = searchfoods(day1_age6_12,target_codes);
day1_fc_age13_19 = searchfoods(day1_age13_19,target_codes);
day1_fc_age20_up = searchfoods(day1_age20_up,target_codes);
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day1_fc_age2up = searchfoods(day1_age2up,target_codes);
%
day2_fc_age0_1 = searchfoods(day2_age0_1,target_codes);
day2_fc_age1_2 = searchfoods(day2_age1_2,target_codes);
day2_fc_age2_5 = searchfoods(day2_age2_5,target_codes);
day2_fc_age6_12 = searchfoods(day2_age6_12,target_codes);
day2_fc_age13_19 = searchfoods(day2_age13_19,target_codes);
day2_fc_age20_up = searchfoods(day2_age20_up,target_codes);
day2_fc_age2up = searchfoods(day2_age2up,target_codes);
%
disp('Number of subjects eating target food on Day 1 aged 0-1')
size(day1_fc_age0_1)
disp('Number of subjects eating target food on Day 1 aged 1-2')
size(day1_fc_age1_2)
disp('Number of subjects eating target food on Day 1 aged 2-5')
size(day1_fc_age2_5)
disp('Number of subjects eating target food on Day 1 aged 6-12')
size(day1_fc_age6_12)
disp('Number of subjects eating target food on Day 1 aged 13-19')
size(day1_fc_age13_19)
disp('Number of subjects eating target food on Day 1 aged 20 and up')
size(day1_fc_age20_up)
disp('Number of subjects eating target food on Day 1 aged 2 and up')
size(day1_fc_age2up)
%
disp('Number of subjects eating target food on Day 2 aged 0-1')
size(day2_fc_age0_1)
disp('Number of subjects eating target food on Day 2 aged 1-2')
size(day2_fc_age1_2)
disp('Number of subjects eating target food on Day 2 aged 2-5')
size(day2_fc_age2_5)
disp('Number of subjects eating target food on Day 2 aged 6-12')
size(day2_fc_age6_12)
disp('Number of subjects eating target food on Day 2 aged 13-19')
size(day2_fc_age13_19)
disp('Number of subjects eating target food on Day 2 aged 20 and up')
size(day2_fc_age20_up)
disp('Number of subjects eating target food on Day 2 aged 2 and up')
size(day2_fc_age2up)
% scale food consumption of each food in grams to number of servings
% now do Day 1
serv_day1_age0_1 = searchsizes(day1_fc_age0_1,serving_sizes);
serv_day1_age1_2 = searchsizes(day1_fc_age1_2,serving_sizes);

110

serv_day1_age2_5 = searchsizes(day1_fc_age2_5,serving_sizes);
serv_day1_age6_12 = searchsizes(day1_fc_age6_12,serving_sizes);
serv_day1_age13_19 = searchsizes(day1_fc_age13_19,serving_sizes);
serv_day1_age20_up = searchsizes(day1_fc_age20_up,serving_sizes);
serv_day1_age2up = searchsizes(day1_fc_age2up,serving_sizes);
% now do Day 2
serv_day2_age0_1 = searchsizes(day2_fc_age0_1,serving_sizes);
serv_day2_age1_2 = searchsizes(day2_fc_age1_2,serving_sizes);
serv_day2_age2_5 = searchsizes(day2_fc_age2_5,serving_sizes);
serv_day2_age6_12 = searchsizes(day2_fc_age6_12,serving_sizes);
serv_day2_age13_19 = searchsizes(day2_fc_age13_19,serving_sizes);
serv_day2_age20_up = searchsizes(day2_fc_age20_up,serving_sizes);
serv_day2_age2up = searchsizes(day2_fc_age2up,serving_sizes);
% now calculate mean Expected Daily Intakes (EDIs) using the mass of additive that the
client wants to add to each food.
% Day 1
disp('Mean Expected Daily Intakes (EDIs)')
mean0_1day1 = mean(serv_day1_age0_1(:,4))*dose; % mg EDI
mean1_2day1 = mean(serv_day1_age1_2(:,4))*dose; % mg EDI
mean2_5day1 = mean(serv_day1_age2_5(:,4))*dose; % mg EDI
mean6_12day1 = mean(serv_day1_age6_12(:,4))*dose; % mg EDI
mean13_19day1 = mean(serv_day1_age13_19(:,4))*dose; % mg EDI
mean20_upday1 = mean(serv_day1_age20_up(:,4))*dose; % mg EDI
mean2upday1 = mean(serv_day1_age2up(:,4))*dose; % mg EDI
% now do day 2
mean0_1day2 = mean(serv_day2_age0_1(:,4))*dose; % mg EDI
mean1_2day2 = mean(serv_day2_age1_2(:,4))*dose; % mg EDI
mean2_5day2 = mean(serv_day2_age2_5(:,4))*dose; % mg EDI
mean6_12day2 = mean(serv_day2_age6_12(:,4))*dose; % mg EDI
mean13_19day2 = mean(serv_day2_age13_19(:,4))*dose; % mg EDI
mean20_upday2 = mean(serv_day2_age20_up(:,4))*dose; % mg EDI
mean2upday2 = mean(serv_day2_age2up(:,4))*dose; % mg EDI
% to make histograms of exposure data here, add a breakpoint and use
% hist(). For example, copy and paste
% bins=round(sqrt(size(serv_day2_age2up(:,4))))
% bins=bins(1)
% hist(serv_day2_age2up(:,4),bins)
%
% average day 1 and day 2
disp('Mean EDI ages 0 to 1')
medi0_1=(mean0_1day1+mean0_1day2)/2
disp('Mean EDI ages 1-2')
medi1_2=(mean1_2day1+mean1_2day2)/2
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disp('Mean EDI ages 2-5')
medi2_5=(mean2_5day1+mean2_5day2)/2
disp('Mean EDI ages 6-12')
medi6_12=(mean6_12day1+mean6_12day2)/2
disp('Mean EDI ages 13-19')
medi13_19=(mean13_19day1+mean13_19day2)/2
disp('Mean EDI ages 20 and up')
medi20up=(mean20_upday1+mean20_upday2)/2
disp('Mean EDI ages 2 and up')
medi2up=(mean2upday1+mean2upday2)/2
% for 90th percentile calculation of Day 1, produces sorted doses in each age group
sort_day1_age0_1 = sort(serv_day1_age0_1(:,4))*dose;
sort_day1_age1_2 = sort(serv_day1_age1_2(:,4))*dose;
sort_day1_age2_5 = sort(serv_day1_age2_5(:,4))*dose;
sort_day1_age6_12 = sort(serv_day1_age6_12(:,4))*dose;
sort_day1_age13_19 = sort(serv_day1_age13_19(:,4))*dose;
sort_day1_age20_up = sort(serv_day1_age20_up(:,4))*dose;
sort_day1_age2up = sort(serv_day1_age2up(:,4))*dose;
%
sort_day1_age0_1_d1 = sort_day1_age0_1(round(.9*size(sort_day1_age0_1)));
sort_day1_age1_2_d1 = sort_day1_age1_2(round(.9*size(sort_day1_age1_2)));
sort_day1_age2_5_d1 = sort_day1_age2_5(round(.9*size(sort_day1_age2_5))); % 90th
percentile
sort_day1_age6_12_d1 = sort_day1_age6_12(round(.9*size(sort_day1_age6_12)));
sort_day1_age13_19_d1 = sort_day1_age13_19(round(.9*size(sort_day1_age13_19)));
sort_day1_age20_up_d1 = sort_day1_age20_up(round(.9*size(sort_day1_age20_up)));
sort_day1_age2up_d1 = sort_day1_age2up(round(.9*size(sort_day1_age2up)));
%
% Day 2 for 90th percentile calculation, produces sorted doses in each age group
sort_day2_age0_1 = sort(serv_day2_age0_1(:,4))*dose;
sort_day2_age1_2 = sort(serv_day2_age1_2(:,4))*dose;
sort_day2_age2_5 = sort(serv_day2_age2_5(:,4))*dose;
sort_day2_age6_12 = sort(serv_day2_age6_12(:,4))*dose;
sort_day2_age13_19 = sort(serv_day2_age13_19(:,4))*dose;
sort_day2_age20_up = sort(serv_day2_age20_up(:,4))*dose;
sort_day2_age2up = sort(serv_day2_age2up(:,4))*dose;
%
sort_day2_age0_1_d2 = sort_day2_age0_1(round(.9*size(sort_day2_age0_1)));
sort_day2_age1_2_d2 = sort_day2_age1_2(round(.9*size(sort_day2_age1_2)));
sort_day2_age2_5_d2 = sort_day2_age2_5(round(.9*size(sort_day2_age2_5))); % 90th
percentile
sort_day2_age6_12_d2 = sort_day2_age6_12(round(.9*size(sort_day2_age6_12)));
sort_day2_age13_19_d2 = sort_day2_age13_19(round(.9*size(sort_day2_age13_19)));
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sort_day2_age20_up_d2 = sort_day2_age20_up(round(.9*size(sort_day2_age20_up)));
sort_day2_age2up_d2 = sort_day2_age2up(round(.9*size(sort_day2_age2up)));
%
% calculate means of day 1 and day 2 90th percentiles
disp('Mean 90th percentiles')
M90_age0_1 = (sort_day1_age0_1_d1 + sort_day2_age0_1_d2)/2
M90_age1_2 = (sort_day1_age1_2_d1 + sort_day2_age1_2_d2)/2
M90_age2_5 = (sort_day1_age2_5_d1 + sort_day2_age2_5_d2)/2
M90_age6_12 = (sort_day1_age6_12_d1 + sort_day2_age6_12_d2)/2
M90_age13_19 = (sort_day1_age13_19_d1 + sort_day2_age13_19_d2)/2
M90_age20_up = (sort_day1_age20_up_d1 + sort_day2_age20_up_d2)/2
M90_age2up = (sort_day1_age2up_d1 + sort_day2_age2up_d2)/2
% now do body mass calculations
% find masses of each age group
mass0_1 = searchnzero(age0_1,mass);
mass1_2 = searchnzero(age1_2,mass);
mass2_5 = searchnzero(age2_5,mass);
mass6_12 = searchnzero(age6_12,mass);
mass13_19 = searchnzero(age13_19,mass);
mass20_up = searchnzero(age20_up,mass);
mass2up = searchnzero(age2up,mass);
% calculate the mean masses of each age group
disp('Mean mass of each age group')
age_group_masses =
[mean(mass0_1(:,2)),mean(mass1_2(:,2)),mean(mass2_5(:,2)),mean(mass6_12(:,2)),m
ean(mass13_19(:,2)),mean(mass20_up(:,2)),mean(mass2up(:,2))]
allmass_ages=[mean(mass0_1(:,2));mean(mass1_2(:,2));mass2_5(:,2);mass6_12(:,2);m
ass13_19(:,2);mass20_up(:,2);mean(mass2up(:,2))];
disp('Total number of subjects in all mass/age groups')
size(allmass_ages)
disp('Mean weight of all mass/age groups')
mean(allmass_ages)
disp('Percent Users')
disp('age 0-1')
(size(day1_fc_age0_1)/size(ind_age0_1))*100
disp('age 1-2')
(size(day1_fc_age1_2)/size(ind_age1_2))*100
disp('age 2-5')
(size(day1_fc_age2_5)/size(ind_age2_5))*100
disp('age 6-12')
(size(day1_fc_age6_12)/size(ind_age6_12))*100
disp('age 13-19')
(size(day1_fc_age13_19)/size(ind_age13_19))*100
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disp('age 20+')
(size(day1_fc_age20_up)/size(ind_age20_up))*100
disp('age 2+')
(size(day1_fc_age2up)/size(ind_age2up))*100
% now adjust the mean EDI and 90th %-tile for weight
disp('Weight-based Mean EDIs')
disp('age 0-1')
medi0_1/mean(mass0_1(:,2))
disp('age 1-2')
medi1_2/mean(mass1_2(:,2))
disp('age 2-5')
medi2_5/mean(mass2_5(:,2))
disp('age 6-12')
medi6_12/mean(mass6_12(:,2))
disp('age 13-19')
medi13_19/mean(mass13_19(:,2))
disp('age 20+')
medi20up/mean(mass20_up(:,2))
disp('age 2+')
medi2up/mean(mass2up(:,2))
%
disp('Weight-based 90th Percentile EDIs')
disp('age 0-1')
M90_age0_1/mean(mass0_1(:,2))
disp('age 1-2')
M90_age1_2/mean(mass1_2(:,2))
disp('age 2-5')
M90_age2_5/mean(mass2_5(:,2))
disp('age 6-12')
M90_age6_12/mean(mass6_12(:,2))
disp('age 13-19')
M90_age13_19/mean(mass13_19(:,2))
disp('age 20+')
M90_age20_up/mean(mass20_up(:,2))
disp('age 2+')
M90_age2up/mean(mass2up(:,2))
% At this point it would be good to print out the food codes and serving
% sizes used to produce these data. Also the dose of proposed additive.
disp('Dose of Proposed Additive')
dose
disp('Food Codes and Serving Sizes Used to Produce These Data')
serving_sizes
zarray = mean(allmass_ages); % just to put something into the output variable and
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avoid an error
end
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searchfoodcodes
function [foodnums,longfooddesc] = searchfoodcodes(targ_codes)
% This function takes a 1-D list food codes (targ_codes) targeted for an EDI
% calculation in NHANES and zeros out rows (foods) in the food code list
% (food codes.xls, must be in path) that are not in the targeted food code list
[num,txt,raw] = xlsread('food codes.xls'); % read in food codes
% column 1=numbers, 2=TEXT CAPS, 3=long text
c=size(num);
% setting counter maximum
c=c(1);
% first number is loop size needed
zarray = txt(:,3);
% fill output array with long food descriptors
for i=1:c
% loop over all food codes
if any(num(i,1) == targ_codes); % compare subject SEQNs to target codes
a=1;
% if match, do nothing, leave line there
else
zarray(i,1) = cellstr('X0'); % else zero it
end
end
unkeep=find(strcmp(zarray(:,1),'X0')); % delete these foods in the food code list
tu=transpose(unkeep);
% vectors must be the same type, row vector
k=zeros(1,c);
% create indices for set of all food codes
k=k+(1:c);
% indices are now a row vector
keep=setdiff(k,tu); % keep the set of foods we are not deleting
zarray = zarray(keep,:);
% by deleting lines with x zeros
longfooddesc = zarray;
% return the long food descriptors
foodnums = num(keep);
% return the corresponding food codes
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searchfoods
function zarray = searchfoods(age_diet,targ_codes)
% This function takes the food groups (targ_codes) targeted for an EDI
% calculation in NHANES and zeros out rows (foods) in a dietary age group
% (age_diet) that are not in the targeted food code list
zarray = age_diet;
% initialize output array
c=size(age_diet(:,2)); % setting counter maximum
c=c(1);
% first number is loop size needed
for i=1:c
if any(age_diet(i,2) == targ_codes); % compare subject SEQNs
a=1;
% do nothing
else
zarray(i,:) = 0;
end
end
keep=find(zarray(:,2) ~= 0); % keep foods in the food code list
zarray = zarray(keep,:);

117

searchnzero
function zarray = searchnzero(age_group,dietary_data)
% This function takes the SEQN numbers for an age group for an EDI
% calculation in NHANES and zeros out rows not in that age group
zarray = dietary_data;
% initialize output array
c=size(dietary_data(:,1)); % setting counter maximum
c=c(1);
% first number is loop size needed
for i=1:c
if any(dietary_data(i,1) == age_group); % compare subject SEQNs
a=1;
% do nothing
else
zarray(i,:) = 0;
end
end
keep=find(zarray(:,1) ~= 0);
zarray = zarray(keep,:);
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searchsizes
function zarray = searchsizes(age_diet_fc,serving_sizes)
% This function takes the food groups (targ_codes) targeted for an EDI
% calculation in NHANES and zeros out rows (foods) in a dietary age group
% (age_diet) that are not in the targeted food code list
zarray = age_diet_fc;
% initialize output array
c=size(age_diet_fc(:,2)); % setting counter maximum
c=c(1);
% first number is loop size needed
for i=1:c
if any(age_diet_fc(i,2) == serving_sizes(:,1)); % compare subject SEQNs
[l,loc_fc]=ismember(age_diet_fc(i,2),serving_sizes(:,1)); % find serving size
zarray(i,4)=zarray(i,3)/serving_sizes(loc_fc,2); % scale g to servings
end
end
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ADI Programs:

Generate_ADI_translation_figure
%This program generates two
%elliptical clusters of data for demonstrating translation of clusters
%for ellagic acid ADI paper
mu=[0,0];
sigma=[2,1];
SavedTNSPEC=mvnrnd(mu,sigma,25);
figure
scatter(SavedTNSPEC(:,1),SavedTNSPEC(:,2))
hold on
mu=[3,3];
sigma=[2,1];
SavedTNSPEC=mvnrnd(mu,sigma,25);
scatter(SavedTNSPEC(:,1),SavedTNSPEC(:,2))
%Graph Center
scatter(0,0,50,'b','filled')
%Graph Center
scatter(3,3,50,'r','filled')
legend('No Effects Set','Effects Set',...
'No Effects Set Center','Effects Set Center')
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International Units from King-Bodansky Units
%Conversion of King Armstrong Units into International Units
%This program uses the math laid out by
%“International Enzyme Units and Isoenzyme Nomenclature.”
%Journal of Clinical Pathology 16.4 (1963): 391–393. Print.
%and the two-point definition of a line to predict the equivalent value of
%International Units of enzyme activity from King-Armstrong Units.
%This program requires the input of an integer KingArmstrong.
%The text defines that the commonly accepted range of normal values of
%3 to 13 K.A. units/100 ml. corresponds to about 20 to 90
%micromoles/min./litre.
%The equation of the line that runs through those points is y=7x-1
micromoles_per_min_per_liter=7*(KingArmstrong)-1;
%Bodansky Unit is defined by text as 0.535 micromol/min
Bodansky_Units=micromoles_per_min_per_liter/0.535;

%The text defines that the commonly accepted range of normal values of
%1 to 5 Bodansky units/100 ml. blood plasma corresponds to
%about 5.4 to 27 micromoles/min./litre.
%The equation of the line that runs through those points is y=5.4x
International_Units=5.4*(Bodansky_Units)
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Round the Compass Rose Experiment Programs:
Round the Compass Rose (Simplified)
%Round the Compass Rose
%Description:
%This program tests increasing bootstrap replicates increasing, number of
%dimensions (wavelengths), increasing size of training set, and
%differential proportion of points chosen to be inside of the
%hypercyllinder (radfrac). Radfrac is tested with a given minimum
%radfrac, a step value, and a maximum value.
%Tests the performance of replica.m and qb.m on elliptical clusters of
%data.
%Parameters:
%z: maximum number of bootstrap replicates desired/50.
%dimension: the maximum number of dimensions (variables) wished to be
%
tested
%Max_training: the maximum training set size desired/50, represented by "u"
%Radfrac_min: the minimum radfrac wished to be tested. Radfrac_min must be
%
<=1.
%Radfrac_step: the step wished for testing radfrac
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be
%
<=1.
%Radfrac_min = 1, Radfrac_step=0 is an invalid input.

%CODE BEGINS HERE
%Start by initializing the random number generator.
rng('default');
rng(1);

sensitiv=0;

%Initialize the iteration counter for radfrac loops. Since radfrac is a
%non-integer value that can vary, it can't be used as an index for a cell
%array. Thus, radfrac_iteration_count is used for the index instead.
radfrac_iteration_count=0;
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for radfrac= Radfrac_min : Radfrac_step : Radfrac_max
%a123=1; %This line only exists for the purpose of utilizing
%breakpoints.
if Radfrac_min==1
disp('Radfrac_min must not be 1.')
break %Should resolve Radfrac_min!=1 problem and just
%exit the loop.
elseif Radfrac_step==0
disp('Radfrac_step must not be 0')
break
elseif Radfrac_min==Radfrac_max
disp('Radfrac_min may not equal Radfrac_max.')
break
else radfrac_iteration_count=radfrac_iteration_count+1;
end
for u=1:Max_training
%Begin for-loop. This will allow for the increase of dimensions from 1
%to dimensions with a step of one. Further uses of i are to concatenate
%columns of zeroes and ensure the correct number of coordinates for mu (0
%in all dimensions)and sigma (1 in all dimensions other than one).
for v=0:dimension; %%this was originally from v=1:dimension so that the cell
%indices could be x(v), but it has been modified to
%x(v+1)this has been modified from v=0:dimension so that the cell indices work

%Generate an ellipse
mu=[0,0];
mu = [mu zeros(size(mu,1),(v))];
sigma=[2,1];
sigma=[sigma ones(size(sigma,1),(v))];
TNSPEC=mvnrnd(mu,sigma,50*u);compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5)));
-2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));
0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))];
%Add a column of zeros to compass_points indicating coordinate in
%each of the the new dimensions
compass_points=[compass_points zeros(size(compass_points,1),(v))];
%Define expected standard deviations. CHANGE THIS LINE IF POINTS
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% CHANGE.
expected_standard_deviation = [1;1.2649;2;1.2649;1;1.2649;2;1.2649];
%Test point at each point of the compass rose
for j=1:8
newspec = [compass_points(j,:)];
%This is the innermost iterative loop of the program.
%Initialize storage matrices of sds and sdsskew
%(6+v) syntax increases the size of SDS_matrix to fit the
%coordinate points of each dimension
SDS_matrix=zeros(z,(6+(v)));
SDS_matrix_2=zeros(z,(6+v));
SDS_matrix_3=zeros(z,(6+v));
SDS_matrix_4=zeros(z,(6+v));
SDS_matrix_5=zeros(z,(6+v));
SDS_matrix_6=zeros(z,(6+v));

%How number of bootstrap replicates affects SDS and SDS Skew at those
%points on the compass rose
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end

%Repeat the process to generate SDS_matrix_2
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
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[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_3
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_4
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_5
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME

125

end
SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_6
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%***All storage has to happen here***
%This is the innermost iterative loop of the program.

%Generate a matrix of the average of the 6 runs.
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order
%Note that AVERAGE increases in size as dimension increases.
%When dimension increases by one, one additional column is inserted in
%the three position. This can be expressed by the following:
%sdskew is located in a column position equal to 6+v, or in
%AVERAGE(:,6+v)
%bias is located in (:,5+v)
%sds is located in (:,4+v)
%B is located in (:,3+v,)
%compass points are located in(:,1:v+2)
AVERAGE=zeros(size(SDS_matrix));
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 +
SDS_matrix_5 + SDS_matrix_6))/6;
%Populate SDS_X_STDEV with the SD values of each run
%sds is located in (:,4:v)
SDS_1_STDEV=zeros(z,1);
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v));
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SDS_2_STDEV=zeros(z,1);
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v));
SDS_3_STDEV=zeros(z,1);
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v));
SDS_4_STDEV=zeros(z,1);
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v));
SDS_5_STDEV=zeros(z,1);
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v));
SDS_6_STDEV=zeros(z,1);
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v));
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV
SDS_1_STDEV_calc=zeros(z,1);
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_2_STDEV_calc=zeros(z,1);
SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_3_STDEV_calc=zeros(z,1);
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_4_STDEV_calc=zeros(z,1);
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_5_STDEV_calc=zeros(z,1);
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_6_STDEV_calc=zeros(z,1);
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
% Sum the above and calculate STANDARD_DEVIATION=
FINAL_STDEV=zeros(z,1);
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5);

%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC,
%and each Radfrac
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%bias is located in AVERAGE(:,5+v)
%B is located in AVERAGE(:,3+v,)
Bias_plot=zeros(z,7);
Bias_plot(:,1)=AVERAGE(:,(3+v));
Bias_plot(:,2)=AVERAGE(:,(5+v));
Bias_plot(:,3)=(v+2);
Bias_plot(:,4)=AVERAGE(:,1);
Bias_plot(:,5)=AVERAGE(:,2);
Bias_plot(:,6)=radfrac;
Bias_plot(:,7)=u*50;
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the
%beginning of the v loop
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot;
%Indexing is {radfrac number, training, dimension - 1, compass point
%number}
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)

%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of
%returned standard deviation, total number of dimensions (v+2), radfrac,
%Training Set Size]
RSD=zeros(z,7);
RSD(:,1)=AVERAGE(:,1);
RSD(:,2)=AVERAGE(:,2);
RSD(:,3)=AVERAGE(:,(v+3));
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4)));
RSD(:,5)=(v+2);
RSD(:,6)=radfrac;
RSD(:,7)=u*50;
%Hold all RSD plots for all runs
%Indexing is {Radfrac Iteration Count (must
%separately count Radfrac value),Training Set Size,dimension,Compass Point,}
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
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end
end
end
end
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Regression Codes
RSD_Regression_2
%Regresses RSD as function of Bootstrapping Only
%Requires workspace variables NumVL and RSD_NumVL, Max_training,
%Indexing in NumVL Cell Matrix is as Follows:
%Indexing is {Radfrac Iteration Count (must separately count...
%Radfrac value),Training Set Size,dimension,Compass Point,}
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
%Within matrix:
%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [1.compass point coordinate, 2.compass point coordinate,...
%3.B, 4.RSD of returned standard deviation, ...
%5.total number of dimensions (v+2), 6.radfrac,
%7.Training Set Size]
%Make sure these exist.
NumVL;
RSD_NumVL;
out=[cat(1,RSD_NumVL{:})];
x=size(out);
w=x(:,1);
y=zeros(x(:,1),1);
%Designate compass points - work in progress
newmatrix=[out,y];
%nonprincipal axis points
npa=newmatrix(:,1)==0;
%principal axis points
pa=newmatrix(:,1)==2;
opa=newmatrix(:,1)==-2;
%since diagonals have a calculation that determines the value
%it is hard to tell how many digits of precision
%therefore, diagonals are not equal to 0, 2, or -2.
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%First find indices ~=0
dp=newmatrix(:,1)~=0;
dp2=newmatrix(dp,:);
%Now find indices in the ~=0 subset also ~= 2
fdp=dp2(:,1)~=2;
dp3=dp2(fdp,:);
%Last, find indices in that subset also ~= to -2
ffdp=dp3(:,1)~=-2;
nonprincipalaxis=[newmatrix(npa,:)];
principalaxis=[newmatrix(pa,:);newmatrix(opa,:)];
diagonalpoints=[dp3(ffdp,:)];
for i=1:3
%try to regress output for each degree.
degree=i

%Regress Non-Principal
disp('Non-Principal Axis Regression')
npa_output=[nonprincipalaxis(:,4)];
npa_input=[nonprincipalaxis(:,3)];
%,nonprincipalaxis(:,5),...
% nonprincipalaxis(:,6),nonprincipalaxis(:,7)];
reg = MultiPolyRegress(npa_input,npa_output,degree)

%Regress Principal
disp('Principal Axis Regression')
pa_output=[principalaxis(:,4)];
pa_input=[principalaxis(:,3)];
%,principalaxis(:,5),...
% principalaxis(:,6),principalaxis(:,7)];
reg = MultiPolyRegress(pa_input,pa_output,degree)

%Regress Diagonal
disp('Diagonal Regression')
d_output=[diagonalpoints(:,4)];
d_input=[diagonalpoints(:,3)];
%,diagonalpoints(:,5),...
% diagonalpoints(:,6),diagonalpoints(:,7)];
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reg = MultiPolyRegress(d_input,d_output,degree)
end
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Plotting Codes:
RTCR_Defined_TNSPEC_Size
%Generate and save a training spectrum of a given size, then run and
%increase with different numbers of bootstrap
%replicates to determine whether TNSPEC is the cause of erractic RSD in
%samples
%TNSPEC was saved as SavedTNSPEC
%U HAS CHANGED. CHANGE INDEXING IN PLOT CODE
%RNG is now 20

%Parameters:
%z: maximum number of bootstrap replicates desired/50.
%dimension: the maximum number of dimensions (variables) wished to be
%
tested
%Max_training: the maximum training set size desired/50, represented by "u"
%Radfrac_min: the minimum radfrac wished to be tested. Radfrac_min must be
%
<=1.
%Radfrac_step: the step wished for testing radfrac
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be
%
<=1.
%Radfrac_min = 1, Radfrac_step=0 is an invalid input.

%CODE BEGINS HERE
%Start by initializing the random number generator.
rng('default');
rng(20);

sensitiv=0;

%Initialize the iteration counter for radfrac loops. Since radfrac is a
%non-integer value that can vary, it can't be used as an index for a cell
%array. Thus, radfrac_iteration_count is used for the index instead.
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radfrac_iteration_count=4;
radfrac=0.8;
u=200;
z=10;
%Begin for-loop. This will allow for the increase of dimensions from 1
%to dimensions with a step of one. Further uses of i are to concatenate
%columns of zeroes and ensure the correct number of coordinates for mu (0
%in all dimensions)and sigma (1 in all dimensions other than one).
v=0;
%Generate an ellipse
mu=[0,0];
mu = [mu zeros(size(mu,1),(v))];
sigma=[2,1];
sigma=[sigma ones(size(sigma,1),(v))];
TNSPEC=mvnrnd(mu,sigma,50*u);
SavedTNSPEC=TNSPEC
%Compass Points & Expected Standard Deviation
compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));...
0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))];
expected_standard_deviation=[1;1.2649;2;1.2649;1;1.2649;2;1.2649];
%Test point at each point of the compass rose
for j=1:8
newspec = [compass_points(j,:)];
%This is the innermost iterative loop of the program.
%Initialize storage matrices of sds and sdsskew
%(6+v) syntax increases the size of SDS_matrix to fit the
%coordinate points of each dimension
SDS_matrix=zeros(z,(6+(v)));
SDS_matrix_2=zeros(z,(6+v));
SDS_matrix_3=zeros(z,(6+v));
SDS_matrix_4=zeros(z,(6+v));
SDS_matrix_5=zeros(z,(6+v));
SDS_matrix_6=zeros(z,(6+v));
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%How number of bootstrap replicates affects SDS and SDS Skew at those
%points on the compass rose
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end

%Repeat the process to generate SDS_matrix_2
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_3
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
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%Repeat the process to generate SDS_matrix_4
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_5
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_6
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%***All storage has to happen here***
%This is the innermost iterative loop of the program.
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%Generate a matrix of the average of the 6 runs.
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order
%Note that AVERAGE increases in size as dimension increases.
%When dimension increases by one, one additional column is inserted in
%the three position. This can be expressed by the following:
%sdskew is located in a column position equal to 6+v, or in
%AVERAGE(:,6+v)
%bias is located in (:,5+v)
%sds is located in (:,4+v)
%B is located in (:,3+v,)
%compass points are located in(:,1:v+2)
AVERAGE=zeros(size(SDS_matrix));
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 +
SDS_matrix_5 + SDS_matrix_6))/6;
%Populate SDS_X_STDEV with the SD values of each run
%sds is located in (:,4:v)
SDS_1_STDEV=zeros(z,1);
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v));
SDS_2_STDEV=zeros(z,1);
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v));
SDS_3_STDEV=zeros(z,1);
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v));
SDS_4_STDEV=zeros(z,1);
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v));
SDS_5_STDEV=zeros(z,1);
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v));
SDS_6_STDEV=zeros(z,1);
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v));
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV
SDS_1_STDEV_calc=zeros(z,1);
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_2_STDEV_calc=zeros(z,1);
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SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_3_STDEV_calc=zeros(z,1);
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_4_STDEV_calc=zeros(z,1);
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_5_STDEV_calc=zeros(z,1);
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_6_STDEV_calc=zeros(z,1);
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
% Sum the above and calculate STANDARD_DEVIATION=
FINAL_STDEV=zeros(z,1);
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5);

%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC,
%and each Radfrac
%bias is located in AVERAGE(:,5+v)
%B is located in AVERAGE(:,3+v,)
Bias_plot=zeros(z,7);
Bias_plot(:,1)=AVERAGE(:,(3+v));
Bias_plot(:,2)=AVERAGE(:,(5+v));
Bias_plot(:,3)=(v+2);
Bias_plot(:,4)=AVERAGE(:,1);
Bias_plot(:,5)=AVERAGE(:,2);
Bias_plot(:,6)=radfrac;
Bias_plot(:,7)=u;
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the
%beginning of the v loop
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot;
%Indexing is {radfrac number, training, dimension - 1, compass point
%number}
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
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%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)

%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of
%returned standard deviation, total number of dimensions (v+2), radfrac,
%Training Set Size]
RSD=zeros(z,7);
RSD(:,1)=AVERAGE(:,1);
RSD(:,2)=AVERAGE(:,2);
RSD(:,3)=AVERAGE(:,(v+3));
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4)));
RSD(:,5)=(v+2);
RSD(:,6)=radfrac;
RSD(:,7)=u;
%Hold all RSD plots for all runs
%Indexing is {Radfrac Iteration Count (must
%separately count Radfrac value),Training Set Size,dimension,Compass Point,}
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
end

%Plot Code
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Plotting Relative Standard Deviation
%Plotting Relative Standard Deviation
%as Bootstrapping and Radfrac Increase
%This code plots bootstrapping vs. RSD as radfrac increases
%for run_TNSPEC code ONLY
%Changes: u has changed in the run_TNPSEC code from what it
%has in Round_the_Compass_Rose_simplified.m
%Indexing in NumVL Cell Matrix is as Follows:
%Indexing is {Radfrac Iteration Count (must separately count...
%Radfrac value),Training Set Size,dimension,Compass Point,}
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
%Within matrix:
%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [1.compass point coordinate, 2.compass point coordinate,...
%3.B, 4.RSD of returned standard deviation, ...
%5.total number of dimensions (v+2), 6.radfrac,
%7.Training Set Size]

figure('Name','4,1,1 npa')
r4_t50_d2_c01=[RSD_NumVL{4,200,1,1}]
plot (r4_t50_d2_c01(:,3),r4_t50_d2_c01(:,4));
hold on
r4_t50_d2_cneg01=[RSD_NumVL{4,200,1,5}];
plot (r4_t50_d2_cneg01(:,3),r4_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';...
'Radfrac=0.8 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
hold off
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Run TNSPEC Version 2
%Re-run premade Training spectrum with different numbers of bootstrap
%replicates to determine whether TNSPEC is the cause of erractic RSD in
%samples
%TNSPEC was saved as
%U HAS CHANGED. CHANGE INDEXING IN PLOT CODE

%Parameters:
%z: maximum number of bootstrap replicates desired/50.
%dimension: the maximum number of dimensions (variables) wished to be
%
tested
%Max_training: the maximum training set size desired/50, represented by "u"
%Radfrac_min: the minimum radfrac wished to be tested. Radfrac_min must be
%
<=1.
%Radfrac_step: the step wished for testing radfrac
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be
%
<=1.
%Radfrac_min = 1, Radfrac_step=0 is an invalid input.

%CODE BEGINS HERE
%Start by initializing the random number generator.
%Input this first:
%rng('default');
%rng(10);

sensitiv=0;

%Initialize the iteration counter for radfrac loops. Since radfrac is a
%non-integer value that can vary, it can't be used as an index for a cell
%array. Thus, radfrac_iteration_count is used for the index instead.
radfrac_iteration_count=4;
radfrac=0.8;
[u,other]=size(SavedTNSPEC);
z=10;
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%Begin for-loop. This will allow for the increase of dimensions from 1
%to dimensions with a step of one. Further uses of i are to concatenate
%columns of zeroes and ensure the correct number of coordinates for mu (0
%in all dimensions)and sigma (1 in all dimensions other than one).
v=0;
%Generate an ellipse
mu=[0,0];
mu = [mu zeros(size(mu,1),(v))];
sigma=[2,1];
sigma=[sigma ones(size(sigma,1),(v))];
TNSPEC=SavedTNSPEC
%Compass Points & Expected Standard Deviation
compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));...
0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))];
expected_standard_deviation=[1;1.2649;2;1.2649;1;1.2649;2;1.2649];
%Test point at each point of the compass rose
for j=1:8
newspec = [compass_points(j,:)];
%This is the innermost iterative loop of the program.
%Initialize storage matrices of sds and sdsskew
%(6+v) syntax increases the size of SDS_matrix to fit the
%coordinate points of each dimension
SDS_matrix=zeros(z,(6+(v)));
SDS_matrix_2=zeros(z,(6+v));
SDS_matrix_3=zeros(z,(6+v));
SDS_matrix_4=zeros(z,(6+v));
SDS_matrix_5=zeros(z,(6+v));
SDS_matrix_6=zeros(z,(6+v));

%How number of bootstrap replicates affects SDS and SDS Skew at those
%points on the compass rose
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
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try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end

%Repeat the process to generate SDS_matrix_2
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_3
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_4
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
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[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_5
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%Repeat the process to generate SDS_matrix_6
for i=1:z
B=50*i;
sds = nan; bias = nan; sdskew = nan;
try
[BTRAIN,CNTER]=replica(TNSPEC,B);
[sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv);
bias=sds-expected_standard_deviation(j);
catch ME
end
SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew];
end
%***All storage has to happen here***
%This is the innermost iterative loop of the program.

%Generate a matrix of the average of the 6 runs.
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order
%Note that AVERAGE increases in size as dimension increases.
%When dimension increases by one, one additional column is inserted in
%the three position. This can be expressed by the following:
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%sdskew is located in a column position equal to 6+v, or in
%AVERAGE(:,6+v)
%bias is located in (:,5+v)
%sds is located in (:,4+v)
%B is located in (:,3+v,)
%compass points are located in(:,1:v+2)
AVERAGE=zeros(size(SDS_matrix));
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 +
SDS_matrix_5 + SDS_matrix_6))/6;
%Populate SDS_X_STDEV with the SD values of each run
%sds is located in (:,4:v)
SDS_1_STDEV=zeros(z,1);
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v));
SDS_2_STDEV=zeros(z,1);
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v));
SDS_3_STDEV=zeros(z,1);
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v));
SDS_4_STDEV=zeros(z,1);
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v));
SDS_5_STDEV=zeros(z,1);
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v));
SDS_6_STDEV=zeros(z,1);
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v));
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV
SDS_1_STDEV_calc=zeros(z,1);
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_2_STDEV_calc=zeros(z,1);
SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_3_STDEV_calc=zeros(z,1);
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_4_STDEV_calc=zeros(z,1);
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
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SDS_5_STDEV_calc=zeros(z,1);
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
SDS_6_STDEV_calc=zeros(z,1);
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2);
% Sum the above and calculate STANDARD_DEVIATION=
FINAL_STDEV=zeros(z,1);
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5);

%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC,
%and each Radfrac
%bias is located in AVERAGE(:,5+v)
%B is located in AVERAGE(:,3+v,)
Bias_plot=zeros(z,7);
Bias_plot(:,1)=AVERAGE(:,(3+v));
Bias_plot(:,2)=AVERAGE(:,(5+v));
Bias_plot(:,3)=(v+2);
Bias_plot(:,4)=AVERAGE(:,1);
Bias_plot(:,5)=AVERAGE(:,2);
Bias_plot(:,6)=radfrac;
Bias_plot(:,7)=u;
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the
%beginning of the v loop
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot;
%Indexing is {radfrac number, training, dimension - 1, compass point
%number}
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)

%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of
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%returned standard deviation, total number of dimensions (v+2), radfrac,
%Training Set Size]
RSD=zeros(z,7);
RSD(:,1)=AVERAGE(:,1);
RSD(:,2)=AVERAGE(:,2);
RSD(:,3)=AVERAGE(:,(v+3));
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4)));
RSD(:,5)=(v+2);
RSD(:,6)=radfrac;
RSD(:,7)=u;
%Hold all RSD plots for all runs
%Indexing is {Radfrac Iteration Count (must
%separately count Radfrac value),Training Set Size,dimension,Compass Point,}
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
end

%Plot Code
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Plotting_Code_Increase_Radfrac_Bootstrap
%This code plots bootstrapping vs. bias as radfrac increases
%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Set Axis Limits for All Graphs:
graphlimits=[50,500,-40,40];
figure('Name','1,1,1 npa')
r1_t50_d2_c01=[NumVL{1,1,1,1}]
%x 100 to make a percent error
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2));
hold on
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]
%x 100 to make a percent error
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

figure('Name','2,1,1 npa')
r2_t50_d2_c01=[NumVL{2,1,1,1}];
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%x 100 to make a percent error
r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2));
hold on
r2_t50_d2_cneg01=[NumVL{2,1,1,5}];
%x 100 to make a percent error
r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','3,1,1 npa')
r3_t50_d2_c01=[NumVL{3,1,1,1}]
%x 100 to make a percent error
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2));
hold on
r3_t50_d2_cneg01=[NumVL{3,1,1,5}];
%x 100 to make a percent error
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','4,1,1 npa')
r4_t50_d2_c01=[NumVL{4,1,1,1}]
%x 100 to make a percent error
r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100]
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%x is out of original plot, y out of x 100
plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2));
hold on
r4_t50_d2_cneg01=[NumVL{4,1,1,5}];
%x 100 to make a percent error
r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.8 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','5,1,1 npa')
r5_t50_d2_c01=[NumVL{5,1,1,1}]
%x 100 to make a percent error
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2));
hold on
r5_t50_d2_cneg01=[NumVL{5,1,1,5}]
%x 100 to make a percent error
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.9 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
%Generate Last Figure
figure('Name','6,1,1 npa')
r6_t50_d2_c01=[NumVL{6,1,1,1}]
%Out of matrix variables to assign, so is being multiplied
%x 100 to make a percent error
%x 100 to make a percent error
r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100]

150

%x is out of original plot, y out of x 100
plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2))
hold on
r6_t50_d2_cneg01=[NumVL{6,1,1,5}];
%x 100 to make a percent error
r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2))
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=1.0 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
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Plotting_Code_Increase_TNSPEC_Dimension
%This code plots tnspec vs. bias as dimension increases

%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Get all for (0,1) Compass Points
r1_t50_d2_c01=[NumVL{1,1,1,1}];
r1_t100_d2_c01=[NumVL{1,2,1,1}];
r1_t150_d2_c01=[NumVL{1,3,1,1}];
r1_t200_d2_c01=[NumVL{1,4,1,1}];
r1_t250_d2_c01=[NumVL{1,5,1,1}];
r1_t300_d2_c01=[NumVL{1,6,1,1}];
r1_t350_d2_c01=[NumVL{1,7,1,1}];
r1_t400_d2_c01=[NumVL{1,8,1,1}];
r1_t450_d2_c01=[NumVL{1,9,1,1}];
r1_t500_d2_c01=[NumVL{1,10,1,1}];
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);...
r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);...
r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);...
r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)]
%Get all (0,-1) Compass Points
r1_t50_d2_cneg01=[NumVL{1,1,1,5}];
r1_t100_d2_cneg01=[NumVL{1,2,1,5}];
r1_t150_d2_cneg01=[NumVL{1,3,1,5}];
r1_t200_d2_cneg01=[NumVL{1,4,1,5}];
r1_t250_d2_cneg01=[NumVL{1,5,1,5}];
r1_t300_d2_cneg01=[NumVL{1,6,1,5}];
r1_t350_d2_cneg01=[NumVL{1,7,1,5}];
r1_t400_d2_cneg01=[NumVL{1,8,1,5}];
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r1_t450_d2_cneg01=[NumVL{1,9,1,5}];
r1_t500_d2_cneg01=[NumVL{1,10,1,5}];
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);...
r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);...
r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);...
r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)]
figure('Name','1,1,1 npa')
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100));
%gives relative error b/c true value is 1. Answer/1*100% = relative error
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make second graph for dimension=3
r1_t50_d3_c01=[NumVL{1,1,2,1}]
r1_t100_d3_c01=[NumVL{1,2,2,1}]
r1_t150_d3_c01=[NumVL{1,3,2,1}];
r1_t200_d3_c01=[NumVL{1,4,2,1}];
r1_t250_d3_c01=[NumVL{1,5,2,1}];
r1_t300_d3_c01=[NumVL{1,6,2,1}];
r1_t350_d3_c01=[NumVL{1,7,2,1}];
r1_t400_d3_c01=[NumVL{1,8,2,1}];
r1_t450_d3_c01=[NumVL{1,9,2,1}];
r1_t500_d3_c01=[NumVL{1,10,2,1}];
Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);...
r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);...
r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);...
r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)]
r1_t50_d3_cneg01=[NumVL{1,1,2,5}]
r1_t100_d3_cneg01=[NumVL{1,2,2,5}]
r1_t150_d3_cneg01=[NumVL{1,3,2,5}];
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r1_t200_d3_cneg01=[NumVL{1,4,2,5}];
r1_t250_d3_cneg01=[NumVL{1,5,2,5}];
r1_t300_d3_cneg01=[NumVL{1,6,2,5}];
r1_t350_d3_cneg01=[NumVL{1,7,2,5}];
r1_t400_d3_cneg01=[NumVL{1,8,2,5}];
r1_t450_d3_cneg01=[NumVL{1,9,2,5}];
r1_t500_d3_cneg01=[NumVL{1,10,2,5}];
Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);...
r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);...
r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);...
r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)]
figure('Name','1,1,2 npa')
plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100));
hold on
plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a third graph for 4 dimensions
r1_t50_d4_c01=[NumVL{1,1,3,1}];
r1_t100_d4_c01=[NumVL{1,2,3,1}];
r1_t150_d4_c01=[NumVL{1,3,3,1}];
r1_t200_d4_c01=[NumVL{1,4,3,1}];
r1_t250_d4_c01=[NumVL{1,5,3,1}];
r1_t300_d4_c01=[NumVL{1,6,3,1}];
r1_t350_d4_c01=[NumVL{1,7,3,1}];
r1_t400_d4_c01=[NumVL{1,8,3,1}];
r1_t450_d4_c01=[NumVL{1,9,3,1}];
r1_t500_d4_c01=[NumVL{1,10,3,1}];
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);...
r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);...
r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);...
r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)]
r1_t50_d4_cneg01=[NumVL{1,1,3,5}];
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r1_t100_d4_cneg01=[NumVL{1,2,3,5}];
r1_t150_d4_cneg01=[NumVL{1,3,3,5}];
r1_t200_d4_cneg01=[NumVL{1,4,3,5}];
r1_t250_d4_cneg01=[NumVL{1,5,3,5}];
r1_t300_d4_cneg01=[NumVL{1,6,3,5}];
r1_t350_d4_cneg01=[NumVL{1,7,3,5}];
r1_t400_d4_cneg01=[NumVL{1,8,3,5}];
r1_t450_d4_cneg01=[NumVL{1,9,3,5}];
r1_t500_d4_cneg01=[NumVL{1,10,3,5}];
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);...
r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);...
r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);...
r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)]
figure('Name','1,1,3 npa')
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100));
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a graph for 11 dimensions
r1_t50_d11_c01=[NumVL{1,1,10,1}];
r1_t100_d11_c01=[NumVL{1,2,10,1}];
r1_t150_d11_c01=[NumVL{1,3,10,1}];
r1_t200_d11_c01=[NumVL{1,4,10,1}];
r1_t250_d11_c01=[NumVL{1,5,10,1}];
r1_t300_d11_c01=[NumVL{1,6,10,1}];
r1_t350_d11_c01=[NumVL{1,7,10,1}];
r1_t400_d11_c01=[NumVL{1,8,10,1}];
r1_t450_d11_c01=[NumVL{1,9,10,1}];
r1_t500_d11_c01=[NumVL{1,10,10,1}];
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);...
r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);...
r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);...
r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)]
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r1_t50_d11_cneg01=[NumVL{1,1,10,5}];
r1_t100_d11_cneg01=[NumVL{1,2,10,5}];
r1_t150_d11_cneg01=[NumVL{1,3,10,5}];
r1_t200_d11_cneg01=[NumVL{1,4,10,5}];
r1_t250_d11_cneg01=[NumVL{1,5,10,5}];
r1_t300_d11_cneg01=[NumVL{1,6,10,5}];
r1_t350_d11_cneg01=[NumVL{1,7,10,5}];
r1_t400_d11_cneg01=[NumVL{1,8,10,5}];
r1_t450_d11_cneg01=[NumVL{1,9,10,5}];
r1_t500_d11_cneg01=[NumVL{1,10,10,5}];
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);...
r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);...
r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);...
r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)]
figure('Name','1,1,10 npa')
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100));
hold on
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off
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Plotting_Code_Increase_Radfrac_Bootstrap
%This code plots bootstrapping vs. bias as radfrac increases
%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Set Axis Limits for All Graphs:
graphlimits=[50,500,-40,40];
figure('Name','1,1,1 npa')
r1_t50_d2_c01=[NumVL{1,1,1,1}]
%x 100 to make a percent error
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2));
hold on
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]
%x 100 to make a percent error
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

figure('Name','2,1,1 npa')
r2_t50_d2_c01=[NumVL{2,1,1,1}];
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%x 100 to make a percent error
r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2));
hold on
r2_t50_d2_cneg01=[NumVL{2,1,1,5}];
%x 100 to make a percent error
r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','3,1,1 npa')
r3_t50_d2_c01=[NumVL{3,1,1,1}]
%x 100 to make a percent error
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2));
hold on
r3_t50_d2_cneg01=[NumVL{3,1,1,5}];
%x 100 to make a percent error
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','4,1,1 npa')
r4_t50_d2_c01=[NumVL{4,1,1,1}]
%x 100 to make a percent error
r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100]
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%x is out of original plot, y out of x 100
plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2));
hold on
r4_t50_d2_cneg01=[NumVL{4,1,1,5}];
%x 100 to make a percent error
r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.8 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','5,1,1 npa')
r5_t50_d2_c01=[NumVL{5,1,1,1}]
%x 100 to make a percent error
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2));
hold on
r5_t50_d2_cneg01=[NumVL{5,1,1,5}]
%x 100 to make a percent error
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.9 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
%Generate Last Figure
figure('Name','6,1,1 npa')
r6_t50_d2_c01=[NumVL{6,1,1,1}]
%Out of matrix variables to assign, so is being multiplied
%x 100 to make a percent error
%x 100 to make a percent error
r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100]
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%x is out of original plot, y out of x 100
plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2))
hold on
r6_t50_d2_cneg01=[NumVL{6,1,1,5}];
%x 100 to make a percent error
r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2))
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=1.0 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
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Plotting_Code_Increase_Bootstrap_Radfrac

%This code plots bootstrapping vs. bias as radfrac increases
%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Set Axis Limits for All Graphs:
graphlimits=[50,500,-40,40];
figure('Name','1,1,1 npa')
r1_t50_d2_c01=[NumVL{1,1,1,1}]
%x 100 to make a percent error
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2));
hold on
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]
%x 100 to make a percent error
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

figure('Name','2,1,1 npa')
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r2_t50_d2_c01=[NumVL{2,1,1,1}];
%x 100 to make a percent error
r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2));
hold on
r2_t50_d2_cneg01=[NumVL{2,1,1,5}];
%x 100 to make a percent error
r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','3,1,1 npa')
r3_t50_d2_c01=[NumVL{3,1,1,1}]
%x 100 to make a percent error
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2));
hold on
r3_t50_d2_cneg01=[NumVL{3,1,1,5}];
%x 100 to make a percent error
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','4,1,1 npa')
r4_t50_d2_c01=[NumVL{4,1,1,1}]
%x 100 to make a percent error
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r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2));
hold on
r4_t50_d2_cneg01=[NumVL{4,1,1,5}];
%x 100 to make a percent error
r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.8 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
figure('Name','5,1,1 npa')
r5_t50_d2_c01=[NumVL{5,1,1,1}]
%x 100 to make a percent error
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2));
hold on
r5_t50_d2_cneg01=[NumVL{5,1,1,5}]
%x 100 to make a percent error
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2));
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=0.9 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
%Generate Last Figure
figure('Name','6,1,1 npa')
r6_t50_d2_c01=[NumVL{6,1,1,1}]
%Out of matrix variables to assign, so is being multiplied
%x 100 to make a percent error
%x 100 to make a percent error
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r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100]
%x is out of original plot, y out of x 100
plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2))
hold on
r6_t50_d2_cneg01=[NumVL{6,1,1,5}];
%x 100 to make a percent error
r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100];
%x is out of original plot, y out of x 100
plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2))
title({'Average Percent Error as Bootstrap Replicates Increase';...
'Radfrac=1.0 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
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Plotting_Code_Increase_TNSPEC_Dimension
%This code plots tnspec vs. bias as dimension increases

%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Get all for (0,1) Compass Points
r1_t50_d2_c01=[NumVL{1,1,1,1}];
r1_t100_d2_c01=[NumVL{1,2,1,1}];
r1_t150_d2_c01=[NumVL{1,3,1,1}];
r1_t200_d2_c01=[NumVL{1,4,1,1}];
r1_t250_d2_c01=[NumVL{1,5,1,1}];
r1_t300_d2_c01=[NumVL{1,6,1,1}];
r1_t350_d2_c01=[NumVL{1,7,1,1}];
r1_t400_d2_c01=[NumVL{1,8,1,1}];
r1_t450_d2_c01=[NumVL{1,9,1,1}];
r1_t500_d2_c01=[NumVL{1,10,1,1}];
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);...
r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);...
r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);...
r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)]
%Get all (0,-1) Compass Points
r1_t50_d2_cneg01=[NumVL{1,1,1,5}];
r1_t100_d2_cneg01=[NumVL{1,2,1,5}];
r1_t150_d2_cneg01=[NumVL{1,3,1,5}];
r1_t200_d2_cneg01=[NumVL{1,4,1,5}];
r1_t250_d2_cneg01=[NumVL{1,5,1,5}];
r1_t300_d2_cneg01=[NumVL{1,6,1,5}];
r1_t350_d2_cneg01=[NumVL{1,7,1,5}];
r1_t400_d2_cneg01=[NumVL{1,8,1,5}];
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r1_t450_d2_cneg01=[NumVL{1,9,1,5}];
r1_t500_d2_cneg01=[NumVL{1,10,1,5}];
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);...
r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);...
r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);...
r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)]
figure('Name','1,1,1 npa')
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100));
%gives relative error b/c true value is 1. Answer/1*100% = relative error
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make second graph for dimension=3
r1_t50_d3_c01=[NumVL{1,1,2,1}]
r1_t100_d3_c01=[NumVL{1,2,2,1}]
r1_t150_d3_c01=[NumVL{1,3,2,1}];
r1_t200_d3_c01=[NumVL{1,4,2,1}];
r1_t250_d3_c01=[NumVL{1,5,2,1}];
r1_t300_d3_c01=[NumVL{1,6,2,1}];
r1_t350_d3_c01=[NumVL{1,7,2,1}];
r1_t400_d3_c01=[NumVL{1,8,2,1}];
r1_t450_d3_c01=[NumVL{1,9,2,1}];
r1_t500_d3_c01=[NumVL{1,10,2,1}];
Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);...
r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);...
r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);...
r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)]
r1_t50_d3_cneg01=[NumVL{1,1,2,5}]
r1_t100_d3_cneg01=[NumVL{1,2,2,5}]
r1_t150_d3_cneg01=[NumVL{1,3,2,5}];
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r1_t200_d3_cneg01=[NumVL{1,4,2,5}];
r1_t250_d3_cneg01=[NumVL{1,5,2,5}];
r1_t300_d3_cneg01=[NumVL{1,6,2,5}];
r1_t350_d3_cneg01=[NumVL{1,7,2,5}];
r1_t400_d3_cneg01=[NumVL{1,8,2,5}];
r1_t450_d3_cneg01=[NumVL{1,9,2,5}];
r1_t500_d3_cneg01=[NumVL{1,10,2,5}];
Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);...
r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);...
r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);...
r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)]
figure('Name','1,1,2 npa')
plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100));
hold on
plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a third graph for 4 dimensions
r1_t50_d4_c01=[NumVL{1,1,3,1}];
r1_t100_d4_c01=[NumVL{1,2,3,1}];
r1_t150_d4_c01=[NumVL{1,3,3,1}];
r1_t200_d4_c01=[NumVL{1,4,3,1}];
r1_t250_d4_c01=[NumVL{1,5,3,1}];
r1_t300_d4_c01=[NumVL{1,6,3,1}];
r1_t350_d4_c01=[NumVL{1,7,3,1}];
r1_t400_d4_c01=[NumVL{1,8,3,1}];
r1_t450_d4_c01=[NumVL{1,9,3,1}];
r1_t500_d4_c01=[NumVL{1,10,3,1}];
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);...
r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);...
r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);...
r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)]
r1_t50_d4_cneg01=[NumVL{1,1,3,5}];
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r1_t100_d4_cneg01=[NumVL{1,2,3,5}];
r1_t150_d4_cneg01=[NumVL{1,3,3,5}];
r1_t200_d4_cneg01=[NumVL{1,4,3,5}];
r1_t250_d4_cneg01=[NumVL{1,5,3,5}];
r1_t300_d4_cneg01=[NumVL{1,6,3,5}];
r1_t350_d4_cneg01=[NumVL{1,7,3,5}];
r1_t400_d4_cneg01=[NumVL{1,8,3,5}];
r1_t450_d4_cneg01=[NumVL{1,9,3,5}];
r1_t500_d4_cneg01=[NumVL{1,10,3,5}];
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);...
r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);...
r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);...
r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)]
figure('Name','1,1,3 npa')
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100));
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a graph for 11 dimensions
r1_t50_d11_c01=[NumVL{1,1,10,1}];
r1_t100_d11_c01=[NumVL{1,2,10,1}];
r1_t150_d11_c01=[NumVL{1,3,10,1}];
r1_t200_d11_c01=[NumVL{1,4,10,1}];
r1_t250_d11_c01=[NumVL{1,5,10,1}];
r1_t300_d11_c01=[NumVL{1,6,10,1}];
r1_t350_d11_c01=[NumVL{1,7,10,1}];
r1_t400_d11_c01=[NumVL{1,8,10,1}];
r1_t450_d11_c01=[NumVL{1,9,10,1}];
r1_t500_d11_c01=[NumVL{1,10,10,1}];
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);...
r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);...
r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);...
r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)]
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r1_t50_d11_cneg01=[NumVL{1,1,10,5}];
r1_t100_d11_cneg01=[NumVL{1,2,10,5}];
r1_t150_d11_cneg01=[NumVL{1,3,10,5}];
r1_t200_d11_cneg01=[NumVL{1,4,10,5}];
r1_t250_d11_cneg01=[NumVL{1,5,10,5}];
r1_t300_d11_cneg01=[NumVL{1,6,10,5}];
r1_t350_d11_cneg01=[NumVL{1,7,10,5}];
r1_t400_d11_cneg01=[NumVL{1,8,10,5}];
r1_t450_d11_cneg01=[NumVL{1,9,10,5}];
r1_t500_d11_cneg01=[NumVL{1,10,10,5}];
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);...
r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);...
r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);...
r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)]
figure('Name','1,1,10 npa')
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100));
hold on
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off
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Plotting_Code_Increase_TNSPEC_Dimension
%This code plots tnspec vs. bias as dimension increases

%Indexing in NumVL Cell Matrix is as Follows:
%{radfrac number, training, dimension - 1, compass point
%number}
%Within matrix:
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Get all for (0,1) Compass Points
r1_t50_d2_c01=[NumVL{1,1,1,1}];
r1_t100_d2_c01=[NumVL{1,2,1,1}];
r1_t150_d2_c01=[NumVL{1,3,1,1}];
r1_t200_d2_c01=[NumVL{1,4,1,1}];
r1_t250_d2_c01=[NumVL{1,5,1,1}];
r1_t300_d2_c01=[NumVL{1,6,1,1}];
r1_t350_d2_c01=[NumVL{1,7,1,1}];
r1_t400_d2_c01=[NumVL{1,8,1,1}];
r1_t450_d2_c01=[NumVL{1,9,1,1}];
r1_t500_d2_c01=[NumVL{1,10,1,1}];
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);...
r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);...
r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);...
r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)]
%Get all (0,-1) Compass Points
r1_t50_d2_cneg01=[NumVL{1,1,1,5}];
r1_t100_d2_cneg01=[NumVL{1,2,1,5}];
r1_t150_d2_cneg01=[NumVL{1,3,1,5}];
r1_t200_d2_cneg01=[NumVL{1,4,1,5}];
r1_t250_d2_cneg01=[NumVL{1,5,1,5}];
r1_t300_d2_cneg01=[NumVL{1,6,1,5}];
r1_t350_d2_cneg01=[NumVL{1,7,1,5}];
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r1_t400_d2_cneg01=[NumVL{1,8,1,5}];
r1_t450_d2_cneg01=[NumVL{1,9,1,5}];
r1_t500_d2_cneg01=[NumVL{1,10,1,5}];
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);...
r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);...
r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);...
r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)]
figure('Name','1,1,1 npa')
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100));
%gives relative error b/c true value is 1. Answer/1*100% = relative error
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make second graph for dimension=3
r1_t50_d3_c01=[NumVL{1,1,2,1}]
r1_t100_d3_c01=[NumVL{1,2,2,1}]
r1_t150_d3_c01=[NumVL{1,3,2,1}];
r1_t200_d3_c01=[NumVL{1,4,2,1}];
r1_t250_d3_c01=[NumVL{1,5,2,1}];
r1_t300_d3_c01=[NumVL{1,6,2,1}];
r1_t350_d3_c01=[NumVL{1,7,2,1}];
r1_t400_d3_c01=[NumVL{1,8,2,1}];
r1_t450_d3_c01=[NumVL{1,9,2,1}];
r1_t500_d3_c01=[NumVL{1,10,2,1}];
Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);...
r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);...
r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);...
r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)]
r1_t50_d3_cneg01=[NumVL{1,1,2,5}]
r1_t100_d3_cneg01=[NumVL{1,2,2,5}]
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r1_t150_d3_cneg01=[NumVL{1,3,2,5}];
r1_t200_d3_cneg01=[NumVL{1,4,2,5}];
r1_t250_d3_cneg01=[NumVL{1,5,2,5}];
r1_t300_d3_cneg01=[NumVL{1,6,2,5}];
r1_t350_d3_cneg01=[NumVL{1,7,2,5}];
r1_t400_d3_cneg01=[NumVL{1,8,2,5}];
r1_t450_d3_cneg01=[NumVL{1,9,2,5}];
r1_t500_d3_cneg01=[NumVL{1,10,2,5}];
Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);...
r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);...
r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);...
r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)]
figure('Name','1,1,2 npa')
plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100));
hold on
plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a third graph for 4 dimensions
r1_t50_d4_c01=[NumVL{1,1,3,1}];
r1_t100_d4_c01=[NumVL{1,2,3,1}];
r1_t150_d4_c01=[NumVL{1,3,3,1}];
r1_t200_d4_c01=[NumVL{1,4,3,1}];
r1_t250_d4_c01=[NumVL{1,5,3,1}];
r1_t300_d4_c01=[NumVL{1,6,3,1}];
r1_t350_d4_c01=[NumVL{1,7,3,1}];
r1_t400_d4_c01=[NumVL{1,8,3,1}];
r1_t450_d4_c01=[NumVL{1,9,3,1}];
r1_t500_d4_c01=[NumVL{1,10,3,1}];
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);...
r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);...
r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);...
r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)]
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r1_t50_d4_cneg01=[NumVL{1,1,3,5}];
r1_t100_d4_cneg01=[NumVL{1,2,3,5}];
r1_t150_d4_cneg01=[NumVL{1,3,3,5}];
r1_t200_d4_cneg01=[NumVL{1,4,3,5}];
r1_t250_d4_cneg01=[NumVL{1,5,3,5}];
r1_t300_d4_cneg01=[NumVL{1,6,3,5}];
r1_t350_d4_cneg01=[NumVL{1,7,3,5}];
r1_t400_d4_cneg01=[NumVL{1,8,3,5}];
r1_t450_d4_cneg01=[NumVL{1,9,3,5}];
r1_t500_d4_cneg01=[NumVL{1,10,3,5}];
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);...
r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);...
r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);...
r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)]
figure('Name','1,1,3 npa')
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100));
hold on
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';...
'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off

%Make a graph for 11 dimensions
r1_t50_d11_c01=[NumVL{1,1,10,1}];
r1_t100_d11_c01=[NumVL{1,2,10,1}];
r1_t150_d11_c01=[NumVL{1,3,10,1}];
r1_t200_d11_c01=[NumVL{1,4,10,1}];
r1_t250_d11_c01=[NumVL{1,5,10,1}];
r1_t300_d11_c01=[NumVL{1,6,10,1}];
r1_t350_d11_c01=[NumVL{1,7,10,1}];
r1_t400_d11_c01=[NumVL{1,8,10,1}];
r1_t450_d11_c01=[NumVL{1,9,10,1}];
r1_t500_d11_c01=[NumVL{1,10,10,1}];
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);...
r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);...
r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);...
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r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)]
r1_t50_d11_cneg01=[NumVL{1,1,10,5}];
r1_t100_d11_cneg01=[NumVL{1,2,10,5}];
r1_t150_d11_cneg01=[NumVL{1,3,10,5}];
r1_t200_d11_cneg01=[NumVL{1,4,10,5}];
r1_t250_d11_cneg01=[NumVL{1,5,10,5}];
r1_t300_d11_cneg01=[NumVL{1,6,10,5}];
r1_t350_d11_cneg01=[NumVL{1,7,10,5}];
r1_t400_d11_cneg01=[NumVL{1,8,10,5}];
r1_t450_d11_cneg01=[NumVL{1,9,10,5}];
r1_t500_d11_cneg01=[NumVL{1,10,10,5}];
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);...
r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);...
r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);...
r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)]
figure('Name','1,1,10 npa')
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100));
hold on
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100));
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5
Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Percent Error')
legend('CP=(0,1)','CP=(0,-1)')
hold off
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RSD_as_Bootstrap_Radfrac_Increase
%Plotting Relative Standard Deviation
%as Bootstrapping and Radfrac Increase
%This code plots bootstrapping vs. RSD as radfrac increases
%Indexing in NumVL Cell Matrix is as Follows:
%Indexing is {Radfrac Iteration Count (must separately count...
%Radfrac value),Training Set Size,dimension,Compass Point,}
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
%Within matrix:
%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [1.compass point coordinate, 2.compass point coordinate,...
%3.B, 4.RSD of returned standard deviation, ...
%5.total number of dimensions (v+2), 6.radfrac,
%7.Training Set Size]

figure('Name','1,1,1 npa')
r1_t50_d2_c01=[RSD_NumVL{1,1,1,1}];
plot (r1_t50_d2_c01(:,3),r1_t50_d2_c01(:,4));
hold on
r1_t50_d2_cneg01=[RSD_NumVL{1,1,1,5}];
plot (r1_t50_d2_cneg01(:,3),r1_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.5
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
%axis(graphlimits)
hold off

figure('Name','2,1,1 npa')
r2_t50_d2_c01=[RSD_NumVL{2,1,1,1}];
plot (r2_t50_d2_c01(:,3),r2_t50_d2_c01(:,4));
hold on
r2_t50_d2_cneg01=[RSD_NumVL{2,1,1,5}];
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plot (r2_t50_d2_cneg01(:,3),r2_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.6
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
hold off
figure('Name','3,1,1 npa')
r3_t50_d2_c01=[RSD_NumVL{3,1,1,1}];
plot (r3_t50_d2_c01(:,3),r3_t50_d2_c01(:,4));
hold on
r3_t50_d2_cneg01=[RSD_NumVL{3,1,1,5}];
plot (r3_t50_d2_cneg01(:,3),r3_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.7
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
hold off
figure('Name','4,1,1 npa')
r4_t50_d2_c01=[RSD_NumVL{4,1,1,1}];
plot (r4_t50_d2_c01(:,3),r4_t50_d2_c01(:,4));
hold on
r4_t50_d2_cneg01=[RSD_NumVL{4,1,1,5}];
plot (r4_t50_d2_cneg01(:,3),r4_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';...
'Radfrac=0.8 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
hold off
figure('Name','5,1,1 npa')
r5_t50_d2_c01=[RSD_NumVL{5,1,1,1}];
plot (r5_t50_d2_c01(:,3),r5_t50_d2_c01(:,4));
hold on
r5_t50_d2_cneg01=[RSD_NumVL{5,1,1,5}];
plot (r5_t50_d2_cneg01(:,3),r5_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';...
'Radfrac=0.9 Dimension=2 TNSPEC=50'})
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xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','(0,-1)')
hold off
figure('Name','6,1,1 npa')
r6_t50_d2_c01=[RSD_NumVL{6,1,1,1}];
plot (r6_t50_d2_c01(:,3),r6_t50_d2_c01(:,4));
hold on
r6_t50_d2_cneg01=[RSD_NumVL{6,1,1,5}];
plot (r6_t50_d2_cneg01(:,3),r6_t50_d2_cneg01(:,4));
title({'Relative Standard Deviation as Bootstrap Replicates Increase';...
'Radfrac=1.0 Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replications')
ylabel('Relative Standard Deviation')
legend('CP=(0,1)','CP=(0,-1)')
hold off
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RSD_as_TNSPEC_Dimension_Increase
%Plotting Relative Standard Deviation
%as TNSPEC and Dimension Increase

%Indexing in NumVL Cell Matrix is as Follows:
%Indexing is {Radfrac Iteration Count (must separately count...
%Radfrac value),Training Set Size,dimension,Compass Point,}
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD;
%Within matrix:
%Store Relative Standard Deviation (average standard deviation/
%average)
%RSD holds [1.compass point coordinate, 2.compass point coordinate,...
%3.B, 4.RSD of returned standard deviation, ...
%5.total number of dimensions (v+2), 6.radfrac,
%7.Training Set Size]
%Set Axis Limits for Graphs
%axis(limits) syntax is axis(xmin xmax ymin ymax)
graphlimits=[50,500,0,0.1]
%Get all for (0,1) Compass Points
r1_t50_d2_c01=[RSD_NumVL{1,1,1,1}];
r1_t100_d2_c01=[RSD_NumVL{1,2,1,1}];
r1_t150_d2_c01=[RSD_NumVL{1,3,1,1}];
r1_t200_d2_c01=[RSD_NumVL{1,4,1,1}];
r1_t250_d2_c01=[RSD_NumVL{1,5,1,1}];
r1_t300_d2_c01=[RSD_NumVL{1,6,1,1}];
r1_t350_d2_c01=[RSD_NumVL{1,7,1,1}];
r1_t400_d2_c01=[RSD_NumVL{1,8,1,1}];
r1_t450_d2_c01=[RSD_NumVL{1,9,1,1}];
r1_t500_d2_c01=[RSD_NumVL{1,10,1,1}];
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);...
r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);...
r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);...
r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)];
%Get all (0,-1) Compass Points
r1_t50_d2_cneg01=[RSD_NumVL{1,1,1,5}];
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r1_t100_d2_cneg01=[RSD_NumVL{1,2,1,5}];
r1_t150_d2_cneg01=[RSD_NumVL{1,3,1,5}];
r1_t200_d2_cneg01=[RSD_NumVL{1,4,1,5}];
r1_t250_d2_cneg01=[RSD_NumVL{1,5,1,5}];
r1_t300_d2_cneg01=[RSD_NumVL{1,6,1,5}];
r1_t350_d2_cneg01=[RSD_NumVL{1,7,1,5}];
r1_t400_d2_cneg01=[RSD_NumVL{1,8,1,5}];
r1_t450_d2_cneg01=[RSD_NumVL{1,9,1,5}];
r1_t500_d2_cneg01=[RSD_NumVL{1,10,1,5}];
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);...
r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);...
r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);...
r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)];
figure('Name','1,1,1 npa')
plot (Increasing_TNSPEC(:,7),Increasing_TNSPEC(:,4));
hold on
plot (Increasing_TNSPEC_neg(:,7),Increasing_TNSPEC_neg(:,4));
title({'Relative Standard Deviation as Training Set Size Increases';'Dimension=2
Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Absolute Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

%Make second graph for dimension=3
r1_t50_d3_c01=[RSD_NumVL{1,1,2,1}];
r1_t100_d3_c01=[RSD_NumVL{1,2,2,1}];
r1_t150_d3_c01=[RSD_NumVL{1,3,2,1}];
r1_t200_d3_c01=[RSD_NumVL{1,4,2,1}];
r1_t250_d3_c01=[RSD_NumVL{1,5,2,1}];
r1_t300_d3_c01=[RSD_NumVL{1,6,2,1}];
r1_t350_d3_c01=[RSD_NumVL{1,7,2,1}];
r1_t400_d3_c01=[RSD_NumVL{1,8,2,1}];
r1_t450_d3_c01=[RSD_NumVL{1,9,2,1}];
r1_t500_d3_c01=[RSD_NumVL{1,10,2,1}];
Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);...
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r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);...
r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);...
r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)];
r1_t50_d3_cneg01=[RSD_NumVL{1,1,2,5}];
r1_t100_d3_cneg01=[RSD_NumVL{1,2,2,5}];
r1_t150_d3_cneg01=[RSD_NumVL{1,3,2,5}];
r1_t200_d3_cneg01=[RSD_NumVL{1,4,2,5}];
r1_t250_d3_cneg01=[RSD_NumVL{1,5,2,5}];
r1_t300_d3_cneg01=[RSD_NumVL{1,6,2,5}];
r1_t350_d3_cneg01=[RSD_NumVL{1,7,2,5}];
r1_t400_d3_cneg01=[RSD_NumVL{1,8,2,5}];
r1_t450_d3_cneg01=[RSD_NumVL{1,9,2,5}];
r1_t500_d3_cneg01=[RSD_NumVL{1,10,2,5}];
Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);...
r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);...
r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);...
r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)];
figure('Name','1,1,2 npa')
plot (Increasing_TNSPEC2(:,7),Increasing_TNSPEC2(:,4));
hold on
plot (Increasing_TNSPEC2neg(:,7),Increasing_TNSPEC2neg(:,4));
title({'Relative Standard Deviation as Training Set Size Increases';...
'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Absolute Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

%Make a third graph for 4 dimensions
r1_t50_d4_c01=[RSD_NumVL{1,1,3,1}];
r1_t100_d4_c01=[RSD_NumVL{1,2,3,1}];
r1_t150_d4_c01=[RSD_NumVL{1,3,3,1}];
r1_t200_d4_c01=[RSD_NumVL{1,4,3,1}];
r1_t250_d4_c01=[RSD_NumVL{1,5,3,1}];
r1_t300_d4_c01=[RSD_NumVL{1,6,3,1}];
r1_t350_d4_c01=[RSD_NumVL{1,7,3,1}];
r1_t400_d4_c01=[RSD_NumVL{1,8,3,1}];
r1_t450_d4_c01=[RSD_NumVL{1,9,3,1}];
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r1_t500_d4_c01=[RSD_NumVL{1,10,3,1}];
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);...
r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);...
r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);...
r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)];
r1_t50_d4_cneg01=[RSD_NumVL{1,1,3,5}];
r1_t100_d4_cneg01=[RSD_NumVL{1,2,3,5}];
r1_t150_d4_cneg01=[RSD_NumVL{1,3,3,5}];
r1_t200_d4_cneg01=[RSD_NumVL{1,4,3,5}];
r1_t250_d4_cneg01=[RSD_NumVL{1,5,3,5}];
r1_t300_d4_cneg01=[RSD_NumVL{1,6,3,5}];
r1_t350_d4_cneg01=[RSD_NumVL{1,7,3,5}];
r1_t400_d4_cneg01=[RSD_NumVL{1,8,3,5}];
r1_t450_d4_cneg01=[RSD_NumVL{1,9,3,5}];
r1_t500_d4_cneg01=[RSD_NumVL{1,10,3,5}];
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);...
r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);...
r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);...
r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)];
figure('Name','1,1,3 npa')
plot (Increasing_TNSPEC3neg(:,7),Increasing_TNSPEC3(:,4));
hold on
plot (Increasing_TNSPEC_neg(:,7),Increasing_TNSPEC_neg(:,4));
title({'Relative Standard Deviation as Training Set Size Increases';...
'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Absolute Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off

%Make a graph for 11 dimensions
r1_t50_d11_c01=[RSD_NumVL{1,1,10,1}];
r1_t100_d11_c01=[RSD_NumVL{1,2,10,1}];
r1_t150_d11_c01=[RSD_NumVL{1,3,10,1}];
r1_t200_d11_c01=[RSD_NumVL{1,4,10,1}];
r1_t250_d11_c01=[RSD_NumVL{1,5,10,1}];
r1_t300_d11_c01=[RSD_NumVL{1,6,10,1}];
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r1_t350_d11_c01=[RSD_NumVL{1,7,10,1}];
r1_t400_d11_c01=[RSD_NumVL{1,8,10,1}];
r1_t450_d11_c01=[RSD_NumVL{1,9,10,1}];
r1_t500_d11_c01=[RSD_NumVL{1,10,10,1}];
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);...
r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);...
r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);...
r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)];
r1_t50_d11_cneg01=[RSD_NumVL{1,1,10,5}];
r1_t100_d11_cneg01=[RSD_NumVL{1,2,10,5}];
r1_t150_d11_cneg01=[RSD_NumVL{1,3,10,5}];
r1_t200_d11_cneg01=[RSD_NumVL{1,4,10,5}];
r1_t250_d11_cneg01=[RSD_NumVL{1,5,10,5}];
r1_t300_d11_cneg01=[RSD_NumVL{1,6,10,5}];
r1_t350_d11_cneg01=[RSD_NumVL{1,7,10,5}];
r1_t400_d11_cneg01=[RSD_NumVL{1,8,10,5}];
r1_t450_d11_cneg01=[RSD_NumVL{1,9,10,5}];
r1_t500_d11_cneg01=[RSD_NumVL{1,10,10,5}];
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);...
r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);...
r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);...
r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)];
figure('Name','1,1,10 npa')
plot (Increasing_TNSPEC11(:,7),Increasing_TNSPEC11(:,4));
hold on
plot (Increasing_TNSPEC11neg(:,7),Increasing_TNSPEC11neg(:,4));
title({'Relative Standard Deviation as Training Set Size Increases';'Dimension=11
Radfrac=0.5 Bootstrap Replicates=500'})
xlabel('Training Set Size')
ylabel('Absolute Error')
legend('CP=(0,1)','CP=(0,-1)')
axis(graphlimits)
hold off
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Figures_Code
figure
mu=[0,0];
sigma=[2,1];
TNSPEC=mvnrnd(mu,sigma,100);
scatter(TNSPEC(:,1), TNSPEC(:,2))
hold on
%equation of an ellipse

%Graph Compass Points
compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));
0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))];
scatter(compass_points(:,1),compass_points(:,2),50,'r','filled')
%Graph Center
scatter(0,0,50,'r','filled')
%Graph Ellipse
a=2; % horizontal radius
b=1; % vertical radius
x0=0; % x0,y0 ellipse centre coordinates
y0=0;
t=-pi:0.01:pi;
x=x0+a*cos(t);
y=y0+b*sin(t);
plot(x,y)
hold off
figure
mu=[0,0];
sigma=[1,1];
TNSPEC=mvnrnd(mu,sigma,100);
scatter(TNSPEC(:,1), TNSPEC(:,2))
hold on
%Graph center
scatter(0,0,'filled')
%Graph circle for 1 standard deviation
centers=[0,0];
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radii=[1];
viscircles(centers,radii)
%Graph second standard deviation
radii=[2];
viscircles(centers,radii,'Color','b')
hold off
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Graphing_Code_2
%Requires workspace variables NumVL and RSD_NumVL, Max_training,
%Make sure these exist.
NumVL;
RSD_NumVL;
out=[cat(1,NumVL{:})];
x=size(out);
w=x(:,1);
y=zeros(x(:,1),1);
%Designate compass points - work in progress
newmatrix=[out,y];
%nonprincipal axis points
npa=newmatrix(:,4)==0;
%principal axis points
pa=newmatrix(:,4)==2;
opa=newmatrix(:,4)==-2;
%since diagonals have a calculation that determines the value
%it is hard to tell how many digits of precision
%therefore, diagonals are not equal to 0, 2, or -2.
%First find indices ~=0
dp=newmatrix(:,4)~=0;
dp2=newmatrix(dp,:);
%Now find indices in the ~=0 subset also ~= 2
fdp=dp2(:,4)~=2;
dp3=dp2(fdp,:);
%Last, find indices in that subset also ~= to -2
ffdp=dp3(:,4)~=-2;
nonprincipalaxis=[newmatrix(npa,:)];
principalaxis=[newmatrix(pa,:);newmatrix(opa,:)];
diagonalpoints=[dp3(ffdp,:)];
%Regress Non-Principal
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
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%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Columns are
%(bootstrap,bias,dimension,compass,compass,radfrac,training)
npa_output=[nonprincipalaxis(:,2)];
npa_input=[nonprincipalaxis(:,1),nonprincipalaxis(:,3),nonprincipalaxis(:,6),nonprincipala
xis(:,7)];
reg = MultiPolyRegress(npa_input,npa_output,5)

%Regress Principal
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Columns are
%(bootstrap,bias,dimension,compass,compass,radfrac,training)
pa_output=[principalaxis(:,2)];
pa_input=[principalaxis(:,1),principalaxis(:,3),principalaxis(:,6),principalaxis(:,7)];
reg = MultiPolyRegress(pa_input,pa_output,5)

%Regress Diagonal
%B is located in Bias_plot(:,1)
%bias is located in Bias_plot(:,2)
%dimension is located in Bias_plot(:,3)
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5)
%radfrac located in Bias_plot(:,6)
%Training set size located in Bias_plot(:,7)
%Columns are
%(bootstrap,bias,dimension,compass,compass,radfrac,training)
d_output=[diagonalpoints(:,2)];
d_input=[diagonalpoints(:,1),diagonalpoints(:,3),diagonalpoints(:,6),diagonalpoints(:,7)];
reg = MultiPolyRegress(d_input,d_output,5)
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RTCR_Point_Bias2
%RTCR_Point_Bias2.m
%This program calculates the average percent error of RTCR outputs and graphs
%the average percent error for each compass point at increasing numbers of
%bootstrap replications.

%TNSPEC=mvnrnd(mu,sigma,50*u);compass_points=[0,1;...
%(-2/(sqrt(5))),(2/(sqrt(5)));...
%-2,0;...
%(-2/(sqrt(5))),(-2/(sqrt(5)));...
% 0,-1;...
%(2/(sqrt(5))),(-2/(sqrt(5)));...
%2,0;...
%(2/(sqrt(5))),(2/(sqrt(5)))];
A=NumVL{1,1,1,1}
point_0_1=A;
point_0_1(:,2)=( point_0_1(:,2)/(expected_standard_deviation(1))*100)
figure
plot(point_0_1(:,1),point_0_1(:,2),'-*r')
hold on
A=NumVL{1,1,1,2}
point2=A;
point2(:,2)=( point2(:,2)/(expected_standard_deviation(1))*100)
plot(point2(:,1),point2(:,2),'-*b')
hold on
A=NumVL{1,1,1,3};
point3=A;
point3(:,2)=( point3(:,2)/(expected_standard_deviation(1))*100)
plot(point3(:,1),point3(:,2),'-*k')
hold on
A=NumVL{1,1,1,4}
point4=A;
point4(:,2)=( point4(:,2)/(expected_standard_deviation(1))*100)
plot(point4(:,1),point4(:,2),'-ob')
hold on
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A=NumVL{1,1,1,5}
point5=A;
point5(:,2)=( point5(:,2)/(expected_standard_deviation(1))*100)
plot(point5(:,1),point5(:,2),'-or')
hold on
A=NumVL{1,1,1,6}
point6=A;
point6(:,2)=( point6(:,2)/(expected_standard_deviation(1))*100)
plot(point6(:,1),point6(:,2),'-sb')
hold on
A=NumVL{1,1,1,7}
point7=A;
point7(:,2)=( point7(:,2)/(expected_standard_deviation(1))*100)
plot(point7(:,1),point7(:,2),'-ok')
hold on
A=NumVL{1,1,1,8}
point8=A;
point8(:,2)=( point8(:,2)/(expected_standard_deviation(1))*100)
plot(point8(:,1),point8(:,2),'-pb')
hold off
legend('(0,1)','(-2/(sqrt(5))),(2/(sqrt(5)))', '(-2,0),',...
'(-2/(sqrt(5))),(-2/(sqrt(5)))', '(0,-1)', '(2/(sqrt(5))),(-2/(sqrt(5)))',...
'(2,0)','(2/(sqrt(5))),(2/(sqrt(5))','Location','southoutside')
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5
Dimension=2 TNSPEC=50'})
xlabel('Bootstrap Replicates')
ylabel('Average Percent Error of Six Runs')
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